 
 
 
 
COVER PAGE FOR PROTOCOL AND STATISTICAL ANALYSIS PLAN  
 
 
 
 
 
 
 
 
 
 
Official Study Title: A Phase II Study of Induction Docetaxel, Cisplatin, 
Cetuximab and Bevacizumab (TPE -A) Followed by [CONTACT_744561], 
Cisplatin, Cetuximab and Bevacizumab (XPE -A) in Patients with Locally 
Advanced Head and Neck Cancer (CTRC# 11 -36) 
 
 
NCT number: NCT 0158 8431  
 
 
IRB Approval Date: 11-02-2016  
 
 
Unique Protocol ID: CTRC 11 -36 
Page 1 of 3  
 
 
STOP  
 
NOT IRB 
APPROVED  CCTTRRCC## 1111--3366 
 
 
Protocol  Change s for the Revised  Protocol  dated  October  25, 2016  for the study : A Phase II 
Study of Indu ction Docetaxel, Cisplatin, Cetuxim ab and B evac izumab (TPE-A) Followed by 
[CONTACT_744561], Cisplatin, Ceh1ximab and Bevacizumab (X PE-A) in Patients with Locally 
Advanced Head and Neck Cancer (CTRC # 11-36) 
 
PREVIO USLY READ:  Cove r Page , date of pr-oto-co-l ---------------  
VERSIO N DATE:  
 
 
 
 
 
 
 
 
NOW READS : 
VERSIO N DATE:  [ADDRESS_1018467] 22, 2 011 
Janua1y 4, 2012 
April 25, 2012 
November 2 , 2012 
December 19, 2012  
March 25, 2013 
May 28 , 2013  
Janua1y 14, 2015 
October 25, 2016  RECEIVED  
BByy RReegguullaattoorryy AAffffaaiirrss aatt 22::4444ppmm,, OOcctt 2255,, 22001166 
 
 
 
 
 
 
RATIONALE:    Upda ted the version date of protocol. 
 
PREVIO USLY  READ:  Header , entire  protocol  
Janua1y 14, 2016  
 
NOW READS : 
RATIONALE:  October 252 2016  
Updated the date of protocol 
PREVIO USLY READ:  Cover Page, Principal Inve stigator  
 
Woon dong Jeong , MD 
Professor o f Medic ine 
UT Health  Science  Center at San Antonio 
Cancer Therapy & Research  Center 
[ADDRESS_1018468] MC8232  
Zeller Building - 4th Floor, Room Z4 l 8 
Page 2 of 3  San Antonio, TX [ZIP_CODE]  
 
E-mail: jeongw@uthscsa .edu 
Phone number: [PHONE_15526]  
Fax number: [PHONE_15527] 
 
 
NOW READS :  
Anand Kamad, M D 
Professor of Medic ine 
UT Health Scie nce Ce nter at Sa n Antonio 
Cancer Therapy & Research C enter 
[ADDRESS_1018469] MC8232  
Zeller Building- 4th Floor, Room Z4l 8 
San Antonio, TX [ZIP_CODE]  
 
E-mail: kamad @uthscsa .edu 
Phone number: [PHONE_15528] 
Fax number: [PHONE_15529] 
 
RATIO NALE:  Update p1in cipal investigator info rmation 
 
 
PREVIO USLY READ:  Page 37  
 
This is an investigator-initiated study. The principal investigator, Woondong  Jeon, g  
 
MD, who 
may also sometin1es be refen ed to as the sponsor-investigator, is conducting the study and acting 
as the sponsor. 
 
NOW READS : 
 
This is an investigator -initiated study. The principal investigator, Anand Karnad , MD, who 
may also sometimes be refen ed to as the sponsor-investigator, is conducting the study and acting 
as the sponso r. 
 
RATIO NALE : Update principal inves tigator info1m ation 
 
 
 
PREVIO USLY READ:  Page 41  
 
For questions regarding the eligibility of subjects,  Woondong  Jeong , MD, should be contact[CONTACT_299209] ([PHONE_15530] . 
 
NOW READS : 
 
For questions regarding the eligibility of subjects, Anand  Karnad , MD, should be contact[CONTACT_6811] 
([PHONE_15531] . 
Page 3 of 3  RATIO NALE:  Update princ ipal investigato r information  
CONFDI ENTIAL  CCTTRRCC## 1111--3366 
 
 
 
 
 
PROT OCOL NUM BER: 
PROTO COL TITL E: 
 
 
 
VERSIO N DATE: CTRC #11-36 
 
A Phase II Study of Induction Docetaxel , Cisplatin , Cetuximab and 
Bevacizumab (TPE-A) Followed by [CONTACT_744562] , Cisp latin, 
Cetuximab and Bevac iz umab (XPE -A) in Patients with Locally 
Advanced Head an d Neck Cancer  
 
[ADDRESS_1018470] 22, 2011 
Janmuy 4, 2012  
April 25 , 2012 
November 2, 2012 
Decembe r 19, 2012 
March 25 , 2013  
May 28 , 2013  
Decembe r 5, 2013  
Januaiy 14, 2015 
October 25, 2016  
 
PRINCIPAL I NVES TIGATOR: 
Anand Ka m ad, MD 
Professor of Medic ine 
UT Health Science Cente r at San Antonio 
Cance r Therapy & Research Center  
[ADDRESS_1018471] MC8232  
Zeller Building -4th Floor , Room  Z4l 8 
San Antonio, TX  [ZIP_CODE]  
 
E-mail: kainad @uthscsa.ed u 
Phone number : [PHONE_15528]  
Fax number : [PHONE_15529]  
 
BIO STATI STICIAN:  
Bradley Pollock, PhD  
UT Health Science Cente r at San Anto nio 
Depaitment of Epi[INVESTIGATOR_744486] [ADDRESS_1018472] Floor , Room 314 
San Antonio , TX [ZIP_CODE]  
 
E-mail: BPollock@uthscsa.e du 
Phone n umber : [PHONE_15532]  
Fax n umber: [PHONE_15533] 
 
CO-I NVES TI GATORS: See FDA  1572  
RECEIVED  
BByy RReegguullaattoorryy AAffffaaiirrss aatt 22::4422 ppmm,, OOcctt 2255,, 22001166 
CTRC at UTHSCSA 
CTRC# 11-[ADDRESS_1018473] ................................ ................................ ................................ .....................  4 
STUDY SCHEMA ................................ ................................ ................................ ................................ ....................  5 
1 BACKGROUND  AND  RATIONAL E................................ ................................ ................................ ................................ ....... 6 
1.1 Head  and Neck  Cancer.  ................................ ................................ ................................ ...........  6 
1.2 Chemotherap y for LocoregionallyAdvance d Diseas e ................................ ................................ ....... 6 
1.3 Comb inedModailty Therapyfor  OrganPreservation ................................ ................................ ................................ .... 6 
1.4 ConcomitantChem oradiotherapy  ................................ ................................ ................................ . 7 
1.5 RadiationplusCisplatin  for Locall y Advanced Head  and Neck Cance r ................................ ................................  7 
1.6 InductionChem otherapy  ................................ ................................ ................................ .............  9 
1.7 Cisplatinand Docetax el  ................................ ................................ ................................ ...............  9 
1.8 Epi[INVESTIGATOR_744487](rEGFR) and Cetuximab ................................ ................................ .................  10 
1.9 InductionChem otherapyFollowed by [CONTACT_744563] y  ................................ ...............................  18 
1.1O   Beva cizumabClinical Experienc e  ................................ ................................ ................................  19 
1.11 BevacizumabStudie s in Head and Neck Carcinoma at the University of Pi[INVESTIGATOR_106735] h  .............................  25 
1.12 Study  Rationale................................ ................................ ................................ ................................ ........................  25 
2 OBJECTIVES ................................ ................................ ................................ ................................ ................................ ................................ ...... 26 
2.1 Primary ................................ ................................ ................................ ................................ ................................ ....... 26 
2.2 Second ray ................................ ................................ ................................ ................................ ................................ ...........  26 
3 STUDYDESIGN ................................ ................................ ................................ ................................ ................................ ......................  26 
3.1 InductionTherapy (TPE-A) ................................ ................................ ................................ ................................ ......................  26 
3.2 Conc urrentRadiotherapy,Cisplati n, Cetuximaband Bevaczi umab(XPE-A)  ................................ ........  28 
3.3 RadiationTherapy  ................................ ................................ ................................ ................................ ..... 29 
3.4 Supp ortive Care  ................................ ................................ ................................ ........................  34 
3.5 Gastr otsomy Tubes  ................................ ................................ ................................ ....................  34 
4 SAFETY REPORTING OF ADVERSE EVENTS  ................................ ................................ ...................  35 
4.1 Definitions ................................ ................................ ................................ ................................ .........................  35 
4.2 Reporting  to IRB ................................ ................................ ................................ ................................ ...... 38 
5 STUDYSUB JECTS ................................ ................................ ................................ ................................ ............................  39 
5.1 Eligibility Criteria ................................ ................................ ................................ ................................ ...............  39 
5.2 ExclusionCriteria ................................ ................................ ................................ ................................ .......................  40 
6 PATIENTREGISTRATIO N  ................................ ................................ ................................ ..................  41 
7 DOSE MODIFICATION S- InductionDocetax el / Cisplatin/ Cetuxima b / Beva cizumab(TPE-A)  .....................  41 
7.1 HematologicTox icity (Docetaxel) ................................ ................................ ................................ ................................ .... 41 
7.2 Neurologic Toxicity (Docetaxel, Cisplaitn)  ................................ ................................ ......................  43 
7.3 Ototoxicity (Cispla itn) ................................ ................................ ................................ ................................ ................  43 
7.4 Gastr ointestinal Toxicity (Docetaxel, Cispl atin)  ................................ ................................ ...............  43 
7.5 Renal  Toxicity (Cisplatin) ................................ ................................ ................................ ................................ ........ 43 
7.6 Hepati c Toxicity (Docetaxel) ................................ ................................ ................................ ................................ ........... 44 
7.7 Hyperse ntsiviity Reaction s (Doceta xle)  ................................ ................................ ..........................  45 
7.8 Fluid Retention(Docetaxel)  ................................ ................................ ................................ .........  45 
7.9 Other Non-Hem atologi cToxicities  ................................ ................................ ...............................  45 
8 DOSE MODIFICATOI NS- Radiation plusCisplati n / Cetuximab/ Bevaczi umab(XPE-A)  ..............................  45 
8.2 Managementof CetuximabAd verseReactionsand  Dose  Modfiications ................................ .......................... 49 
8.3 BevacizumabDose Modfiicationand Toxicity Management.  ................................ ..........................  52 
8.4 Doce taxel-Assoc iatedHypersens tiivity Reactions ................................ ................................ ................................ ............  54 
8.5 Fluid Reten tionSyndrome  ................................ ................................ ................................ ...............................  55 
8.6 Hyperlarcimation ................................ ................................ ................................ ................................ ................................ .....................  56 
CTRC at UTHSCSA 
CTRC# 11-36 October 25. 2016 
- 2 - CONFDI ENTIAL  
 9 DURAT IONOF  THERAPY / WITHDRAWA L FROM  STUDY  ................................ ...............................  56 
10 DRUG FORM ULATIONAND PROCUREMENT   ................................ ................................ ................  56 
10.1 Docetaxe.l ................................ ................................ ................................ ................................ ................................ ...........  56 
10.2 Cisplafin (Cis-diaminedichloroplatin u,mCDDP)  ................................ ................................ ..............  62 
10.3 Carbo platin  ................................ ................................ ................................ ............................... 63 
10.4 Cetuxima b(C225, ERB ITUX)  ................................ ................................ ................................ ..... 65 
10.5 Bevacizuma b  ................................ ................................ ................................ ........................... 66 
11 CLINICALA ND LABORATORY  EVALUATIONS ................................ ................................ ................................ .................  69 
11.1 Evaluationsat  Screening / Baseline ................................ ................................ ................................ .............................. 69 
11.2 EvaluationDuringTreamt ent  ................................ ................................ ................................ ....... 70 
11.3 Evaluationsat  FollowUp  ................................ ................................ ................................ .............................  71 
12 SUBJECTDISCO NTINUA ITON ................................ ................................ ................................ ................................ ................  74 
13 STATISTICALM ETHODS  ................................ ................................ ................................ ................................ ...........................  74 
13.1 Sample  Size ................................ ................................ ................................ ................................ ................................ ...........................  74 
13.2 Analyses ................................ ................................ ................................ ................................ ................................ .... 75 
13.3 Defintiionof respons e  ................................ ................................ ................................ ................  75 
14 CORR ELATIVESTUDIES   ................................ ................................ ................................ .............  76 
14.1 Background  and Methods  ................................ ................................ ................................ ..... 76 
14.2 Material Subm ission ................................ ................................ ................................ ................................ ................................ .............  76 
14.3 Banking  ................................ ................................ ................................ ................................ . 77 
14.4 BloodCorrelativesfor Lavend eTr op and SerumRed Top Tubes  ................................ ......................  77 
14.5 Methods ................................ ................................ ................................ ................................ ................................ ................................ ..... 77 
14.6 Shipp ing ................................ ................................ ................................ ................................ ................................ ................................ ..... 78 
15 DATA  SAFETY  MON ITORING ................................ ................................ ................................ .............................  79 
16 RETENT IONOF RECORDS  ................................ ................................ ................................ ...... 83 
17 REFERENCES  ................................ ................................ ................................ ........................  84 
APPENDIX A: ECOG  Performance Status................................ ................................ ............................  91 
APP END IX B: Procedure for Obtaining a Urine Protein / Creatinine Ratio ................................ .... 92 
APPENDIX C: NCI  Commo n Toxicity  Criteria (CTCAE  v 4.0) ................................ ............................  93 
APPENDIX D: FDA MedWatch  3500a Form ................................ ................................ .........................  94 
APPENDIX  E: New  York Heart Associatio n (NYHA)  Guidelines ................................ .........................  95 
APPENDIX F: FACT  - H&N ................................ ................................ ................................ ...............................  96 
APPENDIX  G: AJCC  Staging System, 7th Editio n ................................ ................................ ................  100 
APPEN  DIX H: Gene  ntech Safety  Repo rting Fax Cover  Sheet. ................................ ............................  114 
CTRC at UTHSCSA 
CTRC# [ADDRESS_1018474] 
Locally  advanced  squamous  cell carcinoma  of the head  and neck  (SCCHN)  is ti-eated  with vaiious 
combi nations of radiation  and chemot herapy.  Docetaxel  and cisplatin have been  comb ined in Phase II 
trials in recun ent or meta static head  and neck  cancer  with very encoura  ging re sults. Induct  ion therapy  
with docetaxel/ci splatin fo llowed by [CONTACT_744564] s investigated in a randomized Phase II study 
in naso phaiyngea l cancer and showed superior PFS and OS in compa1 i son with chemoradiat ion alone. 
Cetuximab is a ch imerized EGFR monoclonal ant ibody that ha s produ ced po sitive results in Phase III 
trials in comb ination wi th either radiat ion for locally advanced d isease or chemo therapy for me tastatic 
disease. Upregulation o f vasculai·endothelia l growth factor (VEGF ) has been a ssociated with cetuxi mab 
resistance. Bevaci zumab, an anti -VEGF antibody is cutTen tly being investiga ted in SCCHN with 
promi sing results . Two trial s of bevac izumab -based regimens ai·e being conducted at UPMC (UPC I 
05-002 and UPC I 05-087) with ve1y promi sing results. We have previously shown that cisplatin , 
docetaxel  and cetuximab  (TPE) followed  by [CONTACT_114658] , cisplatin  and cetuximab  (XPE) is feasible and 
highly  efficac ious in locally  advanced  SCCHN  (UPC I 05-003, presented at ASCO  2008 ). In this Phase II 
study we evaluate  the addition  ofbevacizumab  to induction  thera py with TPE (TPE-A) and to subsequent 
XPE  (XPE-A). 
Specific aims 
To eva luate the rate of complete responses with induction therapy (primaiy endpoint ) and progre ssion­ 
free survival, overall survival and object ive response  rates. Also , we plan to investigate a pane l of EGFR 
and angiogene sis biomarker s in pre - and post- tt·eatment tutnor b iopsies. Finally, we will evaluate the 
associated treatment  toxic ities and the quality ofl ife. 
Subject population  
We will emoll patients with previou sly untreated  locally advanced  SCCHN  (see detai led eligibility 
criteria). 
Treatment plan  
Induction therapy consists of 3 cycle s of bevac izumab 15mg/kgon day 1, cetux imab weekly day s 1, 8, 15 
(loading do se of cetuximab 400mg/m2 on cycle 1 , day 1, then 250 mg/m2  on all subsequent 
administt·ation )s, cisplatin 75mg/m2 on day 1,  docetaxe l 75mg/m2 on day  1, repeated eve1y [ADDRESS_1018475] radiation 70-74 Gy/ 200 cGy/ daily, 5 days/ 
week w ith concmTent weekly cisplatin 30m g/m2, cetuximab 250mg/m2 and beva cizumab 15 mg/kg eve1y 
3 week s x 3. There is optional smge1y for non -responders in the primaiy (stable disea se) after TPE-A. 
Statistical design and sampl e size 
Phase II, two-stage study with co mplete re sponse r ate afte r induction therap y as the p1imaiy endpoint. 
The sainple size is 33 patient s. 
CTRC  at UTHSCSA 
CTRC#  11-36 October 25,  2016  
- 5 - CONFI DENTIAL  
 *Selec ted patients who undergo  comple te resection  will recei ve postoperative  doses up to 66 Gy • HPV  testing  for all patients.  Patients who are HPV  positive  or pl6 positive  and have  smoking histmy  
:::;10 pack -years are no t eligible . Tumor biopsies at baseline (optional ) and on cycle 1 , day 21 
(plus /minus 2 days ) (optional) 
• Blood samp les at baseline (mandatory) , after cycle 1 (before staiting cycle 2) and after cycle 3 of 
induction  therapy  (the week  prior  to staiting  radiation ,)8 weeks  after completion  of radiation  and at six 
months  after  comp letion  of radia tion therapy.  
• G-CSF prophy laxis during  induc tion (recommended ), Neulasta  on day 2 or Neupogen  on days  2-11, or 
ciprofloxacin  500 mg BID days  5-14. 
• PET/CT at baseline , after 3rd cycle  (befo re start ofradiation)  and 8 weeks after  RT completion  *after loading  dose  of 400 mg/m2 R Every  21 daysx  3cycles E PS 0-1  Cis platin  75 mglm2 , day 1 T ! 
_,. Cetuximab  250 mg/rn2  days1,8,15• -+ s I 111-I VB 
SCCHN  Docetaxel 75 mglm2 , day1 G Stage  Bevacizumab  15mg/Kg  day 1 R 
 
   E 
Radia tion x 7-8 weeks (70-74Gy )* 
 
 
Bevacizumab15  mg/Kg  Q 3w 
Cetux imab 250 mg/m2  weekly 
Cis platin  30 mg/rn2  weekly  Response assessment by [CONTACT_10052]/CT . 
 
Surgery for pat ientswith stable disease in primary 
tumor (opti onal)  
 
STUDY SCHEMA  
 
 
 
CT RC at UTHSCSA 
CTRC#  11-36 October 25.  2016  
- 6 - CONFDI ENTIAL  
 - 
.  
 
 
 
1 BACKGROUNDAND  RATIO NALE  
 
1.1 Head and Neck Cancer 
More  than 45,000 new cases  of head and neck  cancer  are diagnosed  annually  in the [LOCATION_002]1. Of 
these  patients, two-thirds  present  with locoregionally  advanced  disease  (AJCC  stage  III or IV) and one­ 
third with early stage  disease  (AJCC  stage  I or II) . At presentat ion 10%  of patients  may be found  to have 
involvement of distant organs , most commo nly the lung. In addition, 20% of patients will deve lop 
clinica lly detected distant metastases over the course of their disease . In autopsy series up to 50% of 
patients with head and neck  cancer  are found to have  metastases2•3. Approx imately 90%  of all head  and 
neck  malignancies  are squamous  cell carcinomas.  The vast major ity of head  and neck  malignanc ies can 
be attr ibuted to the use of tobacco and alcohol. Human Papi[INVESTIGATOR_744488] a 
significant portion  of oropharyngeal  squamo us cell carcinomas75 77. Due to their  frequent histo1y  of 
exposure to tobacco and alcoho l patients with head and neck cance r are in high risk fo r other 
comorb idities associated with tobacco and alcoho l, such as corona1y aite1y disease , chronic obst rnctive 
pulmona1ydisease , and liver disease4. In addition, they ai ·e at high 1isk for the development of second 
primaiy t umors , synchronous or metac hronous , that may involve the head and neck region as well as 
other organs , predominan tly the lungs5 
1.2 Chemotherap y for Locoregionall y Advanced Disease 
The addition of chemotherapy with RT to the overa ll treatment p lan in pat ients with locoreg ionally 
advanced head and neck cance r has been studied in an effort to improve o rgan prese 1vation, locoregiona l, 
and distant control, and srnvival rates ove r RT alone. Reseai ·ch studies have evaluated the use of induction 
(neoadjuvant) or adjuvant chemothera py, as well as conc01nitant chemotherapy and radiation . The 
primaiy  goal of such research  is to improve  local contro l and srnv ival. 
1.3 Combin ed Mod ality Therapy for Organ Preservation 
An imp01tant goal of adding chemothera py to radiat ion therapy is to improve local contro l and avoid 
mutilating surge 1y , therefore , achieve organ prese1vation in pat ients  with resectab le disease. Two-phase 
III randomized tiials , one by [CONTACT_744565]1yngeal Study Group and the other by [CONTACT_152853] , showed that organ 
prese 1v ation is feasible in la1yngea l and hypo phaiyngeal cancers . In both studies, induction chemothera py 
with cisplatin and 5 -FU followed by [CONTACT_744566] a llowed for organ prese1vation 
witho ut a comprolnise in srnvival compai·ed to standard management with surgica l resect ion fo llowed by 
[CONTACT_744567]6.7. Howeve r, one-third or more o f patients req uired laiyngectomy for t reatment 
failure. In the VA laiyngea l cancer study, the laiynx was prese1ved in 64% of all patients ass igned to the 
induction chemotherapyaim , whereas in the EORTC ti"ial, in wh ic h a complete response was mandato1y 
to proceed  with organ  prese1vation,  the 5-yeai· srnviva l with a functioning  la1ynx  (censo  li ng data for local 
failures only) was 35%, if all patients (n=l OO) who received induction chemotherapy were considered, 
and 58% , if only the group of [ADDRESS_1018476] RC at UTHSCSA 
CTRC#  11-36 October 25.  2016  
- 7 - CONFDI ENTIAL  
 - 
. 
• • • . 
- • • .  
 
A multicenter  phase III randomized  study  evaluated the role of concomitant  chemoradiation  in lruyn  gea l 
cancer  (RTOG 91-11)8. T his th ree -aim study compru·ed  the orga n preservat  ion strategy  used in the VA 
lruyn  gea l study  to radiotherapy  alone  (without  induction chemotherapy) , and to concomitant  
chemorad iotherapy w ith single-agent c isplatin. Although no differences in survival were observed 
between aims , laiyngea l prese rvation was optimal in the concom itant chemoradiation treatmenta im. 
Therefo re, concwTent che morad iation is now conside red the standru·d  regimen  for organ  prese1vation  in 
the management o f la1yngeal  cance r. 
1.[ADDRESS_1018477] used infus ional 5-FU as 
the radiosensitize r based on wo rk initially p ublished by [CONTACT_744568]11 . The add ition of cisplati n12•13 , or 
cisplatin with 5 -FU / leucovorin and hype rfractionated radiotherapy14, or hydroxyurea15 [ADDRESS_1018478] led to ve1y enco uraging response and smv:ival data. In a randomized study , Merlano et al17 
demonstrated signific antly inc reased swvival in patients with unresectab le disease treated with 
radiotherapy alternating w ith cisplatin and bo lus 5-FU com pared to patients t reated with radiotherapy 
alone. 
A meta-analysis that incl uded 63 ra ndomized stud ies cond ucted betwee n 1965 and 1993, demonstrated an 
absol ute swv ival benefit o f 8% at 5 yeru·s with conc [ADDRESS_1018479] co nclusively 
demonstrated that conc wTent chemorad iotherapy is supe rior to radiation therapy a lone in locall y 
advanced head and neck cance r8•1·[ADDRESS_1018480] of these studies favored conco mitant chemorad iotherapy with an approxi mately 20% gain in 
swvival at three  to five years  (approxi mately 30%  versus 50%) , whereas  the study  by [CONTACT_744569]24 
showed  that concomitant  chemoradiotherapy  with cisplatin in resectab le la1yngea l cancer  is supe1ior  in 
tenns of la1yngeal prese1 vation8 
1.[ADDRESS_1018481] estab lished conventional  radio therapy plus cisplatin 100 
mg/m2 eve1y 3 weeks as the standai·d non-surgical treatment ofl ocally advanced head and neck cancer. In 
unresectab le disease  and nasopha1yngeal  cance r a smv ival advantage  was demo nsti·atedover  radiotherapy  
alone22 23 , where as in la1yngea l cance r, concmTent chemoradiotherapy with cisplati n resulted in a h igher 
rate of organ prese1vat ion8 
For unresectab le head and nec k squamous ce ll carcinoma, concmTent chemoradiotherapy has emerged as 
standru·dtherapy after the results of a randomized phase III tt·ial conducted by [CONTACT_744570] (SWOG) and Eastern Cooperat ive Oncology Group (ECOG)23. This t rial enrolled [ADDRESS_1018482] RC at UTHSCSA 
CTRC#  11-36 October 25.  2016  
- 8 - CONFDI ENTIAL  
 . 
. 
,2  
 
with umesectable s quamous ce ll head and nec k cancer , before closing to s low accrual. So far , it is the 
only study that has a llowed a comparison , even indirectly, between single and combination 
chemot herapy.  Three treatment  anns  were compared:  (A) convent ional radiotherapya lone (70 Gy at 2 Gy 
per day); (B) conventional radiotherapy plus single -agent cisplatin 100 mg/m2 eveiy 3 weeks; and (C) 
split course radiothera py with conc utTent cisp latin 75 mg/m2 on day 1 and 5-FU 1000 mg/m2/d as a 
contin uous infus ion, on days  1-4, repeated  eveiy  4 weeks . Preliminaiy  results  showed  an improveme nt of 
3-yeai· overall s urvival with single-agent cisplatin compai·ed to radiotherapy alone , from 20% to 37% 
(p=0.016). Survival rates  between  the two chemot herapy arms and between  CRT and radiotherapy  alone 
were not significan tly diffe rent. Spl it course radiotherapy has been implicated for the subopt imal 
perfoimance  of the cisplatin and 5-FU aim in this  study. 
In laiyngeal cancer , RTOG 9 1-11 showed that the o ptimal laiyngeal preservat ion strategy is conc utTent  
chemorad iotherapy8 This three -aim study, the goal of which was to dete imine whether the add ition of 
chemot herapy to radiotherapy is necessaiy to achieve laiyngeal preservation , compa red the laiyngea l 
preservat ion strategy used in the VA laiyngea l study consisting of induction chemotherapyw ith cycles of 
cisplatin and 5-FU, followed by [CONTACT_744571]  (aim A) to concut Tent chemoradiotherapy 
with cisplatin 100 mg/m2 administered eveiy three weeks (aim B),  and radiotherapy  alone  (aim  C).  A 
total of 510 patients were analyzab le, and the median follow-up at the time of preliminaiy analysis was 30 
months. Sixty-five perce nt of patien ts received a ll three cycles o f single-agen t cisplatin during concutrnnt 
chemoradio therapy. Grade 3 o r 4 mucosit is was seen in 33% of patients in aim  A,  53% in rum B , and 
36% in rum C . An advantage in overall survival could not be demonstrated w ith the use of chemotherapy , 
in spi[INVESTIGATOR_232221] a decre ase in the rate of dist.ant  metas tasis; howeve  r, lruyn  gec tomy -free sutvival  and lruyn  gea l 
preseiv  at ion rates  were  higher  in the concutTent  chemora  diotherapy  aim. At 2 yeru·s , lruyn  gectomy -free 
sutvival rates were 58%, 68% (p=0.07 versus A) , and 53% , and la1yngea l preseivat ion rates 7 4%, 88% 
(p=0.0047 versus A), and 69% for aims A, B, and C, respectively.  
ConcutTent chemoradiother apy w ith cisplatin has beco me standa rd therapy o f locally advanced 
nasop ha1yngeal c arcinoma25. Updated results o f the Intergro up ttial in nasophruyn gea l cru·c ino ma 
demonstt ·ated a 5 -ye ar sutv ival of 67% versus 37% (p<0.00 1) and a 5 -year P FS of 59% versus 29%  
(p<0.001) fo r patients tt·ea ted w ith chemoradiotherapy versus radiotherapy alo ne26  Toxicities with 
concut Ten t therapy were increased but tolerable. Treatment de liveiy of adjuvant chemotherapy was 
subopt imal; 33%  of patients  received no adjuvant chemotherapy.  Also, only two-thirds of patients could 
receive  all three doses  of concu n ent cisplatin , a finding  cons istent among  randomize d studies  with this 
regime n (e.g. laiyngeal R91 -l l and  R95-01). 
While radia tion plus high -dose cis platin (i.e. 100 mg/m2 eveiy 3 weeks x 3 during radiation) has become  
a st.andat· d regimen  for the tt·eatment ofl ocally  advance d SCCH N,8 24   5,  this regimen  result s in 
considerable  toxicities, includ ing grade  3-4 mucosi tis in about 50%  of patien ts as well as in several  out­ 
of-field toxic ities, in cluding nausea/vomiting,nephrotoxic ity and others . As noted, about one-third of 
patients  cannot  receive  the third cisplatin dose  due to the onset of toxicities. This obseivation  had led 
many groups to either red uce the dose of cisplatin to 75 mg/m2 eveiy 3 weeks (for exam ple, ongoing 
ECOG  study  E3303) , or to use lower  dosages  on a weekly schedule of admin istration  when  cisplatin is 
combined  with other agents  and RT. In chemoradiotherapy  regimens, weekly  cisplatin doses  of 20-[ADDRESS_1018483] RC at UTHSCSA 
CTRC#  11-36 October 25.  2016  
-9 - CONFIDENTIAL   
 . 
- _ 
_ · · . 
· . 
· · -4  
 
mg/m2 have  been  previously  investigated  and well tolerated . Low  dose  weekly cisplatin  (20 mg/m2 alone 
combined  with radiation  did not result in a smvival  benefi t in a phase III trial that compared  radiation  plus 
cisplatin with radiat ion alone28. A weekly cisplatin do se of20 mg/m2 used incombination with paclitaxel 
and RT was shown  to be feasible  and active  in an RTOG  study29 . Weekly  cisplatin  40 mg/m2 with RT, 
showed  improved  smvi val over radiation  alone in patients  with locally  advanced  nasopharyngea l cancer30 
A weekly  cisplatin  dose  of 30 mg/m2 was employed  in combinat ion with cetuximab  and RT in a recently 
completed  phase  II randomized  trial by [CONTACT_111527]  (0234 )31 . 
The optimal chemotherapy reg imen fo r incorporation into combined modality therapy ha s yet to be 
determined. It is unclear whethe r combination c hemothera py regimens are superi or to single -agent 
chemotherapy in this setting. 
1.6 Induction  Chemotherapy  
Induction  chemotherapy  has the goal of "downstag ing" the tumor  but more  importantly  to eradicate  early 
micrometa static disease and therefore  improve  distant -site control.  The rationale for using  this 
investigational  approac h has been  revie wed4 [ADDRESS_1018484]  regimens are used for 2 to 3 cycles, including the 
widely used combination o f cisplatin and continuou s infusion 5-FU29  34    The response rates for untreated  
patient s with locally  advanced  head  and neck  cancer  range  between  60-90% , with comp lete response rates 
of 20-50%35. Pathologic complete responses are documented in two-thirds of patients with a clinical 
complete response , and this is associated with a favorab le progno sis35. The toxicity from induction 
chemotherapy is considerable though and severe and, occas ionally, fatal toxicity may occm with the 
cisplatin and 5-FU regimen,  or other  regimens. 
In the past decade , multiple randomized studies have compared induction chemotherapy fo llowed by 
[CONTACT_744572] l treatment  versus immediate  locoregiona l treatment35. Onl y one s tudy , conducted 
by [CONTACT_744573], which included patients with oropha1yngeal cancer, demon strated a smvival 
bene fit with neoadjuvant chemothera py versus locoregiona l therapy a lone36. In addition , subset analys is 
of two other randomized studies showed a smvival advantage with induction  chemotherapy37 [ADDRESS_1018485] failme6 7 37.39 2 _ In order to improve the efficac y of induction therap y, 
newe r combinat ion regimen s (e.g. taxane -based) are c mTently being evaluated in this setting. 
1.[ADDRESS_1018486] been comb ined in phase II ttials in recmrent o r metastatic head and neck  
cancer. The regimen is active with response rate between 33 -54%43-[ADDRESS_1018487] comparab le to the 
activi ty of cisplatin/5 -FU and cisplat in/pac litaxel in the recmTent/meta  static disease  setting.  Cisplatin and 
docetaxe l is well tolerate d even in the palliati ve care setting. The FDA has approved c isplatin and 
docetaxe l for first-line therapy  of meta static NSCLC . The commonly  used doses  are 75 mg/m2 for each 
dtug on day 1. A phase  II tt·ial  of cisp latin and docetaxel  conducted  by [CONTACT_744574]01ted  an object  ive 
response  rate of 89%  in 22 previously untreated  patients  with locally  advanced  or recmTent head and neck ) 
CT RC at UTHSCSA 
CTRC#  11-36 October 25.  2016  
-10 - CONFIDENTIAL   
 • . 
• .  
 
cancer44. Another study repo1ted a response rate of 55% in patients with stage IV, locally advanced , head 
and neck cancer46. Severa l randomized studies have shown that triple combination with cisplatin/5 - 
FU/docetaxel (TPF) impro ves overall s urvival (OS) and progression - free survival (P FS) in compaiison 
with the combination of cisplatin/5 -FU (P F)73 74 
A recently publi shed randomized phase II study investigated the addit ion of induction cisp latin and 
docetaxel to chemoradiotherapy for locally advanced nasophatyngeal cancer. Among 65 eligible patients 
with advanced nasopha1yngeal cai·cinoma, 34 patients received neoadjuvant docetaxe l 75 mg/m2 and 
cisplatin 75 mg/m2 eve1y 3 wee ks for 2 cycles followed by [CONTACT_181615] 40 mg/m2/ weekly concmrnnt w ith 
radiation , whereas 31 patients were randomized to receive the same chemoradiotherapy without induction 
therapy . Patients who recei ved induction therapy had superior PFS and OS 78. 
1.8 Epi[INVESTIGATOR_209839]  (EGFR)  and Cetuximab  
 
1.8.1 EGFR  
The epi[INVESTIGATOR_744489] (EG FR) is a member of the erb B receptor tyros ine kinase family 
that also include s erbB ,-2 erbB -3, and erbB -428. It cons ists of an extracellulai· ligand -bindin g domain , a 
transmembrane region that anchors the recepto r to the plasma membrane , and a cytoplasmic re gion 
containing a tyrosine kinase domain. Among the known natural ligands of EGFR include epi[INVESTIGATOR_744490] (EGF ) and transfonning growth factor a, (TGF -a) which both activate the receptor by 
[CONTACT_744575]1ation of receptor homodimers  or heterodimers , 
followed by [CONTACT_744576]/ligand complex and au to-phospho1y lation . It is now accepted 
that the EGFR signa l transduction network plays an imp01tant role in multiple tum01igenic processes , 
includ in g cell cycle progress ion, angiogenes is, and metastasis , as we ll as protection from apop tosis28•29. In 
this signal netwo rk, erbB-2 is the major paitne r of EGFR because activated heterodimer complexes 
containing e rbB-2 are more stable at the cell smface than complexes containing other EGFR fami ly 
members30 31 In addition erb B -2 can decrease the rate o f ligand dissociation from the cognate receptor  
• . 
EGFR32. 
 
1.8.[ADDRESS_1018488]  epi[INVESTIGATOR_744491]  , A43 1 
squamous epi[INVESTIGATOR_744492]·cinoma cells, and DU145 prostatic cancer cells . These studies suggest that 
blocking EGFR with monoclonal antibodies s uch as cetux imab leads to cell cycle atTest in G1 which is 
accompanied by a decrease in cyclin dependent kinase (CDK) 2 activity , and an increase in the express ion 
of CDK inhibit or p27K1Pl33 34 In addition to inducing GI-phase atTes ,t EGFR blockade was a lso shown  
to lead to cell death v ia apoptosis in DiFi colon adenocarc inoma cells35. 
1.8.3 Cet11ximab  
Cehtximab  binds specifica lly to the epi[INVESTIGATOR_5328]1mal  growth  factor  receptor  (EGFR , HERi  , c-ErbB -1) on both 
nonnal  and tumor  cells , and compet itively  inhibits  the binding  of epi[INVESTIGATOR_5328]1mal  growth  factor  (EGF)  and 
other  ligands , such  as transf01ming  growth  factor - alpha36. Binding  of cehlxim ab to the EGFR  blocks 
phosph01ylation  and activation  of receptor -associated kinases,  resul ting in inhibition  of cell growth , 
CTRC at UTHSCSA 
CTRC# 11-[ADDRESS_1018489] s hown that cetuxi mab inhib its the growth and survival of 
tumor ce lls that over-express the EGFR. No anti-ttllllo r effects of cettIXimab we re observed in h1llllan 
tumor xenografts lacking EGFR expression . The addit ion of cettIXimab to i1inotecan or iti notecan plus 5- 
fluorouraci l in animal stud ies resulted in an increase in anti -tumor effects compared to chemotherapy 
alone.  
1.8.4 Hum an Phar macokinetics 
Cetuximab administe red as monotherapy or in combination wi th concomitant chemotherapy or 
radiotherapy  exhibits  nonlinear  phaim acokinetics36 The ai·ea  unde r the concentrat ion time curve (AUC) 
increased  in a greate r than dose  proportiona l manner  as the dose  increasedfrom  20 to 400 mg/m2 . 
Cetuximab cleai·ance (Cl) decreased fro m 0.08 to 0 .02 L/h/m2 as the dose increased from 20 to 200  
mg/m2, and at doses >200 mg/m2, it appeai·ed to plateau. The volume o f disttib ution (Vd) for cetuximab 
appeai·ed to be independent o f dose and approx imated the vascular space of 2-3 L/m2 
Following a 2-hour infusion of 400 mg/m2 of cetuximab , the maxim um mean semm concentration  
(Cmax) was 184 µg/mL (range: 92-327 µg/mL) and the mean elitninat ion half -life was 97 hours (range 
41-213 hours) . A I-hour infusion of 250 mg/m2 produced a mean Cmax o f 140 µg/mL (range 120-170 
µg/mL) . Following the recommendeddose regime n (400 mg/m2 initial dose /250 mg/m2 weekly dose), 
cetuximab concent rations reached steady -state levels by [CONTACT_12043] w ith mean peak and 
trough concentt·a itons across  studies ranging from  168 to 235 and 41 to 85 µg/mL, respective ly. The mean 
half-life was 114 hours  (range  75-188 hours) . 
Cen1ximab administe red as monotherapy or in combination wi th concomitant chemotherapy or 
radiotherapy exhibits nonlinear phaim acokinetics.The phaimacokinet ics of cen1ximab were similai·in 
patients with squamo us cell carcinoma  of the head  and neck  (SCCHN)  and those  with colorecta l cancer36 
 
 
1.8.5 Randomized Clinical Trials  of Cetuximab in Head and Neck Cancer 
 
[IP_ADDRESS]  Cetuximab in Locall y Advanced Squamous Cell Carcinoma of Head and Neck  
The e fficacy and safety of cetuximab were studied in combinatio n with radia tion therapy in a randomized , 
contr olled ttial of 424 patients with locally or regionally  advanced  squamous cell cai·cinomaof the head 
and nec k versus rad iation alone38. In a mu lticenter contt·olled clinical ttial, 424 patients with stage III/IV 
SCC of the orophaiyn x, hypopha1yn x, or laiyn x with no p1ior  thera py were randomized  1:1 to receive 
cetuximab plus radiation therapy (211 patients) o r radiation therapy a lone (213 patients). Stratification 
factors were Kamo fsky Performance Status (60-80 versus 90-100), noda l stage (NO vers us N+), tumor 
stage ( Tl -3 versus T4 using Ame rican Joint Committee on Cance r 1998 staging c1i te1ia) , and rad iation 
therapy fractionation (concomitant boos t versus once -daily versus twice daily) . Radiation therapy was 
administered fonn 6-[ADDRESS_1018490]. T he planned radiat ion . 
CTRC  at UTHSCSA 
CTRC#  11-[ADDRESS_1018491] ion  was recommended . Staiting 1 week before radiation, cetuximab 
was administe red as a 400 -mg/m2 initia l dose , followed by 250 mg/m 2 weekly for the duration of 
radiation therapy (6-7 weeks). All cetuximab -treate d patients received a 20-mg te st dose on Day 1. 
Cetuximab  was admin istered  1 hour  p1ior  to radiation  therapy , beginning  week  2. Of the 424 randomized 
patients, 80% were male and 83% we re Caucasian . The median age was 57 yeai·s (range 34-83). There 
were 258 patient s enrolled in US sites (61%) and 166 patient s (39%) in non-US sites. Ninety percent of 
patient s had basel ine Karnofsky Perf01mance Status 80%; 60% had orophaiyn geal, 25% laiyn geal, and 
15% hypophaiyn geal p1imaiy tumor s; 28% had AJCC T4 tumor stage. The patient characte1istics were 
similar across the sn1dy aims . Fifty-six percent of the patients received  radiation therap y with 
concomitant boost , 26% received once -daily regimen, and 18 % twice -daily regimen . 
The main outcome measure oft his tiial was duration ofl oco regional control. Overa ll surviva l was a lso 
assesse d. Results are presented below:  
Table 1 Clinical Efficacy in Lo coregionall y Adva nced SCCHN  
 
 Cetuximab + 
Radia tion 
(n = 211)  Radiation 
Alone  
(n = 213)  
Hazard Ratio 
(95% CI*) Stratified 
Log-rank 
p-value  
Locoregional control 
MedianDura tion  
24.4 mo  
14.0mo   
0.68 (0.52-0.89)  
0.005 
Overall Survival 
Mediandur ation  
49.0 mo   
29.3 mo  
0.74 (0 .57-0.97)  
0.03  
*Cl = confide nce inteiva l. 
 
[IP_ADDRESS]  Cetuximab  in Recurrent  or Metastatic  Squamous  Cell Carcinoma  of the Head and Neck  
More recently  the results of EXTREM E t:rial47 have been  repo 1et d. In this multicente r study 442 patien ts, 
with unti·eated recunent or metastatic squamou s cell carcinoma of the head and neck, enro lled. 220 
patients were randoml y assigned to receive cisplatin (at a dose of 100m g/m2, on day 1) plus 5FU (at  a 
dose of 1000m g/m2, for 4 days) eve1y three weeks for a maxim um of 6 cycle s and 222 patients to receive 
the same regime n plus  cetuximab (at an initia l loading dose  of 400mg/ m2,  then weekl y doses  of 
250mg/m2) for 6 cycles . Patients who didn't progress continued monotherapy of cetuximab until disease 
progression . The pa tients in each coho1t were well- balanced regard ing gender , age, pe1formance  status  
(PS, )  primaiy tumor site, exten t of disease  and histologic type. About ninety  perce nt of the patien ts had 
PS> 80% . Results are pre sented below: 
CT RC at UTHSCSA 
CTRC#  11-36 October 25.  2016  
- 13 - CONFIDE NITAL  
  
 
Table 2 Clinical Efficacy in Loc oregionall y Advanced SCCHN  
 
  
Cetuximab  
+ chemo  
 
 
Chemo Alone Hazard R affo or 
Odd s Ratio  
(95%  CI*)  
 
 
p-value 
Overall survival 10.1 mo  7.4mo  0.80 (0.64 -0.99 ) 0.04 
Progrt>ss i o n Free 
Survival  
5.6mo   
3.3 mo  
0.54 (0.43 -0.67)  
<0.001  
Time to treatment 
failu re  
4.8mo   
3.0mo   
0.59(0.48 - 0.73)   
<0.001  
 
Disease control  
81% (75-86%)   
60% (53-67%)  Odds Ratio 
2.88 (1.87 -4.44)  
<0.001  
*Cl = confidence interval.  
A phase ill tlial ofradiation cisplatin w ith or without cetuximab is ongoing in the R TOG (0522 ). 
 
1.8.[ADDRESS_1018492] dose  of cetuxima b on Day 1, followed  by a 400-mg/m2 
initial dose, and 250 mg/m2 weekly  until disease  progre ssion or unaccep table toxicity . Upon  progres sion, 
patients  were  given  the option ofr eceivingcetuximab  plus the platinum  regimen that they failed p1i or to 
emollment. Tumo r response and prog ression were assessed by [CONTACT_744577]  (IRC). The median  age was 57 years  (range  23-77), 82%  were  male , 100% Caucas ian, and 
62%  had a Kamofsky  perfmmance  status  of 80. The objective  response  rate on the monotherapy  phase 
was 13%  (95%  confidence  interval  7%-21%). Med ian duratio n of response was 5.8 months (range  1.2-5.8 
months ). 
A phase II study conducted at Memorial -Sloan Ketter ing Cancer Center explored the combination o f 
radiation, cisp latin, and cetuximab49. This study employed altered fractionatio n radiotherapy with 
accelerated boost. There were 2 deaths during treatment (one patient died of pneumonia and the other 
from  unknown  cause) in a total of 22 patients  and 3 other  out-of field serious adverse  events  (arrhythmia , 
myocru·dial  infarction  , and bacteremia) . However , the progress ion-free surviva l was prom ising (80%  at 2 
yeru·s)49 .  It was thought that a lower  dose  of cisplati n than 100 mg/m2 would be safer with this 
combination  regimen . A phase  II study  with cisplatin, radiation , and cetuximab  was comp leted in ECOG 
(E3303 ). This study employed  a lower  cisplatin  dose  of75  mg/m2eve1y  3 weeks  x 3. 
Expe1ience with TPE followed by [CONTACT_744578] o f Pi[INVESTIGATOR_744493]1i ence  at the Unive rsity of Pi[INVESTIGATOR_744494],  docetaxel,  and cetuximab  (TPE). This phase  II tlial (UPC I 05-003)comp letedacc rnal of [ADDRESS_1018493] been presented at ASCO 2008 (abst1·act 6002) and the manu script was 
published in JCO in 2010 (Argiris et al JCO 2010) . The treatlnent regimen consisted of 3 cycles of 
induction  (TPE) therapy  with docetaxel  (T) 75mg/m2 dl , cisplatin  (P) 75mg/m2 dl and cetuximab  (E) 
CTRC at UTHSCSA 
CTRC# 11-36 October 25.  2016  
-14 - CONFIDE NIATL  
  
 
dl ,8,15 (q21d) followed  by (XPE)  RT (X) 70Gy , cisplatin (P) 30mg/m2 weekly and then cetuxi mab (E) 
main tenance for 6 months. Treatment was assoc iated with expected and manageab le toxic ities.. Of 39 
emolled patients, 36 had stage IV disea se and 23 an oropha1yngeal  p1ima1y.Acute  toxic ities during TPE 
included neutropenic fever (10 %) and dmi ng X PE, grade 3 or 4 ora l muco sitis (54%) and 
hypomagneselnia  (39%). After TPE, we obse rved two comp lete responses (CRs) and 30 partia l response s 
(PRs), overall  response  rate (ORR) of 86% (95% CI, 75% to 98%) in 37 evaluable patients. The comp lete 
response using  PET p01tion  of PET/CT was 21%. After  XPE, we observed  an ORR  of 100% (95% CI, 
91% to 100 %), 24% CRs and 76 % PRs, in 33 eva luable patients. In another pa per by [CONTACT_744579] 
(Annals  of Oncology  2010;21:2278 -83), we demon strated  that reposnse by [CONTACT_744580] 
1.0 con elated  with progre ssion-free survival.  With a median  follow-up of 36 month s, 3-year progression­ 
free smvival and overa ll smvival were 70% and 74 %, respectively. Eigh t patients progre ssed in 
locoregio nal sites, three in distant, and one in both. HPV positivity was not a ssociated with t reatment 
efficacy . No progre ssion-free patient remained G-tube depe ndent. The H&N subscale QOL scores 
showe d a significant decrement  at 3 months  after  XPE, which  normalized  at I year. We concluded  that 
this cetuximab -containing  regime n resulted in excellent long-te1m smv ival and safety , and wa1rnnts 
fmther evaluation  in both HPV -positive and -negative head  and neck  cancer. 
Safety  of Cetuximab in Clinical  Tti als 
[IP_ADDRESS]  Anticipated Adverse Events  
Squamous Ce ll Cance r of the Head and Nec k 
Except where indicated , the data desc1ibed below reflect expo sure to cehlximab in 208 pat ients with 
locally  or regionally advanced  HNSCC  who received  cetuximab  in combination  with radiation  and as 
monotherap y in I 03 patients w ith recmrnnt or meta static HNSCC. Of the 103 patient s receiving 
cetuximab mono therapy , 53 contin ued to a second phase with the combi nation of ceh1ximab plus 
chemotherapy . Patients receiving cetux imab plus radiation therapy  received a median of 8 doses (range  1- 
11 infusion s). The population had a median age of 56; 81% were male an d 84% Caucas ian. Patients 
receiv ing cetuximab  mono therapy  received  a median of 11 doses (range  1-45 infosions). The population 
had a median age of 57; 82% were  male  and 100% Caucasian. 
The most se1·ious adverse reactions associated  with cetuximab in combination with radiation therapy in 
patient s with head and neck cancer  were: 
• Infusion react ion (3%) 
• Cardiopulmona 1y  atTest (2%) 
• De1matologic toxic ity (2.5%) 
• Mucositi s (6%)  
• Radiation de1matitis (3%) 
• Confosion  (2%) 
• Dian hea (2%) 
• Fomteen (7%) patients receiving ce tuximab p lus radiation therapy and 5 (5%) patient s receiving 
cetuximab monotherapy , disco ntinued treatmen t primai ·ily because o f adver se events 
• The most comm on adverse events seen in 208 patients receiving cetuximab  in combinat ion with 
radiation  therapy were acnefonn  rash (87%), mucositis (86%), radiation  de1mat itis (86%), weight / 
CT RC at UTHSCSA 
CTRC#  11-36 October 25. 20 16 
- 15 - CONFI DENTIAL  
  
 
loss (84%), xeros tomia (72%) , dysphagia (65%) , asthenia (56%) , nausea (49%) , consti pation  
(35%) , and vomiting (29%)  
• The most  common  adve rse events  seen in 103 patients receiving cetuxima b mono therap y were 
acnefonn  rash (76%) , asthenia  (45% ), pain (28%) , fever  (27% ), and weight  loss (27%).  
 
The da ta in the table that follows a re based on the expe rience of 208 patient s with locoregiona lly 
advanced HNSCC treated with cetuximab plus radia tion therapy compared to 212 patients treate d with 
radiat ion therapy a lone. 
Table 3 Incid ence of Selected Adve rse Events ( 10%) in Patients with L ocoregio nally Advanced HNSCC  
 
 
 
 
Body Syste m 
Prefened Tenn  Cetuximab plus Radiation  
(n=208)  RadiationTherapyAlone  
(n=212) 
Grades 
1 - 4 Grades  
3 and4  Grades 
1 - 4 Grade s 
3 and4  
% of Patients  
Body as a Whole     
Asthenia/Malaise  56 4 48 5 
Fever1 29 1 13 < l 
Headache  19 <1 8 <1 
Infusion Reaction2 15 3 2 0 
Infectio n 13 1 9 1 
Chills1 16 0 5 0 
Digestive     
Mucosit is/Stomatitis  93 56 94 52 
Xerostom ia 72 5 71 3 
Dysphagia  65 26 63 30 
Nausea  49 2 37 2 
Constipatio n 35 5 30 5 
Vmniting  29 2 23 4 
Anorexia 27 2 23 2 
Diauhea  19 2 13 1 
Dyspeps ia 14 0 9 1 
Meta bolic/Nutritional     
Weight Loss  84 11 72 7 
Dehydration  25 6 19 8 
Respi[INVESTIGATOR_744495]  26 3 19 4 
Cough Increased  20 <1 19 0 
Skin/ Appendages      
Acnefonn Rash3 [ADDRESS_1018494] ion     
Pruritus  16 0 4 0 
CTRC  at UTHSCSA 
CTRC#  11-36 October 25, 2016  
- 16 - CONFI DENTIAL  
  
 
Table 3 Incide nce of SelectedAdve rse Events ( 10%) in Patients with Locore!rlona ll v Adva n ced HNSCC  
 
 
 
 
Body Syste m 
Prefened Te1m  Cetuximab plus Radiat ion 
(11=2 08)  RadiationTherapy Alone  
( n = 212) 
Grades  
1 - 4 I Grades  
3 and4  Grades  
1 - 4 I Grade  s 
3 and4  
% of Patient s 
1 Include s cases also reported a s infilsion reactions . 
2 Infilsion reaction is defined as any e vent desc1ibed at any time dming the clinica l study as "allergic reaction " or 
"anaphylactoidreaction " or any event  on the first dayof dosing  desc1ibed  as "allergic reactio n", "anaphylactoid reaction ", 
"fever", "chills ", "chills and fever" or "dyspnia ". 
3 Acnefonn  rash as defined  as any event desc1ibed  as "acne", " rash", " maculopapularash ", "pustular  rash", "d1yskin " or 
"exfoliati ve dermatitis ". 
 
The data in the table below a re based on the experience of 222 patient s with recmrnnt or meta static 
HNSCC treated with cetuximab plus chemotherapy compared to 220 patients treated with chemotherapy 
alone . 
 
Table 4 Incidence of Selected Adverse  Even ts ( 5%)  in Patients with Metastaticor recurrent 
HNSCC  
 
 
 
 
 
Event  Cetuximab plus che mo 
(n=222)  chemo Alone  
(n=220)  
Grade s 
3 - 4  
Grade 4  Grades  
3 - 4  
Grade4  
% of Patient s 
Any event  82 31 76 31 
Neutropenia  22 4 23 8 
Anemia  13 1 19 I 
Thrombocytopenia  11 0 11 I 
Skin reaction*  9 2 <l 0 
Hypokalemia  7 1 5 <l 
Card iac events  7 5 4 3 
Vomit ing 5 0 3 0 
Asthenia  5 < l 6 <l 
Anorexia  5 1 1 <l 
Hypomagne  se m i a 5 4 1 <l 
*S kin reactions  include : acne, msh, maculopapula r rash, ceUulities, face edema, dry skin, erysipelas, folliculi tsi, naildisorde r, 
paron ychia , skin hyperpi[INVESTIGATOR_744496].  
 
 
Six patien ts (3%) developed infusion - related reaction grade 3 or 4. Grade 2 skin reaction was observed in 
abou t 35% of the pat ients in cetuximab group.  
Late Radiation Toxicity  
The overall incidence of late radiation toxicities (any grade) was higher in cetuximab in combination with 
radiation therapy compared with ra diation thera py alone. The following sites were affected: saliva1 y 
CT RC at UTHSCSA 
CTRC#  11-36 October 25.  2016  
- 17 - CONFIDE NIATL  
  
 
glands (65% versus 56% ), larynx (52% vers us 36%), subcutaneo us tissue (49 % versus 45% ), mucous 
membrane (48 % versus 39% ), esophagus (44% versus 35 %), skin (42% versus 33%), brain (1 1% versus 
9%), lung (11% versus 8% ), spi[INVESTIGATOR_1831] (4% versus 3%), and bone (4% versus 5%). The inc idence o f 
Grade 3 or 4 late rad iation toxic ities were generally similar between the radiat ion therapy a lone and t he 
cetuximab p lus radiation trea tment grou ps. 
[IP_ADDRESS]  Infusion Reac tions 
In clinical trial s, severe , potent ially fatal infu sion reac tions were rep01ted. The se event s include the rap id 
onset of aiiway ob struct ion (bronchospa sm, st:ridor and hoar seness), mticaria , and/or hypoten sion. In 
studie s in advanced co lorectal cance r, severe infusion reactions were obse1ved in 3% of patient s receiving 
cetuximab p lus iii.notecan and 2 % of patients rece iving cetuxiinab mono therap y. Grade [ADDRESS_1018495] day o f initial do sing, were 
obse1ved in 16 % of patien ts receiving cetuxiinab plus iti.notecan and 19% of pat ients receiving cetuximab 
monotherapy.  
A 20-mg test dose was administered intr·aveno usly over IO mi n u te s p1i.or  to the initial dose to all patients 
in ear lier studies. The test dose did not reliab ly identify patient s at risk for severe allergic reaction s. 
Severe infusion reactions  occmTed with the admini stration  of cetuxiinab  in approximate ly 3% of patients, 
rarely with fatal outcome  (<1 in 1000 ). Approx imate ly 90% of severe infusion  reaction s were  associated 
with the first infusion of cetuximab  despi[INVESTIGATOR_744497] s. These reaction s were 
characte1i.zed by [CONTACT_744581] y obstrnction (bronchosp asm, stridor and hoarsen ess), urtica ii.a, 
and/or  hypoten sion. 
[IP_ADDRESS]  Pulmonary Toxicity 
Interstitial lung disease  (ILD) was rep01ted  in 3 of 774 (<0.5%) patients with advanced  colorecta l cancer 
receiv ing cetuxi mab. Interstit ial pnemnonitis with non -cardiogenicp ulmona1yedema re sulting in death 
was rep01ted  in one case. Two patient  s had pre-existing fibrotic  lung disease and expe1i.encedan  acute 
exacerbation o f theiI·d isease while rece iving cetuximab in combina tion with iti.no tecan. In the clinica l 
investigationa l prograin , an addit ional case of interstitial pneumoniti s was rep01ted in a patient w ith head 
and neck cancer  treated  with cetuximab  and cisplatin. The onset of symptomsoccmrnd  between  the fomth 
and eleventh doses of treatment in all reported  cases. 
[IP_ADDRESS]  Dermatologic  Toxicity 
In cynomo lgus monkey s, cetuximab , when admini stered at doses of approximate ly 0.4 to 4 times the 
weekly human ex posme (based on total body smfa ce ai·ea) resulted in dermato logic finding s, including 
inflammat ion  at the injection site and desquamation of the  external integument50.  At  the highest dose 
level , the epi[INVESTIGATOR_24603] l mucosa of the nasal pa ssage, esophagu s, and tongue were similai·ly affected , and 
degenerat ive changes in the renal tubulai· epi[INVESTIGATOR_744498]. Death s due to sepsis were obse1ved in 50% 
(5/10) of the animal s at the highe st dose level beginning a fter approxiinate ly 13 week s of treatment.  
In clinical studies of cetuxiinab , dennatologic toxic ities, includ ing acneform ra sh, skin dty ing and 
fissming, and inflammat01y and infec tious sequelae (eg, blephariti s, cheilitis, cellulitis, cyst) were 
repo1t ed50. In patients  with advanced  colorectal cancer, acnefo 1m rash was repo1t ed in 88% (686/774) of 
CTRC at UTHSCSA 
CTRC# 11-36 October 25. 2016  
- 18 - CONFI DENTIAL  
 . • - .  
 
all treated patients , and was severe (Grade 3 or 4) in 12% (79/633) of these pat ients. Subsequent to the 
development  of severe de1matologic  toxicities  , complicat  ions including  S. aureus  sepsis and abscesses 
requiiing  incision and drainage  were  repo1ted.  
Non-suppura  tive acnefo1m  rash described  as "acne",  "rash", "maculopap ular rash", "pustular rash" , "diy 
skin", or "exfoliative de1m atitis" was observed in patients receiving cetuximab plus ilinotecan or 
cetuximab  monotherapy50. One or more  of the de1matological  adverse  events  were  repo1t ed in 88%  (14% 
Grade  3) of patients receiving  cetuxilnab  plus ilinotecan  and in 90%  (8% Grade  3) of patients  receiving 
cetuxilnab  monot herapy . Acnefmm  rash most  commonly  occurred  on the face, upper  chest , and back , but 
could exten d to the extremities  and was characte1ized  by [CONTACT_744582]- or pustular -appea1ing  
lesion s. Skin diying and fissming were common in some instanc es, and were a ssociated with 
inflamma to1yand infectious sequelae  (eg, blepha1itis , celluli tis, cyst). Two cases  of S. aureus  sepsis were 
repo1ted . The onset  of acnefo1m  ras h was general  ly within the first two weeks  of therapy.  Although in a 
majmity  of the patients the event  resolved  following  cessation  of treatment , in nearly  half of the cases , the 
event  contin ued beyond  28 days. 
A related  nail disorder, occm1ing in 14% of patient s (0.4% Grade  3), was characte1ize d as a paronychia l 
inflammat ion with associated  swelling of the lateral  nail folds of the toes and fingers, with the great  toes 
and thumbs as the most commonly affected  digit s. 
1.[ADDRESS_1018496] failed to demonstrate that the addition of induction chemotherapy to surge1y 
and/or radiotherapy confers a survival advantage in patient s with locally advanced head and neck cancer. 
The rationale of induction therapy was questioned and its use was thought to be expe 1imenta l33 [ADDRESS_1018497] repo 1t ed encouraging survival 
data. A study by [CONTACT_744583] w ith cisplatin/5-FU followed by 
[CONTACT_744584] 1y and/or radiat ion showed a survival benefit but only in patient s with unre sectable tumor s37 
Dome nge et al36 repmted the only positive trial that enrolled 3 18 patients with locally advanced  
oropha1yn geal cancer. Disease -free smvival was ilnproved in the induction chemotherapy arm but the 
diffe rence did not reach statistical significance (p=O .1 1); overa ll smv ival was superior in the induction 
chemotherapy aim (p<0 .05). These  two  tlials were included in a metaana lysis by [CONTACT_25715][INVESTIGATOR_744499] 200018. In this metaanaly sis, when all induction chemotherapy studies were examined together, there 
was no smv ival benefit with induction chemotherapy . However , when the subset of ti·ials with 
platinum/[ADDRESS_1018498] ratio of0.88 (95% CI 0.79-0.97) . A study by [CONTACT_744585] l and 
comparable smviva l to induct ion chemotherapy54. However, no study ha s evaluate d the role of  the 
addition of induction chemotherapy when concmrnnt chemorad iotherapy is used in both aims in head and 
neck cancer.  
CT RC at UTHSCSA 
CTRC#  11-36 October 25.  2016  
- 19 - CONFDI ENTIAL  
 . 
. 
, · , 
- .  
 
Multip le chemothera py regime ns have been tested in the induction setting in head and neck cancer. The 
most wide ly used has been cisplatin and 5-FU. Carbop latin may be inferior to cisplatin  as demonstrated in 
a randomized compa rison between c isplatin/5 -FU and carbop latin/5 -FU in the induction setting55 Also , 
the activ ity of carboplatin/5 -FU in rec un ent/metastaticd isease is inferior to that o f cisplatin/5-FU56 The 
combi nation  of platinum  and the taxanes  has been  paiticularly  active in head  and neck  cancer.  Moreover , 
the incidence  of stomat itis seen  with this regimen is less than  what  is observed  when  5-FU is a pait of the 
regimen.  Cai-bop latin and pacl i taxe l have  been  used in many  studies with objective  response  rates  80%  or 
higher57 . 
The co mbination of cisplatin and docetaxe l is active in rec mTent/metastat ic head and neck cancer w ith 
object ive response rates between 33 -54%[ADDRESS_1018499] ive response rates between 55 -89%4446 which is compai·ab le to the activ ity of c isplatin/5 -FU and  
cisplatin/pa clitaxel.  The feasibility of platinum-based  induction  chemotherapy  for 2-3 cycles  followed  by 
[CONTACT_744586] l concmTently  with radiotherapy  has been  demonstrnted  in multiple  trials57 59 
However , no study has yet shown the feasibi lity of cisplat in/docetaxe l followed  by [CONTACT_744587]. One of the conce rns is whether  cumulative  toxicit ies from  the induction  regimen 
will compro mise dose  delive1ydming  subsequentchemorad iotherapy.  A cons istent finding  among  sn1dies 
with cisplatin 100 mg/m2 eve1y 3 weeks p lus radiation has been tha t all three doses of "high -dose " 
cisplatin can only be delivered in approx imately 60%  of patients.  In this study, we will allow the use of 
cai·bo platin; if out of field cisplatin-related toxicities occm. 
Studies with cisplatin and 5-FU have s hown that the response rate is higher with [ADDRESS_1018500] observed that with add itional cycles of 
induction chemot herapy, the rate of complete response to carbo platin/ifosfamide /paclitaxe l  increased 
from 23% after 2 cycles to 60% after 4 cycles62. For this study we elected to use 3 cycles of 
chemoth erapy that will allow adequate systemi c exposure to chemotherap y. An ongoing study in om 
institution is evaluating cisplatin and docetaxel fo llowed by [CONTACT_744588] 100 mg/m2 eve1y 3 
weeks  x 3 in unresectab le patients  with head  and neck  cancer.  
1.10 Bevacizumab Clinical Experience 
Bevacizumab has been studied in a multitude of Phase I, II, and III clinical trials in more than 5000 
patients and in multip le tumor types. In addition, data are available from 3,863 pat ients enro lled in two 
postmai·ke ting studies in metastat ic colorectal cancer (CRC). Approximate ly 130,[ADDRESS_1018501] been 
exposed  to bevac izumab as a mai·keted  prod uct or in clinica  l tria ls. Th e following  discussion  summarizes 
bevacizumab's safety profile and presents some of the efficacy results pe1tinent to this  pa1ticulai·trial. 
Please refer to t he bevac izumab Investigator Broch me for descriptions of al l comp leted Phase I, II, and III 
tiials rep01ted to date.  
In a large phase  III study  (AVF2 107g)[ADDRESS_1018502]  vascu lar endothe lial growth  facto r (VEG F), to 
iii notecan/5 -fluoro macil/leucovor in (IFL)  chemothera py resulted in a clinically  and statistically  
significant increase in dmation of survival ,  with a hazai·d ratio o f death of 0.67 (med ian smv ival 15.6 vs. 
20.3  months ; p < 0.001).  Simi lar increases  were  seen  in progress ion-free smvival  (6.2 vs. 10.6 months; 
p < 0.00 1), overall response  rate (35%  vs. 45%;  p < 0.01) and duration  of response  (7.1 vs. 10.4  months ; 
CT RC at UTHSCSA 
CTRC#  11-36 October 25.  2016  
- 20 - CONFDI ENTIAL  
 ,  
 
p < 0.01) for the combinatio n arm versus the chemotherapy only arm (bevac izum ab Invest igator 
Brochure, October 2005).  
Based on the survival advantage  demons trated  in Study  AVF2107g , bevacizumab  was designated  for 
pri01ity  review  and was approve d on [ADDRESS_1018503]-line treatment  in 
combination  with IV 5-FU- based  chemotherapy  for subjects  with metastat ic colorectal  cancer.  
Additional data fro m Phase III tlials in metastatic CRC (£3200)64, non- small cell lung cancer (NSCLC ; 
£4599)65, and metasta tic breas t cancer (£ 2100)66 havealso demo nsti·ated clinical bene fit from 
bevac izum ab when  added to chemotherapy . In Study E3200 , the addition of bevacizumabto  FOLFOX 
chemotherapy  resulted in improved  overa ll survival compared  with FOLFOX  alone (13.0  vs. 
10.8 months , respective ly, HR = 0.75; p < 0.01) in a populationof p reviously ti·eated C RC patients . 
There was also improved overall survival in first-line NSC LC patients (E4599) ti·eated with 
carbop latin/paclitaxel + bevacizumab compared with chemotherapy a lone (12.[ADDRESS_1018504] ively; HR = 0.80; p = 0.003 ). The results from this tiial were the basis for FDA approva l of 
bevacizumab  for use in combinat ion with carboplat in + paclitaxel as first-line treatment  of patients  with 
unresectab le, locally  advanced , recurrent  or metas tatic, non-squamo us NSC LC in October  2006 . Finally, 
patients  with unti·eated  metastat ic breast cance r (E2100)  who received  bevac izum ab in combinatio n with 
weekly paclitaxel had a marked  improve ment in PFS compared  with chemot herapy  alone (13.3  vs. 
6.7 months , respectively; HR = 0.48;  p < 0.0001)  (see the Bevacizumab  Investigator  Brochure  for 
additional details). 
Safety Profile  
In the initial Phase I and II clinical tiials, four potenti al bevac izumab -assoc iated safety signa ls were 
identified: hypertension , proteimni a, thromboembo lic events , and hemon hage. Addi tional completed 
Phase II and Phase III studies of bevaciz umab as well as spontaneous repo1t s have finther defined the 
safety  profile  of this agent.  Bevaci zumab-assoc iated adve rse events  identi fied in phase III trials include 
conges tive heait  failure (CHF) p1imai· ily in metastatic  breast  cancer,  gastrointest inal perforat ions, wound 
healing com plications, and a1te1i al thromboembo lic events (ATE). These and other safety s ignals ai·e 
described in finther detai l as follows  and in the bevacizmnab Investigator  Brochure.  
Hyperte nsion: An increase d incidence  of hype 1et nsion has been observed in patients  ti·eate d with 
bevac  izumab . Grade  4 and 5 hypertensive  events  ai·e rai·e. Cli nica l seque  lae of hype  1t ens ion ai·e rare but 
have included hype1tensive crisis, hype1tensive encephalopathy , and reversib le posterior 
leukoencepha lopathy syndrome (RPLS)[ADDRESS_1018505] o f bevac izumab in patients with unco ntrolled hype1tension at the 
time o f initiating bevac izumab therapy. Therefore , caution should be exe rcised before initiating 
bevacizu mab therapy in these patients. Monito1ing of b lood pressure is recommende d dming 
bevacizumab  therapy.  Optimal control  of blood pressure  according  to standai·d  public health guide  lines is 
reco mmended  for patients  on ti·eatme nt with or without  bevacizumab . 
Temporaiy intenu ption of bevac izmnab therapy is recommended in patients with hype1te nsion requiring 
medical therapy until adequate conti·ol is achieved. If hype1tension cannot be co ntrolled w ith medica l 
CT RC at UTHSCSA 
CTRC#  11-36 October 25.  2016  
- 21 - CONFDI ENTIAL  
  
 
thera py, bevac izumab therapy should be permanently d isconti nued. Bevacizu mab should be pe rmanen tly 
discontinued in patients who deve lop hypeitens ive cris is or hyper tensive ence phalopathy.  
Prnteinuria : An increased inc idence of prote inuria has been observed in patie nts treated w ith 
bevacizumab compa red w ith con trol aim patien ts. In the bevac izum ab-containing treatmen t aims o f 
clinica l tii als (across  all indications) , the incidence  of proteinuria (repoited  as an adverse  event)  was up to 
38%  (metasta tic CRC  Study  AVF2l  92g) . The sever ity of proteimui a has ranged  from  asymptomatic  and 
ti·ans ient events detec ted on routine  dipstic k urinalysis to nephrotic  syndrome;  the majo rity of prote inuria 
events have been grade 1. NCI-CTC Grade 3 proteinuria was re pmted in up to 3% of bevac izumab ­ 
ti·eated pa tients , and Grade 4 in up to 1.4% of bevac izumab-treated pat ients. The protein uria seen in 
bevacizu mab clinical trials was no t assoc iated with renal impailme nt and rai·ely requil·edpennanent 
discontinu ation of bevac izumab therapy. Bevac izumab shou ld be discontin ued in patients who develop 
Grade  4 proteinuria (nephrot ic syndrome)  
Patients  with a histoiy  of hypeite nsion may be at increased  iisk for the develop ment of protein uria when 
ti·eated with bevac izumab. There is ev idence fro m the dose-finding , Phase II tiials (AVF0780g , 
AVF0809s , and AVF0757g)  sugges ting that Grade  1 proteinuri a may be related to bevac izumab  dose.  
Protein mi a will be monitored  by [CONTACT_744589]:  creatinine  (UPC)  ratio at least eveiy  6 weeks.  If the UPC 
ratio  is not available, a dipstick mi nalysis may be used to allow  ti·eatme nt to proceed.  
Thromboembolic Events: Both venous and ait eiial thromboembolic (TE) even ts, rangi ng in seveii ty 
from  cathe ter-assoc iated phlebi tis to fatal, have  been  repoited  in patients treated  with bevacizumab  in the 
colorectal cancer  tlials  and, to a lesser  extent,  in patients  ti·eated with bevac izumab  in NSC LC and breast 
cancer  tlials . 
Venou s Thrnmbo emboli sm (includin g deep venou s thrombo sis, pulmonar y emboli sm, and 
thrombophlebitis ): In the phase III pi[INVESTIGATOR_744500] , there  was a slightly  higher  rate of 
veno us TE events  in patients  ti·eated  with bevac izumab plus chemotherapy  compai·ed with chemothera py 
alone (19% vs. 16%). 
In Study AVF2107g , a Phase  III, pi[INVESTIGATOR_744501], VTE events , including  deep  venous 
thrombos is, pulmonaiy embolism , and thrombophleb itis, occ mrnd in 15.2% of patients receiv ing 
chemot herapy  alone and 16.6%  of patien ts receiving chemothera py + bevac izumab.  
The incidence  of NCI-CTC  Grade  3 venous  VTE  events in one NSC LC tiial (E4599)  was higher  in the 
bevacizumab -containing aim compared to the chemo therapyconti ·ol aim (5.6% vs. 3.2%). One event 
(0.2%) was fatal in the bevacizumab -conta ining aim; not fatal events were repoited in the 
cai·boplatin/paclitaxel aim (see Bevacizumab  Investigator  Brochure). In metastatic  CRC  clinical ti·ials, the 
incidence of VTE events was silnilai·in patients receiv ing chemotherapy+ bevac izumab and those 
receiv ing the control chemotherapy  alone . 
In clinical  tli als across  all indications  the overall  incidence  of VTE even ts was 2.8% - 17.3%  in the 
bevacizuma b-containin g aims compare d with 3.2%- 15.6%  in the chemotherap ycontr ol aims . Theuse of 
bevacizumab  with chemotherapy  does  not substantia lly increase  the iisk of VTE  event compared  with 
CTRC at UTHSCSA 
CTRC# 11-36 October 25.  2016  
- 22 - CONFIDE NIATL  
  
 
chemotherapy alone . However, pat ients w ith metastat ic CRC who receive bevac izumab and expe rienced a 
VTE even t may be a t highe r risk for rec1mence of VTE event.  
AI'tel'ial  Thro  mbo  emboti  c Events: An inc reased  incidence  of ATE events  was observed  in patients 
treated w ith bevac izuma b compared w ith those receiving contro l treatments. ATE events include 
cerebrovasc ular accidents, myoca rdial inf arction, trans ient ischemic attacks (TIAs) , and other ATE 
events . In a pooled  analysis of data from  five rando mized Phase  II and III trials  (mCRC  [AVF2 107g, 
AVF2 192g, AVF0780g ]; locally advanced  or metastat ic NSCLC  [AVF0757g ]; metastatic  breast cancer 
[AVF2 119g]), the incidence rate of ATE even ts was 3.8% (37 of963) in patients who received 
chemotherapy+ bevacizumab com pared with 1.7% (13 of782) in patients t reated with chemothera py 
alone.  ATE  even ts led to a fatal outcome  in 0.8%  (8 of963)  of patientstreated  with 
chemotherapy+  bevacizumab  and 0.5% (4 of782)  of patientstreated  with chemotherapy  alone. 
Cerebrovasc ular accidents (incl uding TIAs) occurre d in 2.3% o f patients treated with 
chemotherapy+  bevacizumab  and 0.5%  of patien ts treated  with chemotherapy  alone. Myocardia l 
infarction  occ1med in 1.4%  of patients treated  with chemotherapy+ bevacizu mab compared  with 0.7%  of 
patients treated with chemothera py alone (see the Bevaci zumab Investigator Broc hure for addit ional 
detai ls). 
Aspi[INVESTIGATOR_33930] a stand ard therapy for pr imaiy and secondaiy prophylaxis o f aite1i al th romboembol ic events in 
patients at high risk of such even ts, and the use of aspi[INVESTIGATOR_62300] n ::: 325 mg dai ly was a llowed in the five 
rando mized studies discussed above. Use of aspit-in was assessed rout inely as a base line or concomitant  
medication in these tr ia,ls though safety analyses specifically regai·dingaspit -in use we re not prep lanned.  
Due to the relatively small numbersof aspit·in users and a1ter ial thromboe mbolic events, retrnspective 
analyses  of the ability of aspi1in  to affect  the risk of such  events were  inconclusive.  However,  similarly 
retrospective  analyses suggested  that the use of up to [ADDRESS_1018506] to metas tatic co lorecta l cancer 
patients were presented at ASCO 2005 (Hambleton et al. , 2005). Frnt her analyses o f the effects of 
concomitant  use of bevac izumab  and aspi[INVESTIGATOR_744502] r types  ai·e ongo  in g. 
Ga stl'ointe stinal P erforation Patients with metastat ic carc inoma may be a t increased 1i sk for the 
deve lopmento f gastro intestinal perforation and fistu la when t reated with bevacizumab and che motherapy. 
Bevacizumab should be pe1mane ntly disconti nued in patients who develop gastrointest inal perforation. A 
causa l assoc iation o f intra-abdominalinfla mmat01y processes and gastrointe stinal perforation to  
bevaci zumab treatment has not been established. Neve1thele ,ss ca ution sho uld be exe rcised whe n treating  
patients with in tra-abdominal inflammat01y processes w ith bevacizumab . Gastro intestinal pe1foration has 
been rep01ted in othe r hi als in non-colorecta l cancer pop ulations (e.g., ova1ian , renal cell, pancreas, 
breast , and NSC LC) and may be higher in incide nce in some tumor types . 
Fistula : Bevacizumab use has been associated w ith se1io us cases of fistulae includ ing events resulting in 
death. F istulae in the GI h·act ai·e common (1%- 10% incidence) in pat ients with metas tatic CRC, but 
uncommon (0.1%- 1%) or rai·e  (0.01%-0 .1%) in other indications. In addition , fistulae that invo lve ai·eas 
of the body  other than the GI h·act  (e.g ., tracheoesophageal  , bronchop  leural , urogen ital, biliaiy) have  been 
repo1t ed uncommon ly (0.1%- 1%) in patients receiv ing bevaci zumab in c linical studies and postmai ·keting  
CTRC  at UTHSCSA 
CTRC#  11-[ADDRESS_1018507] , discontinuationof bevacizumab should be cons idered.  
Wound healing complication s:  Wound healing complicat ions such  as wound dehiscence have been 
repo1t ed in patient s receiving bevac izumab . In an analysis of pooled data from two trials in metastatic 
colorecta l cancer , patient s undergoing surge1y 28-60 days before study treatmen t with 5-FU/L V plus 
bevacizumab d id not appear to have an increased risk of wo und healing complications compared to those 
treated with chemotherapy alone69. Surge1y in patien ts cun en tly receiving bevacizumab is not 
recommended . No definit ive data are available to define a safe inte1val after bevacizumab exposure with 
respect to wound healing risk in patient s recei ving elective surge1y; however , the estimated half life of 
bevacizu mab is 21 days. Bevac izumab should be discontinued in patients with severe wound healing 
complications . 
If patients receiving treatment  with bevacizumab  require elective  major surge1y , it is recommended  that 
bevacizumab  be held for 4-8 weeks  prior to the surgicalprocedure . Patients lmderg oing a major  surgical 
procedure  should  not begin or resta1t bevac izumab  until  4 weeks after  that procedure  (in the case of 
high-risk procedure s such as liver re section, thoracotomy, or neuro surge1y , it is recommended that 
chemotherapy be restaited no eai·lier than 6 weeks and bevacizumab no eai·lier than 8 weeks after 
surge1y). 
Hem01Tha ge: Overa  ll, grade 3 and 4 bleeding  events  were  obse1ved  in 4.0% of 1132  patient s treated  with 
bevacizumab in a pooled database from eight phase I, II, and III clinica l trials in multiple tumor types 
(bevacizumab Inve stigator Brochure, October 2005). The hemonhagic events that have been obse1ved in 
bevacizumab clin ical studies were predominantly tumor -as sociated hemonhage (see below) and lninor 
mucocutaneou s hemorrhage . 
Tumo r-Associated Hemorrhage: Major or massive pulmonaiy hemonhage or hemoptysis has been 
obse1ved p1imaii ly in patient s with NSCLC. Life-threatening and fatal hem optysis was identified as a 
bevacizumab -related adverse event in NSCLC tr ials. These event s occrnTed suddenly and presented as 
major or massive hemoptysi s. Among the possible 1i sk factor s evaluated (includin g squamous cell 
histology, treatment with anti -rheumatic /anti-inflammato1ydrngs , treatment with anticoagulants , p1ior 
radiotherapy, bevacizumab therapy, previou s medical hi sto1y of atherosclerosis, centra l tumor locat ion, 
and cavitat ion of tumor s drning therapy ), the only variables that showed sta tistically significant  
con-elations with b leeding were bevacizumab therapy and squamou s cell histology. 
 
GI hemonhage s, including rectal bleeding and melena have been rep01ted in patient s with CRC , and have 
been assessed as tumor -assoc iated hem on hages. 
Tum or-assoc iated hemon -hage s we re also seen rarely in other tumor types and locations, inclu ding a case 
of CNS bleeding in a patient with hepatoma with occult CNS metastase s and a patient who deve loped 
continuous ooz ing of blood from a thigh sarcoma with necro sis. 
CTRC  at UTHSCSA  
- 24 - CONFIDENTIAL  
 • · CTRC#  11-36 October 25,  2016  
 
 
Mucoc utaneus Hemonage:  Across  all bevacizumab  clinica l trials, mucoc utaneous  hemorrhage  has been 
seen in 20%-40% of patients  treated  with bevacizumab . These  were  most  commo nly NCI-CTC  Grade  [ADDRESS_1018508]  also been  less common  events  of minor  mucocutaneous  hemonhage  in other  locations , such 
as gingiva l bleedi ng and vaginal bleeding. 
Reversible Poste rior Leukoencepha lopathy Syndrome: There have been rare repo1t s of beva.cizum ab­ 
trea.ted patients developi[INVESTIGATOR_744503] w ith RP LS, a rare neurolog ic disorder 
that can present with the following signs and symptoms (amongothe rs):  seizures ,  headache ,  altered 
menta l status , visual disturbance , or co1tical blindness , with o r without associated hype1tens ion. Bra.in 
imaging is manda.to1y to confnm the diagnosis ofRPLS. In patients who develop RPLS, treatment of 
specifi c symptom s, including  contr ol of hype 1et nsion, is recommended  a.long  with discontinuatio nof 
beva.cizumab . The safety  ofreinitia.ting  beva.cizumab  therapy  in patients previously  experiencing  RPLS is 
not known67 68 
Congestive heait failure : In clinical trials CHF was obse rved in a ll cancer indications studied to date, b ut 
predominan tly in pat ients with metastat ic breast cancer. In the Phase III clinical tria l of metastatic breast 
cancer (AVF2119g), 7 (3%) beva.cizuma.b -treated patients expe1ienced CHF , compared wit h two (1%) 
control a.nn patients. These events varied in seve1ity from a.symptomatic declines in le ft ventlicular 
ejection fraction (LVEF) to symptomatic CHF requiiing hospi[INVESTIGATOR_5478] t reatment. A ll the patients 
treated with bevac izumab were prev iously ti·eated with anthracyclines (doxo mbic in cumulative dose of 
240(360 mg/m2). Many of these pat ients also had p1ior radiotherapy to the left chest wall. Most of these 
patients showed improved symptoms and/or left venti· icula.r function following approp1ia.te medical 
therapy (Miller et al. 20 05). 
In a randomized , Phase  III trial of patients  with previo usly untreated  metastat ic breast  cancer  (E2l 00), the 
incidence  ofLVEF  decrease  (defined  as NCI-CTC  Grade  3 or 4) in the paclitaxel  + bevacizuma.b  aim was 
0.3%  versus  0% for the paclitaxel alone  ann 
No inf01mation  is available on patients with preexisting  CHF  of New  York  Hea1t  Association  (NYHA) 
Class  II- N at the time of initiating beva.cizumab  therapy  , as these  patients  were  excluded  from clinical 
trials.  
Prior anthracyclinesexposure and/or p1ior rad iotherapy to the chest wall may be poss ible1isk factors for 
the development of CHF. Caut ion shou ld be exerc ised before initiat ing bevacizumab therapy in pat ients 
with these risk factors.  
A Phase II tiial in patients with refract01y acute myelogenous leukemia repo1ted [ADDRESS_1018509] ion (CHF or LVEF decrease to < 40%) among 48 patients treated with sequent ial cyta.ra.bine , 
mitoxanti·one , and bevacizuma.b. All but 1 o f these pat ients had significant prior exposure to 
anthracyclines as well70. 
Two add itional studies investigated concm Tent admin isti·aiton of anthracyclinesand bevac izumab. In 
[ADDRESS_1018510] cancer ti·eated with neoadjuvant docetaxe l, doxombicin , and 
CT RC at UTHSCSA 
CTRC#  11-36 October 25.  2016  
- 25 - CONFIDE NIATL  
 , 
. ) ;  
 
bevac izmnab, no patients developed  clinically  apparent  CHF; however , patients  had asymptomatic 
decreases  in LVE F to < 40%71. In a small Phase II study  in patients  with soft tissue sarcoma , 2 of the 
17 patie nts treated  with bevacizumab  and high-dose doxo rnbicin (75 mg/m2) deve loped CHF (one Grade 
3 event after a cumulative doxo rnbicin dose of 59 1 mg/m2 one Grade 4 event after a cumulative 
doxo rnbicin  dose  of 420 mg/m2 an additional [ADDRESS_1018511]  a 
baseline MUGA  scans  or echoca rdiograms  (ECHOs) with a nmma l LVEF.  
Neutrop enia: Increased rates o f severe neutropenia , feb1i le neutropenia, or infection with severe 
neutropenia  (including  some  fatalities) have  been  observed  in patients  treated  with some  myelotoxic 
chemotherapy  regimens  plus bevac izumab  in compatison  to chemotherapyalone65 
Additional Ad verse Event s: See the bevac izumab Inves tigator Brochure for addi tional details regarding 
the safety expe ti ence wit h bevacizumab . 
1.[ADDRESS_1018512] igating  the combination  of pemetrexed  and bevacizumab  in recmTent  or metas  tatic 
HNSCC is ongo ing with enco uraging results (UPC I 05-002) . [ADDRESS_1018513] been enro lled. In 29 
evaluable patients, 9 (31%) have  had an objective  response  (3CR  + 6PR), 16 (55%)  SD, whereas 4 (19%) 
patients deve loped PD. The median TTP was 4.9 months and the median OS was approximately 12 
months . We had 6 /38 (16%) grade 3-5 bleeding events (2 fatal), none after mod ificationsi n eligibility 
were  made to exclude patie nts with prior histo1yof  tumor-related bleeding  and do not allow retreatment 
after a first  serious tumor -related bleeding. 
Another trial with cetuximab and bevac izumab (UPC I 05-087) has enrolled 32 patien ts. Prelimina1y 
results  (ASCO  2009)  sugges t that the regimen  is active  and safe.  Only  one grade  3 bleedingin  32 patients 
has been  observed . The objective  response  rate is 20%, the median  PFS 2.8 months  and the median  OS 
8.1 months.  
In addition , another  phase  II randomized  trial of radia tion, cetux imab and pemetrexed  with or without 
bevac izumab is ongoing , as well (UPC I 07-021). The regimen is feasible. No bleeding events have 
occutTed in 8 patients  treated.  
1.12 Study Rational e 
Induction che mothera py is gaining momentum in the ma nagement of locally advanced squamous cell 
cai·cinoma o f the head and neck (SCCHN) . The combination o f docetaxe l, cisplatin, and 5 -FU (TPF) was 
supe1io r compare d with PF in a Phas e ill  clinic al ttials73,_14   We have completed a Phase II clinic al trial 
that showed  that docetaxe l, cisplatin , and cetux imab (TPE)  is highly active  and well tolerated  as induction 
chemotherapy in SCCHN (Argitis et al. ASCO 2008 ; A6002). Preliminaiy survival results are very 
encourag ing. 39 patients were enrolled and with median follow up 26 months the 2-yeai· PFS was 70% 
and the 2-year OS 84% .The comb ination  of chemotherapy plus cetuximab  is afready  a standat· d treatment 
CT RC at UTHSCSA 
CTRC#  11-[ADDRESS_1018514] imp01tan t and validated  molecular targets in cancer  therapy.  The 
incorpora tion of nove l targeted  therap ies to chemotherapy  and radiotherapy is of particulru· interest  in 
head  and neck cancer , and may improve  efficacy  without significantly  increasing  toxicity. A Phase III 
trial of carbop latin/pac litaxel/bevac izumab with or without cetuximab in advanced NSC LC has bee n 
proposed  by [CONTACT_99944].  Bevacizumab  is ClllTently  being inves  tigated  in SCCIIN  with promising  results . A 
Phase II study  investigating  the combination  of pemetrexed  and bevacizumab  (UPCI  05-002)  as well as a 
Phase II trial of cetuximab  and bevacizumab (UPCI 05-087)  in recU1Tent or metas tatic SCCHN  ru·e 
ongoing  at the University  of Pi[INVESTIGATOR_744504] (ASC O 2008  and ASCO  2009) . In this 
study , [ADDRESS_1018515]  been  afready  emolled . There was only I patient with grade  3 hemo1Thage.  The objective 
respo nse rate is 20%,  the median  PFS 2.[ADDRESS_1018516] cycle  and evaluate 
the modulation of biomru·kers post combi  nation  thera  py. Data  from induction  with TPE (presented  at 
ASCO 2009) indicate the potential significance of cytokine levels in patient outcome . Also, we will 
evaluate  the feasib ility of subseq uent conclllrnn t radiation , cisplat in, cetuximab  and bevac izumab . 
Patients  with stable disease  in the prima1y could be considered candida tes to smgical resection  at the 
discret ion of their physician, if the tumor  is resectab le. 
2 OBJE CTIV ES 
 
2.1 P1imar  y 
To eva luate the rate o f complete responses w ith induc tion with c isplatin, docetaxe l, cetuximab and 
bevacizumab (TPE-A) in patients wit h locally advanced head and nec k cancer. 
2.2 Secondar y 
• To evaluate se1um cytokines and to co1Te l ate wit h com p lete respo n se ra te post inductiontherapy.  
• To co llect tumor t issue from pretreatment and post -treatment (optional) biops ies for bio marker 
studies on tumor t issue. We plan to investigate a pane l of EGFR and angiogenes is biomar kers on 
Tissue Microrurnys (TMAs) . 
• To eva luate the toxic ities associatedwith induction TPE-A and  subsequent  concU1Tent  rad iation,  
cis platin , cetuximab and bevacizumab  (XPE-A). 
• To evaluate the objec tive response rate post XPE-A, and the progression- free survival  and 
overa ll surviva l and quality of life. 
 
3 STUDY  DESIGN 
 
3.1 Indu ction Therap y (TPE -A) 
CT RC at UTHSCSA 
CTRC#  11-36 October 25,  2016  
- 27 - CONFIDENTIAL  
  
 
3.1.1 Treatment and Premedications  
Note:  If a cycle  is missed  or a subject's  treatme nt and/o r testing days  need  to be rescheduled  due to the 
subject's  inability  to comply  with the study  calendar  (i.e., hospi[INVESTIGATOR_602] , business  and vacation  travel 
plans , illness , transp01tation  issues , holidays , family  emergencies , etc.), a window  of± one (1) week  is 
available for rescheduling of treatment and procedures pe r the discretion of the treating physic ian 
investigator , and as discussed  with the principal  invest igator.  
 
Cycles will be re peated eve1y 21 days for 3 cycles  
Chemotherapy will be given on day 1 of a 21-day schedule and repeated eve1y 21 days for a total of 3 
cycles. The doses of docetaxe l, cetuximab , and cisplatin will be calc ulated using the patient's actua l body 
weight on day 1 of each cycle. Fluids give n during the administration of docetaxel , bevac izumab and 
cetuximab is counted as pa1t of cisplatin pre -hydration . 
• Bevacizumab 15mg/kg  IV, day [ADDRESS_1018517]-medicat ion for 
docetaxel and as an antiemetic (see below). Dexamethasone decreases incidence and 
seve1ity and de lays the onset o f late-occm1ing fluid retention and may decrease the 
incidence  and severity  of acute hypersens itivity  reactions. Dexa methasone  8 mg po bid x 3 
days, starting 12-24 hours before the p lanned docetaxel infusion has been an effective 
schedule.  
• Docetaxe l 75 mg/m2 IV over 1 hour, day I. 
• In an effo1tto prevent a hypersensitivity reaction from cetuximab , all patients should be 
premedicated with diphenhydramine hydroch loride (Benadlyl) 50 mg (or an equiva lent 
antih istamine) by [CONTACT_483943] [ADDRESS_1018518] igator 's discretion , the dose of 
diphenhyd ·la1nine(or a similar agent ) may be reduced.  
• Cehlximab  400 mg/m2 IV over 1201ninutes  on day 1 of cycle  1 ONLY.  
• Cehlximab  dose  will be 250 mg/m2 IV over 60 1ninutes  weekly on ALL  subsequent 
adlninistrations (days  8 and 15 of cycle  1 and days  1,8,15 of cycles  2 and 3). 
• Cisplatin  75 mg/m2 IV over  1-2 hours , day 1. It is strongly  recommended  that patients  receive G­ 
CSF sta1ting on day 2 of each TPE-A cycle. If this is not possible , patients will receive 
prophy lactic  cipro floxacin  500 mg twice  daily  for 10 days , on days  5-14. 
• Furosemide  will be given as needed.  
• Antiemetic therapy , acute and delayed , including dexamethasone and serotonin receptor 
antagonists , for [ADDRESS_1018519].  
The fo llowing hydl·ation regimen is recommended : 
• Cisplat in will require  aggressive  hydl·ation.  Any preexis ting dehydl·ation  should  be coITected.  Pre­ 
cisplatin hydrat ion wi ll consist of 1 L NS admin istered over 2 hours (taking into account the fluid  
volumes received from p rior dlug administration). Mann itol 12.[ADDRESS_1018520] 
before or conc un ently with cisplatin. Pre-cisplatin hydl·ation can occur while patient is receiv ing 
CTRC at UTHSCSA 
CTRC# [ADDRESS_1018521] not occur in the sa me IV line as 
chemotherapy (i.e. use pat ient' s other a nn). 
• Cisplat in will be administered in 500 -1000 cc of IV fluids over 1-2 hours and fo llowing adeq uate 
hydratio n and the establ ishment of adequate urina1yo utput. 
• Post cisplatin hydration  will consist  of 1 L ½ NS + 30 meq KCL/L  over  2 hours  (mannitol  25 g 
IV may be added).  
3.1.2 Cet11ximab Admini stration 
In an effo1t to prevent  an infosion reactio n, all patients should  be premedicated  with diphenhydra 1nine 
hydroc hloride  50 mg (or an equivalent antihista mine) by [CONTACT_483943] 30-[ADDRESS_1018522] dose  of 
cetuximab. Premed ication may be administered prior to subsequent doses , but at the Investigator's 
discretion , the dose  of diphenhydramine  (or a similar agent)  may be reduced.  
The initial dose  of cetuxi mab is 400 mg/m2 intraveno usly administe red over  120 minu tes, followed  by 
[CONTACT_744590] 250 mg/m2 IV over  [ADDRESS_1018523]  never  excee d 5 
mL/min. Patients must be continuously observed  dming  the infosion for signs  of anaphy laxis. 
Patients w ill be closely monitored fo r treatment -related adverse events , especial ly infosion reactions (see 
management of cet uximab adverse events).  
For the duration  that patients are on study  therapy , adve rse event  mon itoring will be done  continuo usly. 
Patients  will be evaluated  for adverse  even ts at each  visit and are to be instmcted to call their phys ician to 
repmt any clinically  significant adverse  events  between  visits.  
3.1.3 Bevaciz111nab  Adm inistration 
Bevaci zumab w ill be dil uted in a total vo lume o f 100mL of 0.9% Sodi mn Chloride Injectio n, USP. 
Administra tion wi ll be as a contin uous IV infos ion. Anaphylaxis precaut ions sho uld be obse1ved dur ing 
study dmg administration. It is not necessaiy to con -ect dos ing based o n ideal weight. 
Initial and all subseq uent doses will be delivered over [ADDRESS_1018524] expe1iences an infusion­ 
assoc iated adverse event , he or she may be premedicated (aceta 1ninop hen, diphenhydra mine, steroids or 
other medications given for sym ptom con trol) at the investigators discret ion, p1io r to the next sn1dy dmg 
infosion; however , the infosion  time may not be decreasedfor the subsequent infosion. Surge1y for 
3.1.4 Selec ted Patients after Induction Therapy and as Salvage  
Patients w ill be evaluated after completion of induction therapy with PET/CT. Patients with SD in the 
primaiy could be considered ca ndidates for surgical resection at the discret ion of their treating phys icians , 
if the tumor is resectable. Sa lvage surge1y should be perfonned if there is progress ive disease or residual 
disease in the prima1y at the end of therapy . At least [ADDRESS_1018525] bevacizumab 
dose and any surge1y. Neck d issection should be considered , if there is high probabi lity for resid ual 
disease  in the neck  after  comp letion of chemoradiotherapy  (>8 weeks  later) . 
3.2 Concun  ent Radiothe. -apy, Cisplatin  , Cetu ximaband  Bevacizum ab (XPE-A) 
Bevac izumab , 15 mg/kg IV over 30 minutes (if this infos ion rate was well tolerated) , eve1y 3 weeks until 
comp letion o f radiation; 
CT RC at UTHSCSA 
CTRC#  11-36 October 25.  2016  
- 29 - CONFIDENTIAL   
  
 
Followed by: 
[CONTACT_744591] , 250 mg/m.2 IV over 60 minutes , weekly x 7-8 weeks dU1i.ng days of radiation (Benadt y l 
premedication 30-60 minutes prior to cetuxim.ab infusion as required, see 3 .1.1); 
Cisplatin , 30 m.g/m.2 over 1 hom , weekly x 7 -8 wee ks dming days of radiation (the same day that 
cetuximab is given).  
Patients who receive radiat ion over 8 weeks m.ay receive an 8th dose of cisplatin and cetuxim. ab. 
Radiation therapy 70 Gy/200 cGy/daily , 5 days /week (see 3.3):  
• One hom  of observat ion shou ld elapse  before  staiting  cisplatin  (dming  that pe1io d of time 
patients  will be receiving  pre-cisplatin  hydt·ation) . 
• Bevacizumab  will be given  first followed  by [CONTACT_693943]  (when  it should  be given)  and finally 
cisplatin  on the same  day (only on days  that radiation  is administe red). 
• Radiation will be admin istered following cisplatin  adtninistration . 
 
Radiotherapy will sta1t appro ximately 3-4 weeks after Cycle 3 , Day 1. 
 
Admini strationof Cisplatin  
Cisplatin will require aggressive hydt·ation. Any preexisting dehydt·ation should be co1Tec ted. The 
following hydration regime n is recommended:  
• Pre-cispla tin hydration  will consist  of 1 L NS adtnin istered over 2-3 homs  (taking  into acco unt 
the fluid volumes received from prior dtug admin istration). Mannitol 12.[ADDRESS_1018526] before  or concmrently with cisplatin. 
• Cisplatin wil l be adtninistered in 500 -1000 cc of IV fluids over 1-2 hom s and following adequate 
hydration and the establ ishment of adequate mina1y  output.  
• Post cisplatin hydt·ation will consist of 1 L ½ NS + 30 m.eq KCL/L over 2-4 hours (mannitol 25 g 
IV m.ay be  added).  
Furosemide will be given as needed.  
 
Antiemetic therapy , acute and de layed , including dexam.ethasone and serotonin receptor antagonists is 
recoIIlIIlended . 
3.3 Radiation  Thernpy  
 
3.3.1 Physical Factor s 
• Equipment:  Lineai· acce lerator  with appropriate  photon  and electron  energies  for supp lemen tal 
boost ing to the  nodes.  
• Photon energies of 1.25 to 6 MV and/or approp1ia te electron energies for boos ting the nodes are 
allowed . Photon energies > [ADDRESS_1018527] tai·get loca lized 
centra  lly. 
• Minim.um. treatment distance must be  =::>: 80 cm SSD (or SA  D for isocentiic  techniques).  
 
3.3.[ADDRESS_1018528] R C at UTHSCSA 
CTRC# 11-36 October 25, 2016  
- 30 - CONFIDEN TIAL  
  
 
[IP_ADDRESS]  Simulation  
Simul ation o f all fields is ma ndato1y. Patients must be re producib ly immob ilized. Radio-opaque ma rkers 
should be used to d elineat e the extent of nodal disease and whenever possib le, the pr ima1ytumor , if 
conve ntiona l treatment p lanning is used. The use of cus tomized Ce1rnbend blocks is recommended to 
shape the field and limit dose to no nnal st rnctures. Use o f multileaf collimator to shape the field is 
suggested. For CT simulation, I. V. contrast is recommended and the da ta should be acq uired using 3 mm 
slice w idth and spacing using the spi[INVESTIGATOR_20116] l mode of scanner.  
[IP_ADDRESS]  Verification  
 
Check films should be weekly. Beam po1ta l films m ust be obtained to each field. Electron fie lds utilized 
for supplemen tal nodal boost ing must be ve1ified by [CONTACT_744592]1tal ve1 i fication, simu lation, or diagram.  
3.3.3 RadiationDo se 
Treatmen t to the p1i mruy  tumor  and upper  neck will be given at 2 Gy/fract ion once  each day, five days  a 
week . A total dose  of70  Gy/35fraction/ 7week s will be delivere d. Fields must be reduced to exclude the 
spi[INVESTIGATOR_744505] [ADDRESS_1018529] 46- 50 Gy (even  in NO stage)  at anato mic levels  of lymph  nodes  usually 2-4 cm benea th 
the skin s urface. Clinically positive neck nodes shou ld also receive a dose of 70 Gy/[ADDRESS_1018530]  has been  shielded. Hence, the total dose  to the p1imruy  tumor 
and clinica lly positive  nodes  will be 70 Gy/35 continuous  fractions/7  weeks.  The ante1ior  lower  neck will 
be trea ted at 2 Gy/fraction once a day (3 cm dep th) from the ante1ior to a total dose of 46 -50 Gy /25 
continuous  fractions  (if clinically negative)  in [ADDRESS_1018531] TP E-A can strut XPE-A within an interval of 4 -10 weeks after surge1y 
(6 weeks recommended). In that case the tota l posto perative radiatio n dose wi ll be up to 66 Gy.  
3.3.4 Target Volume Irradiation and Radiation Doses 
A combination  of lateral  opposing  fields is recommended  for the treatment  of the prima 1y tumor  site and 
uppe r neck.  A single  anterior AP field  will be used  to treat  the lower  neck  below the fields of the p1i ma1y 
tumor /upper neck. When there are cl inically invo lved lymph nodes in the lower neck, an addit ional 
poster ior (PA)  field may be necessruy  to deliver a supp lemen tal dose  to the positive nodes.  All fields must 
be treated at each treatment sessio n. The upper and lower fields shou ld be matched us ing a "three 
dimens ional" technique  (i.e., approp1iate rotat ion of the treatment  table and appropriate angulation  of the 
collimator  or beam  split techn ique). However,  if such a three-dimensional  match  is not poss ible, the upper 
neck  and supraclavicu lru· fields may be abutted  at the skin.  The latter  case, a small  block should  be placed 
either in the lower latera l position  in the upper  neck  fields, or in the midl ine of the ante1ior  
supraclav icular field (wh icheve r is approp1iate and does no t block tumor) to the shield ru·eas of potent ial 
over lap of dive rgin g beams over the spi[INVESTIGATOR_1831]. 
3.3.5 Upper Neck Primary Volume 
• The p1ima 1y treatmen t fields shou ld encompass the p1ima1y n1mor and/or suspecte d lymph node 
CT RC at UTHSCSA 
CTRC#  11-36 October 25.  2016  
- 31 - CONFIDE NIATL  
  
 
disease in the u pper neck us ing the sh rinking fie ld techni que as fo llows:  
• The initial target volume should include the primruy tumo r, pos iti ve nodes w ith an approximately  
3.0 cm mru·gin  and the next echelo n of uninvo lved lymphatic  nodal  drainage  sites to a dose  of [ADDRESS_1018532] at 36 
Gy. 
• The secondfie ld reduction will occur at 50 Gy and contin ue to 60Gy with the new tat·get volume 
encompass  ing the p1ima1y  tumor  and known  areas  of nodal  disease  with at approximately  2.0 cm 
margm . 
• The third  and final field reduc tion will occur  at 60 Gy and continue to 70 Gy with the new target 
volume encompass ing the prima1ytumor  and known ru·eas of nodal disease  with at approximately  
1.0 cm marg in. 
As a genera l mle, both ipsilatera l and contralateral  poster ior cervical  noda l chain  and the adjacent 
echelon  of uninvolved lymp hatic nodal  drainage  sites will be treated  to a dose  of 46-50 
Gy/5 weeks . 
3.3.6 Lower Neck Volume 
• A single  lower neck field will be used  to treat the lower  neck  and the supraclavicular fossae. 
When there is (are) positive node (s) in the lower neck , an additional poste 1i or field may be 
necessa1y  to deliver a supplemental  dose  to the positive node (s). The boos t dose  shou ld not 
exceed 70  Gy. 
• The lower  borde r of the lower  neck  field will be just below  the clavicu lar head with appropr iate 
mru·gins when  there  ru·e pos iti ve nodes  in the Supraclavic ular fossa . The lateral  borders of the 
lower neck field w ill extend to the intersection of the stemo cleidomastoid muscle and the 
clavicle . 
• For all patients with clinically positive nodes g reater than 6 c m, or with clinically pos itive 
supra clavicu lru· nodes  , a med iast ina l "T " field may be used . The latera l limbs  of the T field  will 
extend below the clavic ular heads with mru·gin, and the centra l po1tion of the field extends [ADDRESS_1018533] doses may be given through reduced field to persistent tumor and/o r clinically pos itive 
nodes , or to compensate for significant intem1p tions in rad iation thera py treatments (i.e., > 57 elapsed 
days) . The add itiona l boos t dose should not exceed 4 Gy (i.e., 74 Gy maximum). The spi[INVESTIGATOR_744506]. 
3.3.8 Dose Calculation s 
Photon Beam Portal A n angements  
• Dose  specificatio n for two paralle l-opposed  coax ial equa lly weighted  beams  is to be on the 
centra l ray at mid-separat ion of the beams.  
• Dose  specification for two or more  intersecting  beams  is at the intersection  of the centra l ray of 
the beams . 
• For other complex treatment rurnngemen  ts, dose is specified at the center of the clinical tru·get 
volume.  
CTRC  at UTHSCSA 
CTRC#  11-36 October 25. 2016  
- 32 - CONFI DENTIAL  
  
 
Note: There may be seve ral target volumes . 
• For a single an terior AP lower neck field , the prescr ibed does will be delivered at a de pth of 3.0 
cm as determine d by [CONTACT_106623] -axis "supraclavicular point" . When AP -PA fields are used to treat the 
lowe r neck , the dose shall be prescribed at the mid-separat ion of the two beams a long the central 
ray. 
3.3.9 Isodose  Distribut ions 
Isodose distribut ion at central axis is required. All trnatment volumes and c ritical stmctures s hould be 
indicated . Complete isodo se curves are req uired. Attempts s hould be made to keep the dose variation 
within the planning target volume to be w ithin + /- 5% of the target dose . 
3.3.10  Electron Beam Dose Specifications  
The target dose shall be prescribed at the depth of maximum dose . The energy and field size shall be 
chosen so that the target vo lume is encompassed w ithin 90% of the presc1ibed dose . 
3.3.11  Time and Dose Modifications  
• Treatment intem.1ptions  are   strongly discouraged . Treatme nt breaks must be clearly indicated in 
the treatment record when they occur. If the  total treatment  inte1ruptions exceed  ten  treatment  
days , the trea tment will be considered  a  protocol  deviation. The intenuption of  radiation therapy 
for grade 4 muco sitis/denn ati tis/dysphagia is at the discretion of the treating  onco logist. 
• The maximum  permitted  spi[INVESTIGATOR_744507] 45 Gy. 
• Mandibula r osteoradionecros is will rarely occur  if pretreatment  dental  evaluation  is conducted 
prior to radia tion therapy  treatmen t. Pretherapy  extractions  of badly  diseased  teeth  should be 
canied out with conservation of restorab le teeth when poss ible. If an extraction site in the 
mandibl e has to be included  in the ilrndiated  field , 10 to 14 days  shou ld be allowed  for healing 
befo re the initiation of  ilrndiation.  
3.3.12  Radi otherapy Guidelines/IMRT  
Intens ity Modulated Radiation (IMRT) is recommended in thi s study. 
 
[IP_ADDRESS]  Proposed Radiotherapy  Guidelines  
•  All patients will have immobilization devices w ith treatment planning based on Computerized 
Tomography (CT) inform ation in treatment position . The CT slice thickness through target will 
be 3 mm.  
• CT and Magne tic Resonance  Imaging  (MRI)  data will be used  to define  the vaiio us target s and 
contour  normal  stmcture s. MRI  infonnation  will be used  when indicated.  Image  fusion will be 
used  to relate CT/MRI data when  necessaiy.  
• The field sizes and atTangements will be at the discretion of the attend ing Rad iation Oncologist.  
ICRU 50 guide lines will be used for vaiious  Tumor and Target  Nomenclature:  
o The Gross  Tumor Volume  (GTV) : All gross  disease  detemlin ed from  clinical 
exatmnat ion and radiographic studies  (CT/MRI) . 
o The Clin ical Tai·get Volume (CTV) : The ai·ea that potentially contains micro scop ic 
disease . Lymph node groups at risk o f microscopic disease will be outlined as pait of 
CTRC  at UTHSCSA 
CTRC#  11-36 October 25. 2016  
- 33 - CONFI DENTIAL  
  
 
correspond ing CTV.  The margin  between  each  GTV  and co1Tesponding  CTV  can vruy 
from  0.2 cm to 2.5 cm depending  upon  the proximity  to the critical  and uninvolved 
strnctures.  
o The Planning  Tru·get Vol ume (PTV): Provides  a margin  around  CTV  to compensate  for 
internal motion and set up errors . Typi[INVESTIGATOR_897] a 5 mm margin may be used around  CTV.  
 
[IP_ADDRESS]  Radiat ion Target and Dose Specifica tions 
The following is the definition of tru·gets and their dose specificatio ns. 
• Prima1y  T ru·get (PTV3 ): Includes  PTV 's of prima1 y tumor  and the lymph  nodes  containing 
disease . The dose will be ?.70 Gy at 2 GY/ fractions.  
• Secondruy Target (PTV2 ): Includes PTV 's of area at modera te to high 1isk of microscopic  disease  
i.e. first echelon nodes. The dose wi ll be ?. 60 Gy. This is at the treating physican discretion . 
• Te1tiruy  T ru·get (PTV,): Includes  PTV' s of areas  that are at low 1isk of microscopic  disease  i.e. 
second  echelon  lymph  nodes.  The dose  will be approximate ly ?. 46-50 Gy. 
 
Low Neck: The midjugulru· , lo w ju gul ar, and supraclavic ulru·nodes can be treated with IMRT or 
alternatively with an AP field that is beam split to the IMRT fields. Dose Volume Histograms (DVH) will 
be generated for each plan. Radiation doses will be as outlined above.  
Treatment Planning : Either fo1ward or inverse planning can be used in order to achieve the following:  
• The radiation  dose  will be prescribed  to the isodo se line that encompasses  95%  of PTV. 
• No more  than 15% of the PTV  will receive  >110%  of the prescribed  dose.  
• The maximum  dose  within  PTV  does  not exceed  >25%  of the prescribed  dose . 
• No more  than 1% of the tissue outside PTV  will receive  >110% of the prescribed dose . 
• No more than 1% of any PTV will receive < 93% of the prescribed dose. 
• Tissue heterog eneity co1Tection is manda to1y.  
• The planning  priorities  inclu de critical  normal  stmcture  constraints  followed  by [CONTACT_744593]. 
 
No1mal  Tissues  : The appropriate  n01mal  organs  will be contoured.  Dose Volume  Histograms  (DVH) will 
be generated . An attempt will be made to keep the maximum radiation doses to the following organs as 
follows:  
Brain Stems:  
Optic Nerve /Chiasm: 
Spi[INVESTIGATOR_35406] : 
Man dible/TM Joint: 
La1ynx  54Gy  
55 Gy 
45 Gy 
70 Gy or 1 cc of the PTV not to exceed 75 Gy 
70Gy  
 
Pru·otid Glands:  Attempt  will be to achieve mean  dose :'.S [ADDRESS_1018534] 20cc  of the 
comb ined volume of both parotid glands w ill receive < [ADDRESS_1018535] 50% of the gland w ill receive < 
30 Gy (shou ld be achieved in at least one  gland ). 
CTRC  at UTHSCSA 
CTRC#  11-36 October 25. 2016  
- 34 - CONFI DENTIAL  
  
 
Othe r No1ma l Stmcrures: Submandibular /sublingual g lands , inner and middle ears, eye, lens will be 
considered low priority. The aim should be to decrease the dose s as much as possible without 
compromis ing target.  
Toxi cities, and all int erventions for toxi city, must be recorded on th e data forms. 
For patients who have undergone surgery  withou t macroscopic residual  disease  a total radiation 
dose of up to 66 Gy will be admini stered (as postope rative treatment). 
3.4 Supportive Care 
• All supp01t ive measure s consistent with optima l patient care will be given throughout the srudy. 
Aggressive  oral and skin care and analgesics  are recommended.  
• Antiemetic s: Patient s will receive antiemetic  therapy  as recommended  in the treatment  plan.  
• Concomitant  Dmg s 
The prophy lactic  use of G-CSF is recomme nded during  induction  chemotherapy  (i.e. Neulasta on 
day 2 of each induction TPE-A cycle o r Neupogen on days 2-11). If G-CSF cannot be 
admin istered  for any reason , prop hylactic  antibiotics  (e.g. ciprofloxacin  500 mg BID will 
be administered  on days  5-14 of each  cycle  of TPE-A). The use of G-CSF is not allowed 
dming  radiotherapy.  
The u se of erythropoietin is not allowed.  
No other antitmnor agents will be given dming protoco l therapy . 
o The use of amifostine is not pe1mitted. Pi[INVESTIGATOR_744508] (Salagen) is not encouraged dming  
treatment but is allowed. If used, it should be recorde d in the treatment  fo1ms.  
3.5 Gastros tomy Tubes 
Prophylac tic placemen t of a gastrostomy rube before any treatme nt begins is recommen ded but is at the 
discretion of the treat ing physician. It is strongly recommende d in patient s with significant dy sphagia and 
weight loss of >10-15% at baseline or poor overall nutlitional starus. 
CT RC at UTHSCSA 
CTRC#  11-36 October 25,  2016  
- 35 - CONFDI ENTIAL  
  
 
4 SAFETY REPORTI NG OF ADVERSE EVEN TS 
 
4.1 Definition s 
Adve rse event (AE) means any untoward medical occunence in a patient or s ubject administered a 
medic inal investigationa l dmg; the untoward medica l occunence does not necessar ily have to have a 
causal relationship wit h this treatment. An AE can the refore be any unfavorab le and uni ntended sign 
(includ ing an abnonna l laborato1y finding , for examp le), symptom,  or disease  temporally  assoc iated with 
the use of an investigationalmed icinal product whether or not it is considered to be related to the 
medic inal investigational  dtug. This  includes any newly occu ni ng event , or a previous  condit ion that has 
increased  in severity or frequency  since  the adtninistration  of study  drng. 
An ab no1mal laborat01y va lue w ill not be assessed as an AE un less that val ue leads to discont inuation or 
delay in t reatme nt, dose mod ification , therapeutic inte1vent ion, or is cons idered by [CONTACT_140800] a 
clinica lly significantc hange from baseline.  
 
Serio us Adverse Event De finition 
 
Se1io us AE (SAE) means any untoward med ical occunence that at any dose:  
• Results in death. 
• Is life-threatening . (The  te1m "life-threatening"in  the definition of "se1io us" refers  to an event  in 
which the patient  was at risk of death  at the time of the event ; it does  not refer  to an event , which 
hypothetically  lnight  have  caused death  if it were more  severe). 
• Requires  inpatient  hospi[INVESTIGATOR_744509] (see cla1ification 
in the paragraph be low on planned  hosp italizations).  
• Results in persistent or signifi cant di sability/incapacity. Disabi lity is defined as a substantia l 
dismption of a person's ability to co nduct n01ma l life funct ions. 
• Is a cong enit al anomal y/birth  defect. 
• Is a medically important e vent that may not be immediately life threatening o r result in death or 
hospi [INVESTIGATOR_744510]1vent ion to prevent one of the 
other outcome s listed in the definition above, or involves suspected translniss ion via a med icinal 
produc t of an infectious agent. Examples of such medica l events include allergic bronchospasm 
requiting intens ive treatment in an emergency room or at home , blood dyscrasias or convuls ions 
that do not res ult in inpatient hospi[INVESTIGATOR_3094], or the deve lopmento f dmg dependency or  dtug 
abuse; any organism , vims , or infectious pruticle (e .g., prion prote in translnitt ing Translnissible 
Spongifo1mEncephalopathy) , pathogenic or non pathogenic , is considered an infect ious agent.  
 
Cla1ification should be made between the te1ms selious and severe because they ARE NOT synonymo us. 
The te1m seve re is often used to descr ibe the intens ity (seve tity) of a specific event (as in lni ld, moderate , 
or severe myocard ial infru·c iton);  the event itself, however , may be ofr elatively minor medica l 
significance (such as a severe headac he). This is NOT the same as se1io us, which is based on 
patient /event o utcome or action c1iter ia desc1ibed above and is usually assoc iated with events that pose a 
threat to a patient' s life or fimctioning. A severe AE does not necessa1 liy need to be considered serious. 
For exrunp le, persistent nausea of severa l hours duration may be considered severe nausea but not  an 
CTRC  at UTH SCSA 
CTRC#  11-36 October 25. 2016  
- 36 - CONFI DENTIAL  
  
 
SAE . On the other hand , a stroke resulting in on ly a mino r degree of disab ility may be considered mild 
but would be defined as an SAE based o n the above noted criteria. Se1iousness (not seve1ity) serves as a 
guide for definin g regulato1y repo1ting ob ligations.  
 
Unanti cipated Prob lem Involving Risk to Subjectsor Others (UPI[INVESTIGATOR_9961])  
 
Unanticip ated problem involving lisk to subjectsor others include s any incident, ex pelience or outcome 
that meets all of the following criteria: 
(1) unexpecte d (in te1ms of nature, severity, or frequency) g iven (a) the research procedures that are 
described in the protocol-related documents , such as the IRE-approved research protocol and 
info1med consent doc ument; and (b) the character istics of the subject popu lation being  studie d; 
(2) related or possibly related to paiticipation  in the reseai·ch; and 
(3) suggests that the resea rch places subjects or others at a greater risk of harm (incl uding physical , 
psycho logical, economic , or social ha1m) than was previously known or recognized.  
Procedures for Recording and Rep01ting Adverse Events , Se1ious Adverse Events and UPI[INVESTIGATOR_744511]1ted by [CONTACT_5363]/o r in response to an open question from s tudy 
personnel or revealed by [CONTACT_744594]1v ation , physical examina tion, or other d iagnostic procedures will be 
recorded on the approp1iate page of the CRF . Any clinically relevant deterioration in laborat01y 
assessments or other clinical finding is conside red an AE and must be recorde d on the approp 1ia te pages 
of the CRF. When possible, signs and symptoms indicating a common underlying pathology should be 
noted as one comprehensive  event.  
 
All SAEs , se1ious pretreatment events and UPI[INVESTIGATOR_20865] (as defined in Section 4.3) must be rep01ted by [CONTACT_744595]·d (DSMB#2) (See Section 15) in addition to Genetech (See 
Appendix I) o r designee (contact [CONTACT_744596]01mation provided below) by [CONTACT_744597]/UPI[INVESTIGATOR_744512]1m within 1 worki ng day after becoming aware of the event. In addit ion notification via facsimile to 
Genetech (See Appendix I) is required within [ADDRESS_1018536] be rep01ted whether or not considered ca usally 
related to the study mug or stu dy procedures ; howeve r, se1ious pretreatment events that ai·e directly 
related to disease progression , and unrelated to study procedures , ai·e not req uired to be rep01ted . SAE 
report info1m ation and  the dataprov ided on the CRF must match.  All SAEs sho uld be mon itored until 
they ai·e resolve d or are cleai·ly dete1mined to be due to a patient's stable or chron ic condition or 
intercmi:ent illness(es). The SAE rep01 t  must include event te1m (s), se1ious c1ite1i a, and  the investigator 
or sub-investigator's dete1mination of both the intensity of the event(s) an d the relationship of the event (s) 
to study d rng adinin istration. 
 
Planned  hosp ital adinissions  or surgical  procedures  for an illness  or disease  that existe d before the patient 
was enrolled  in the tiial are not to be conside red AEs unless  the condit ion dete1io rated in an unexpected 
manner  dming  the tiial (e.g., surge 1y was perfo1med  earlier or later  than planned).  
CTRC  at UTH SCSA 
CTRC#  11-[ADDRESS_1018537] determine both the intensity of the even t and the relationship of the even t to study 
procedures . 
 
Intens ity for each AE , including any lab abnotma lity, will be dete1mined using the NCI CTCAE , Vers ion 
4.0, 28 May 2009.  
 
Monitoring of Adverse Events and Pe1iod of Observation  
 
AEs, both nonse1ious  and serious  (which include  all deaths) , will be recorded  on the CRF s. AEs will be 
repmted from dosing on Cycle 1, Day [ADDRESS_1018538] dosing on 
study; however , seriou s pretreatmen t events  that are directly  related to disease  progressi on, and unrelated  
to sn1dy procedure ,s are not required to be reported. SAEs will be repotted from the first dose of study  
dtug up to and including  the 30 days  after administration  of dtug in the study. All SAEs  (which include 
all deaths ) must  also be reported  to Genentech  (See Appendix  I) in addit ion to the Data  Safety  Mon it01ing 
Committee  (DSMC).  All SAEs  should  be monitored until they are resolved or are clearly  detennined  to 
be due to a patient 's stable or chronic  condition  or intercunent  illnes s(es). 
Any SAE  that occurs  at any time after  complet ion of the study  and the designa ted follow -up petiod  that 
the investigator considers  to be related  to study dtug must  be repmted  to Genentech  and the DSMB.  
 
This is an investigator -initiated study. The ptincipal investigator, Anand Kamad , MD, who may also 
sometime s be referred to as the sponsor-investigator , is conducting  the study and acting  as the sponso r. 
Therefore , the legal/ethical  obligat ions of the ptincipal  investiga tor include  both those of a sponsor  and 
those  of an investigator.  In the event  that this is a multi site study,  the sponsor -inves tigator  is responsible 
to ensure  that the SAE  repmts  are sent to Genentech  and FDA  from  all sites pattici pating  in the study. 
Subinvestiga tors must repott  all SAEs  to the sponsor -investigator so that the sponsor -investigator can 
meet  his/her foregoing  repmting  obligation s to the IRB, Genentech  and FDA , unless othe1wise  agreed 
between  the sponsor-investigator  and subinvestigator (s). The IRB, Genentech  and FDNJllay request 
follow -up infotmation to a repo1ted SAE , which the sponsor-investigato r will be responsible for 
providing.  
Sponsor -investigator must also provide  Genentech  with a copy  of all communications  with applicable 
regulato1y auth01ities related to the sn1dyor study dtug(s), including, but not limited to, telephone 
conversation  logs, as soon as possible but no later than 5 calendai · days  of such  communication.  
 
Genentech will send to the sponsor-investigator a monthly listing of the SAE repmts received for SAE 
verification . Sponso r-investigator will be responsible for fotwarding s uch repmt s to any 
subinvestigator( s). 
CT RC at UTHSCSA 
CTRC#  11-[ADDRESS_1018539] (IRB). The IRB cunently requires the repo1ti ng of serious (includ ing life­ 
threatening and fatal) adverse events that are unanticipated (i.e., unexpected) and fe lt to be assoc iated 
with (i.e., possib ly related  or related to) the research  intervention(s) . Fatal and life-threatening  adve rse 
events  meet ing these  c1ite1 i a are to be rep01ted  to the Univers  ity IRB within 24 homs of the investigato r­ 
sponso r beco lning aware o f this infon nation. Se1io us adve rse events meet ing these c1ite ria are to be 
reported to the University IRB within [ADDRESS_1018540] igator -sponsor becolning aware of this 
infonnation. 
MedWa tch 3500a Repo rting Guidelines: 
In additio n to comp leting approp1iate patient demographic and suspect medication i nfonnat ion, the repo1t 
should include the following info1mation wi thin the Event Desc1iption (section 5) of the MedWatch 
3500a  fonn: 
• Treatmen t regimen (dosing frequency , combination therapy)  
• Protocol desc1ip tion (and number, if assigned)  
• Desc1iption of Event, Seve1ity , Treatment and Outcome ( if known)  
• Suppo1tive laborat01y res ults and diagnostics  
• Invest igator's  assessmen t of the relationship of the adve rse event  to each investigationa l product 
and suspect  medication  
Follow-up informat ion: 
Additiona l informationmay be added to a p reviously sublnitted report by [CONTACT_744598]:  
 
• Adding  to the origina l MedWatch  3500a  rep01t  and sublnitting  it as follow-up 
• Adding  supplemental summa1y  information  and sublnitt  ing it as follow -up with the 01iginal 
MedWatch 3500a  fo1m  
• Summa rizing new info1mation and faxing  it with a cover  letter includ ing subject  identi fiers (i.e. 
D.O.B. initial , subject  number) , protocol  desc1iptio n and number , if assigned , suspect drug, b1i ef 
adve rse event desc1iption , and notat ion that additional or follow-up inf01mation is being  
sublnitted  (The subjec t identifiers  are imp01tan t so that the new information  is added  to the 
con ect ini tial repo1t ) 
 
Occas ionally Genentech may con tact the repo rter for additiona l info1ma tion, claii fication, or cmTent 
stat us of the subject for whom and adverse event was repo1ted. 
Assess ing Causa lity: 
Invest igators  ai·e required to assess  whether  there is a reasonab le poss ibility that bevac izumab  caused or 
contributed to an adve rse event. The following  general  guidance  may be used . 
: if the tempora l relationship of the clinical event to bevacizum ab adlninistration makes a causal 
relationship possible, and other diugs, therapeut ic inte1vent ions or underlying  conditions  do not prov ide a 
sufficient explanat ion for the obse1ve d event. 
CTRC  at UTHSCSA 
CTRC#  11-36 October 25.  2016  
- 39 - CONF IDENTIAL  
  
 
No: if the tempora l relationship  of the clinical  event  to bevac iZUII1ab  administration  makes  a causal 
relationship unlikel y, or other chu gs , therapeutic interventions or underlying cond itions pro vide a 
sufficient explanat ion for the observed  event.  
 
 
5 STUDY SUBJEC TS 
 
5.1 Eligibility Cii teria 
• Patients with AJCC 7th edition stage III-IVB head and neck cancer , aU sites, including unknown 
primaiy  tumors. 
• Prior  to ent:J.y  in the  study  the resectabi lity and alternati ve treatment  options  for each patient  will 
be determined by a team composed of an Eai·, Nose, and Throat Surgeon , a Radiation Oncologist 
and a Medical  Oncologi st. Stage  determination , optimal  local  t:J.·ea  t:J.nent  , and its timing  according 
to this protocol  will be detennined  at this evaluation . The unequ ivocal demonst:J.·at ion    of   di  stan   t 
metastasis (M1) confers  ineligib ility. 
• Histolog ically  or cytologically  confinned  diagnos is of squainous  cell or poorly differentia ted 
carcinomas , or WHO  types  I-III of the nasopha1ynx.  
• UnidimensionaUymeasurable  disease  is required (REC IST 1.1). 
• No prior chemotherapy , biologic /moleculai·tai·geted  therap  y (including  any prior therap y which  
specifical ly and directly tai·ge ts the EGFR pathway) , or radio therapy for head and neck  cancer.  
• Prior surgical therapy will consist only of incisional or exc isiona l biop sy, and organ spai·ing  
procedures such as debulking of ailway compromising tumors or neck dissection in a patient with 
an ex isting prima1y tumor. Any non-biopsy procedure mu st have taken place > 4 weeks but < 3 
months of initiating protocol  treatment.  
• ECOG  perfonnance  status  0-1. 
• Age of :2:18  y ears. 
• Inf01med  consent  must be obtained  from  all patient s prior to beginnin g therapy.  Patient s should 
have  the ability  to under stand and the willingne ss to sign a written informed  consent  document.  
• All patients should have their tumor ti ssue  tested  for  HPV  (in  situ  hybrid ization  and/or  p16 
staining  by [CONTACT_744599] t:J.y ) , and re sults mu s t be known prior to study ent:J.y, and w ill 
consent to have available archival  tumor samples,  unstained slides or  blocks from previous 
diagnostic or therape utic procedure s submitted for c01Telative studie s, including assessment of 
tai·get molecule s EGFR, VEGF and related biomarkers. Also , patient s must agree to submit blood  
samples for co1Telative stud ies at least at baseline  . 
• Abso lute neu troph il count :2: 1 500  / µl , P latelet  co u nt :2: 100 ,000 / µl 
• Creatinine  clearance  60 ml/min  or higher  calculated  using the Cockcroft -Gault  formula : 
Calculated Creatinine Clearance=  O40-age) X actual body wt (kg) 
72 X sernm creatinine  
Multiply this number by 0.85 if the patient is fema le 
• Total  bililu bin within  nonnal  limits and AST /ALT  less than 3 times the upper  limit  ofnonnal.  
• U1ine  dipstick  must be < 0-1+ within  2 weeks  (14 days)  of randomization.  If urine  dipstick  result 
is > 1+, a calculation  of U1ine  Protein  Creatinine (UPC)  ratio  is requil·ed . Patient s must have a 
CT RC at UTHSCSA 
CTRC#  11-36 October 25. 2016  
- 40 - CONFIDE NIATL  
  
 
UPC ratio < 1.0 to patticipate in the study. 
NOTE:  UPC  ratio of spot mi ne is an estimation  of the 24-mi ne protein excretio n - a UPC  ratio of 
I is roughly  equivalent to a 24-hour urine protein of l gm. UPC  ratio  is calculated using 
one of the following fo1m ula: 
o [mi ne protein] /[urine creatinine] - if both p rotein and creatinine ai·e rep 01ted in mg/DI 
o [(urine protein) x 0.088] /[urine creat inine] - if urine creat inine is repo1ted in mmol/L 
• Patien ts with a prior histo1y of squamous cell or basal carcinoma of the skin or in situ cervical 
cancer  must have  been  curative ly treated.  Patients with a histo1y of other prior malignancy  must 
have been h·eated with curat ive intent and must have remained disease -free fo r [ADDRESS_1018541] 
diagnosis.  
• Patien ts may not be receiving any other invest igationa l agen ts. 
5.2 Exclusion  Criteria  
• Histmy of severe  allergic  reactio ns ath·ibuted  to docetaxe l or compounds  of similar chelnical or 
biologic  compos ition to docetaxe l, or other  drugs  fmm ulated with polysorbate 80. 
• Plior severe  infusion react ion to a monoclonal antibody  or known hype rsensi tivity to any 
component of bevac izum ab 
• Unconh·olled intercmTenti llness incl uding , but not limited to, ongoing or active infect ion or 
psychiatric illness /social situations that would lilnit compliance with study  requirements. 
• All patients will have a baseline EKG . If abn01 m alities cons istent with active coron aiy ait e1y 
disease ai·e detected  , the patient  will be refen ed to a cai·diologist  for approp1iate  evaluation and 
management pr ior to treat ment on  study 
• No patie nts with significant baseline senso1y or motor neurologic deficits (> grade I neuropathy) 
will be treated o n this study. 
• Beca use patients with immun e deficiency ai·e at inc reased1isk of lethal Infe ctions when h·eated  
with matTow -suppressive  therapy  , HIV-positive  patients ai·e ex cl uded  from the study . Appro priate 
studies will be unde1take n in patients with HIV and those receiving combination anti - reh·ov iral 
therapi[INVESTIGATOR_014] w hen indicated.  
• Patients  with HPV positive tumors  (Pl 6+ by [CONTACT_744600]/or HPV+ by [CONTACT_93756]) AND  smoking  histmy =<10 pack-years 
• Inade quately conh·o lled hype 1tension (defined as systo lic blood pressure  >150 mmH g and/or 
diasto lic blood press ure > 100 mmH g) 
• Pi·ior histo1yof  hype 1tensive c1i sis or hype1te nsive encepha lopathy  
• [LOCATION_001] Hea1t Assoc iation  (NYHA)  Grad e II or greater  congestive  hea1tfailure (see Appendix 
F) 
• Histo1y of myocardia l infai·ction or unstab le ang ina within 12 months p rior to  Day I 
• No histmy o f sh·oke or h·ansient ischelnic attack within 6 months p1ior to Day I 
• Significant vascular disease  (e.,g. ao1t ic anemy sm, requiting  surgical repait·or recent pelipheral  
a1te1ial thrombosis) w ithin 6 mo nths p1ior to Day I 
• Histmy of hemoptysis ( 1/2 teaspoo n of b1ight red blood pe r epi[INVESTIGATOR_1865]) w ithin I month prior to  
Day I 
CTRC at UTHSCSA 
CTRC# 11-36 October 25.  2016  
- 41 - CONFDI ENTIAL  
  
 
• Evidence  of bleeding  diathesis  or signi ficant coagu lopathy  (in the absence  of therape utic 
anticoagula tion) 
• Patients should not be on therape utic anticoagulat ion therapy (prophy lactic use of warfarin 1mg 
per day is allowed)  and INR should be <1.5 at registratio n 
• The use of anti-platelet agents (e.g. dipyridamo le (Persatine), ticlop idine (Ticlid) , clopi[INVESTIGATOR_7745]  
(Plavix))  is allowed  only if patient  is not receiving  aspi[INVESTIGATOR_744513]' s known  to inhibit platelet 
function. 
• Majo r surgical proced ure (inclu ding neck  dissection) , open  biopsy, or signi ficant traumatic  injmy 
within 28 days prior to Day 1 or anticipation of need fo r major surgica l procedure during the 
course of the study  
• Core biopsy  or other minor  surgica l proced ure, excluding  placement of a vascu lar access  device, 
within 7 days  prior to Day 1 
• History  of abdominal  fistula or gastroin testinal  perforation  within 6 months  prior  to Day 1 
• Se1ious , non-healing wound, active ulcer, or untreated bone  fracture  
• Pregnant  or breast-feeding women  will be excluded . 
 
 
6 PATI ENT REGISTRATION  
Patients mus t not strut protoco l treatment p1ior to consent be ing signed and be ing registrru· . Treatme nt 
shou ld statt within fi ve working days a fter registration. Subjects can be e molled after eligibility criteria 
are met by [CONTACT_744601] n urse or des ignee . 
 
For quest ions regarding the eligibility of subjec ts, Anand  Kamad,  MD, should be contac ted at (210)  450- 
1267.  
 
Registratio n will requit·e the following infmmation: 1) your name, telephone and page number; 2) 
protocol name  [CONTACT_114040]; 3) date treatment begins;  4) subject  name ; 5) date of bitth; 6) subject hospi [INVESTIGATOR_744514]; 7) p1ima1y study  phys ician;  8) pritna1ytreatment  institution; 9) confi1mat ion of 
eligibility; 10) copi[INVESTIGATOR_744515]1med conse nt signature  [CONTACT_3264]; 11) verificat ion that the info1med  consent 
was signed . 
7 DOSE MODIFI CATIO NS - INDU CTIO N DOCETAXE L / CISPLATI N / CETUXIMAB  / 
BEVACIZUMAB (TPE-A) 
All toxic ities w ill be graded acco rding to NC I Common Toxic ity Cr ite1i a AE ve rsion 4.0 
(http://evs.nci.n ih.gov /ftp1/CTCAE /About.html). 
Patients who cannot  tolerate  induc tion chemotherapy  or have delays for more than 3 weeks due to toxicity 
will proceed  dit·ec tly to chemoradiot herapy  even  without the completion of 3 cycles  of induction. 
Cetuximab or / and Bevacizumab will NOT be held for known doce taxel and cisplatin toxicities. If 
doce taxel and cisplatin are held to allow for the resol ution of known  toxic ities to these  dtugs,  cetuximab 
will be allowed to be adtninistered weekly. 
7.1 Hematologi c Toxici ty (Docetaxel)  
ANC  must be 1,500/mm3   and  platelet  count must be 100,000/ LLo n day 1 of each cycle. 
(Reduce doses o nly for feb1ile neutropen ia or if ANC is < 1,000 for > 5 days.)  
CTRC  at UTHSCSA 
CTRC#  11-36 October 25.  2016  
- 42 - CONFI DENTIAL  
 And  
 
Dose modifi cations on Da y 1 based on nadir  during previous cycle  Cisplatin Docetaxel  
ANC  (per mm3) Platelets (per mm3) Dose Dose 
ANC  >= 1000  >75,000 100%  100%  
Or <1000for <5 days  
500-1000  for >= 5 days or 50,000- 75,000  100%  80%  
<500 for >= 5 days or <50,000 100%  70%  
 
Febri le neut:ropenia  ** 100%  70% 
 
**Neutropenic fever is defined as one reading of ora l temperanire >38.5°C or tln·ee readings of oral temperanire  
>38.0°C in a [ADDRESS_1018542] remain <1,000 
for :::: 5 days before a dose reduction is made . 
If docetaxel i s withheld due to hematologic toxicity , cisplatin shou ld also be withhe ld, and administered 
when the docetaxel is resumed. No do se reductions of cisplatin wi ll be made for hematologic toxic ity. 
In the event  that dose adjustment s are needed  for both  ANC  and platelet s, patients are to receive  the lower 
dose. 
Note: prop hylactic G-CSF  use is recomm ended. Neutropenic  fever is defined  as one reading  of oral 
temperature  > 38.5°C or three  reading s of oral temperature > 38.0°C in a 24-hour  period . 
Treatment should be delayed for up to 2 weeks until the day I ANC i s ::::1500 and the plate let count is 
::::[ADDRESS_1018543] not re cove red in 3 weeks, the patient should start  radiot herapy.  
 
Patients and inves tigators need to be attentive to the possibility of fever and infection so that these 
complications can be promptly and appropr iately managed.  
• When  a dose  reduction  is made  for a decrea sed ANC,  platelet  count  or febri le neutropenia  and the 
reduced  dosage  results in no toxicity , an attempt  should  be made  to gradually  re-escalate  the dose  
in subsequent courses. For examp le, the next course should be given at inte1media te dose rather  
than full dose, e.g., if a 70% dose results in no toxicity, the next course shou ld sta1t at 80% dose 
rather  than 100% (i.e., 70%  dose  increased  to 80%  of dose , and 80%  dose  would be increased  to 
100%). 
• If chemotherapy must be withheld due to hematolo gic toxicity, CBC and platelet counts should  
be obta ined at least weekly until the counts reach the lower limits for treatment as outlined . The 
treatment  sched ule will then proceed  in the u sual sequence . 
• No dose reduction s will be made for anemia. Patient s should be suppo1ted per the treating  
physician 's discretion . 
CTRC  at UTHSCSA 
CTRC#  11-36 October 25.  2016  
- 43 - CONFI DENTIAL  
  
 
 
 
7.2 Neurologic Toxicity(Docetaxe l, Cisplatin) 
Docetaxel and cisplatin doses shou ld be modified as follow s for neurologic toxicity.  
 
 
Grade of tox icity  
Cisplatin/d ocetaxe l doses to g ive 
0 100%  
1 100%  
 
2 Hold treatment until patient recovers to grade O or 1 toxicity , 
then resume treatment at 75% dose. 
 
3 or worse  
Discontinue treatment  
 
If patients do not recover to grade 0 or I neurotoxicity w ithin 2 weeks , they will be taken off-study. Dose 
modification s made for neurotoxicity are pe1manent reductions.  
7.3 Ototoxicity  (Cisplatin) 
Cisplatin i s well known to ca use high-frequenc y heaiing loss. Cont inued u se of the mug does not always 
result in hearing loss, although it may do so. If grade 2 or worse hearing loss is noted , the patient should 
be presented with a disc ussion of the relative 1isks of hea1ing lo ss versus the potential benefit of 
continuing cisplatin therap y, and a decision made on the continuation of cisplatin . Severe hea1ing lo ss 
(grades 3 or 4) is an indication to discon tinue the mug.  
7.4 Gastro intestinal Toxicity (Doce taxel, Cisplatin) 
 
7. 4. 1 Nausea and/or  Vomiting  
Adeq uate antiemetics  for acute  and delayed emes is should  be given.  If grade  3 nausea/vo miting occurs in 
spi[INVESTIGATOR_744516] s, the cisplatin  dose  should  be reduce d by 25% for the next course . Doses of docetaxe l 
may be reduced  by 25%  in subsequentcycles  if needed.  If tolerated , increase  back  to I 00% dose  as soon 
as possible.  
7. 4. 2 Stomatitis  
If stomatit is is present on day I of any cycle , treatment should be withhe ld until stomatiti s has resolved to 
grade 0. 
If Grade  3/4 stomatiti s occurs at any time, the dose of docetaxe l should be given  at 75%  dose when  the 
muco sitis is completely  cleared . 
7.5 Renal Toxicity  (Cisplatin) 
Measurement of sernm creatinine is required before each cycle of mug. Modify the C isplatin dose using 
the follo wing pai·amete sr for calculated creatinine clearance determ ined in the we ll-hydrated patie nt 
using the Cockcro ft-Gault for mula. The actual weigh t will be used for the calculation of creatin ine 
clearance.  
CTRC  at UTHSCSA 
CTRC#  11-36 October 25.  2016  
- 44 - CONFI DENTIAL  
  
 
CrClcma1e )s=  (140-age) x  weighl(l<: gy'(creatinine  x 72) 
CrC  l(females)= CrCl(male)s X 0.85  
 
Creatinine C learance  Cisplat in to give  Docetaxel to give  
60 mL/min 100%  100%  
50-60 mL/min 50%  100%  
< 50 mL/min 0% 0% 
 
If semm creatinine is increased by 100% over base line or is increased above upper institutional limits , a 
24-hour urine collection with measurement of creat inine clearance is recommended . 
If creatinine clearance is decreased s uch that treatment is not ad!ninistered as scheduled , repeat the 
abn01ma l tests  eve1 y week at least . If  the senu n creatinin e/creatinin eclearance returns  to baseline  (    60 
mL/min) , cisplatin may be reinstituted at 50% of the full dose during the next cycle (permanent dose 
reduction) . 
If the creatinine clearance is between 50 -60 mL/inin , docetaxe l should be cont inued at the dose dictated 
by [CONTACT_744602]. If the creatinine clearance is < 50 mL/min, 
withhold any therapy until creatinine clearance improves. Delays in therapy shou ld not be more than 2 
weeks. If a delay of >2 weeks is necessaiy patients should be taken off study . 
If semm creatinine increased at any time to 2-4 mg/dL, a pe1manent dose reduction of cisplatin by 20% 
will be app lied; if semm creatinine increased at any time to >4 mg/dL , a pe1manent dose reduction of 
cisplatin by 40% will be applied.  
7.6 Hepatic Toxicity( Docetaxel) 
The day [ADDRESS_1018544] and ALT should be dJ·awn. The more abn01mal of the two val ues (AST or ALT ) should be 
used in dete1mining the dose . 
Patients who develop abno1mal liver funct ion tests for any reason while on the study wi ll have the 
following do se reduct ions: 
Docetaxel Dose M odifications fo1· Abnormal Liver Function 
 AST 0 1· ALT : 
ALK P HOS: ULN  >1xbut 1.Sx >1.Sx but x >SxULN  
ULN  Full Dose  Full Dose  Full Dose Hold*  
> Ix but 2.Sx  Full Dose Full Do se Reduce Dose by 20% Hold*  
>2.Sx but Sx Full Dose Reduce Dose by 20% Hold*  Hold*  
>Sx ULN  Hold* Hold* Hold*  Hold*  
CTRC  at UTHSCSA 
CTRC#  11-36 October 25,  2016  
- 45 - CONF IDENTIAL  
  
 
*Hold until recovered, maximum 14 days, then re -treat at a reduced dose by 20%. "Recove red" is defined as 
meeting the study baseline eligibility criteria.  
 
Biliru bin: Doce taxel should not be administered to patie nts with senun total bilirnbin >ULN. If serum 
total bilirnbin is >ULN  on treatment  day, hold docetaxel  until sernm  total bilirnbin is ::;; ULN  (maximum 
14 days), then re-trea t at a reduced  dose by 20%. 
7.7 Hyperse nsitivity Reactions (Docetax el) 
See section 8.4 for managemen t guide lines. Discontinueprotocol  treatment  for Grade  3 or 4 infusion 
related reaction s or allergic reactions . There  are no dose  reductions  for infusion  related  reactions  or 
allergic  reactions . 
7.8 Fluid R etention  (Docetaxel) 
Fluid retention should be managed a s outlined in section 8.5. 
 
7.9 Other Non-Hematologic Toxicities 
For any grade 3 or 4 toxicity not mentioned above , the trea tment should be withheld until the patient 
recovers  completel y or to grade  1 toxicity then reinstituted (if medica lly approp 1aite). The treatmen t (both 
cisplatin and docetaxel) should then be resumed at 75% dose (pe1manent dose reduction).  
For grade 1 and 2 toxicities, no dose reduction shou ld be made . 
 
8 DOSE MO DIFICATIO NS- RADI ATION PLUS CISPLATIN / CETUXIMAB / 
BEVAC IZUMAB (XPE -A) 
Prior  to initiating  chemoradiat ion, all p1ior  toxicities occuned  during inductionchemotherapy , except 
alopecia and aneln ,ia should have resolved to grade  0-1. 
The follo wing cr ite1ia should be met to sta1tchemoradiation as per protocol : 
 
• Stomatiti s should have  completely  resolved (grade  0) 
• ANC  1500  cells/mm3 
• Platelet count o f > 100,000 cells/mm3
 
• Creatinine  clearance  60 mL/min 
 
If these parameter s are not met , patient s may strut radiation therapy a lone and receive cisplatin / 
cetuximab / bevacizumab when these c1ite1ia are met. 
If  patients develop  significan tnon-hematolo gci  cisplatin -associate d toxicities, such as ototoxicit y, 
nausea/volniting , and neuropathy  (see 8.1.3 below) , will receive  carboplatin  AUC  1.5 weekly  instead  of 
cisplatin dmi ng chemoradiotherapy. Cisplatin, cetuximab and bevacizumab will only be given 
concunent ly with radiation . 
Cetuxim ab or/and bevaciz umab will NOT be held for known cisplatin  toxicities. If cisplatin is held 
to allow for the resolution of known cisplatin toxicities, cetuximab or /and bevacizumab will be 
allowed to be  admini stered. 
CTRC  at UTHSCSA 
CTRC#  11-36 October 25,  2016  
- 46 - CONF IDENTIAL  
  
 
Dose Modification s for Cisplatin During Chemoradiotherap y 
(For  cetuximab  and bevacizumab  dose modifi cation  see above) 
8.1.1 Neutropenia 
If on the day of scheduled treatment with c isplat in the abso lute neutrnph il count {ANC ) is < 1000 , hold 
cisplatin until ANC >= l0 00 , then t reat at 100% dose. Neut:ropenic fever wi ll require pe1mane nt 25% 
dose reduction.  
8.1.2 Tlirombocytopenia 
If on the day of scheduled treatment with cisplatin the plate let count is < 75,000, hold treatment until 
platelets  are 2:: 75 , 000 , the n treat at 100%  dose.  Thrombocytope nia that results  in bleeding  will require 
pe1m anent  25%  dose  reduction . 
8.1.3 Neurotoxicity 
If persistent grade 2 neuropathy (>1 week) , see 8. 1.9 (carbo platin substitution).  
If any signs  of grade  [ADDRESS_1018545] cisplatin disco ntinued.  
8.1.4 Renal Toxicity 
Meas urement of senun creatinine is req uired before each cycle o f dtug. Mod ify  the cisplatin dose using 
the fo llowing parameters for calc ulated creatinine clearance dete1mined in the well-hydt·atedpatient  using 
the Cockcroft -Gault fo1mula.  
CrC l(mates) = (140-age) x weight(kgy(sen un creatinin e x 72) 
CrCl(females)= ClCr(males) X 0.85 
The actual weight w ill be used for the calcu lation of C reatin ine C learance . 
 
Cisplat in shou ld be adtninistered on the schedu led day of treatment using the fo llowing gu idelines:  
 
Creatinine C learance  
2:: 60 mL / min 
< 60 ml/min  C isplat in Dose 
l00%  
0 (Substitute Carboplatin AUC 1.5 weekly)  
 
*If at the time of treatment serum creatinine is increased by 100% or more over baseline or to above 
institutional  upper  limits  of nonnal , a 24-hour mi ne collection  with  calculation  of creatinine  clearance  is 
recommended . 
If semm creati nine increased at any time to 2 -4 mg/dL , a pe1manent dose reduction of 20% w ill be 
applied; if senun creatinine increased at any time to >4 mg/dL , carboplatin wi ll be used instead of 
cisplatin on a ll subsequent cycles.  
8.1.5 Ototoxicity  
Cisplatin is well known to ca use high -frequency hearing loss. Continued use of the dt ug does not always 
result in hearing loss , although it may do so. If pers istent grade 2 heating loss is noted , the patient should  
CTRC  at UTHSCSA 
CTRC#  11-36 October 25,  2016  
- 47 - CONF IDENTIAL  
  
 
be presented with a discussion of the relative risks of hearing loss versus the potential benefit of 
continuing c isplatin therapy , and a decision made on the continuation of cisplatin or switching to 
carboplatin (see 8.1.9). Severe hearing loss (grades 3 or 4) is an indication to discontinue the chu g . 
8.1.6 Nausea and/or  Vomiting  
Adequate  antiemetics  for acute  and delayed  emesis  should  be given.  If grade  3 nausea/vomiting  occurs  in 
spi[INVESTIGATOR_744517] , the cisplatin  dose  should  be reduced  by 25%  for the next course . If tolerated , increase 
back  to 100% dose  as soon as possible.  
8.1.7 In-field Toxicities During Radiation: Radiation Mucositis I Dysphagia I Dermatitis  
No cisplatin dose adjustments for grade 3 or less radiation muco sitis/dysphagia/de1matitis.  
 
Grade 4 radiation muco sitis / mucositi s / or de1matiti s that develops at any time will require pe1manent 
25% dose reduction of cisplatin on all subsequent cycles. If radiation is given in the setting of grade 4 
muco sitis / dysphagia / de1matitis , cisplatin will be achnini stered with a 25% dose reduction.  
IfRT is held because ofmucositis, hold cisplatin , cetuximab and bevacizumab until RT is resumed.  
8.1.8 Otller  Toxicities  
For any grade 3 or 4 toxicity not mentioned above (exce pt fatigue , anorexia , weight loss, alopecia , 
electrolyte  abn01malities  that are being  cotTected  , and any cetuximab -related  toxicity) , cisplatin  should be 
withheld tmtil the patient recovers completely or to grade 1 toxicity after discussing the case with the 
principal  investigator.  Cisplatin  should  then be resumed  at 75%  dose  (pe1manent  dose  reduction).  
For grade 1 and 2 toxicities , no dose reduction should be made . 
8.1.9 Carboplatin Substitution During  Chemoradiotllerapy  
Patient s developi[INVESTIGATOR_744518] -induced toxicities will discontinue Cisplatin and substitute 
Carboplatin , AUC 1.5, achninistered as a 30-minute infusion weekly using the follo wing formula to 
calculate the total dose:  
(CrC l + 25) x 1.5 = total mg dose*  
• Persistent grade 2 senso1y  or motor  neuropathy  (objective  weakness  or sens01y  loss intetfering 
with function  but not interfering  with activities  of daily  living) 
• Nephrotoxicity with creatinine clearance < 60 ml/min on the day of sched ule chemotherapy 
achninistration , a 1ise in sem m creatinine to >4 mg/dL at any time, or per sistent/ refract01y  
hypomagnesemia or other electrolyte imbalances and severe kidney abnonnalities that can be 
atttibuted to cisplatin.  
• Ototoxicity - Carboplatin may also cause ototoxicity. If hearing loss of grade 1 -2 from  
carboplatin is noted , the patient should be presented with a discussion of the relative ri sks of 
heating  loss versus  the potential  benefit  ofreceiving  cai·boplatin  therap  y. Seve  re heating  loss 
(grades  3 or 4) is an indication  to discontinue  the carboplatin.  
• Grade  4 nausea  and vomitin g despi[INVESTIGATOR_744519]1iate  antiemetics  
CTRC  at UTHSCSA 
CTRC#  11-36 October 25,  2016  
- 48 - CONF IDENTIAL  
  
 
Calc ulation of Carboplatin Dose: The dose of Carboplatin during chemoradiotherapy will be calculated 
using the following f01mula (Coc kc roft-Ga ult fo1mula ): 
Carboplatin Dose (mg) = 1.5 x (CrC I1·2 +25)  
CrClcmates) = (140-age) x weight{kg)/ (serum creatinin e x 72) 
CrClcremales=)  CrCl (males)x 0.85  
The actual weight will be used for the calculation of Creatinine Clearance.  
By [CONTACT_5638] 2010 , all clinical laborator ies in the US will use the new standardized Isotope Dilution 
Mass Spectrometly (IDMS ) method to measure semm creatin ine. The IDMS method appears to 
underestimate serum creatinine values compared to o lder method s when the semm creatinine val ues are 
relatively low ( e.g., ~0.7 mg/dL). Measurement of serum creatin ine by [CONTACT_744603] -method could result in 
an overestimation of the Glomemlar Filtt·ation Rate (GFR ) in some patient s with n01mal renal function. If 
the total carboplatin dose is calculated based on IDMS -measured semm creatinine using the Calve 1t 
f01mu la, carboplatin dosing cou ld be higher than desired and could result in increasedm ug-related 
toxicity.  
The cmrnnt label for carboplat in provide s safe dosing instluctions that are based on actua l GFR 
measmement s. Provided that actual GFR mea surement s are made to assess renal funct ion, carbop latin can 
be safe ly dosed according to the insttuctions desc1ibed in the labe l. 
(http: //dailymed .nlm.nih.gov /dailymed/dtu ginfo.cfm ?id = l 3328 ) 
 
If a patient's GFR is estimated based on semm creatinine measurement s by [CONTACT_92337] , as 
recollllllended by [CONTACT_1622], physician s should consider cappi[INVESTIGATOR_744520] (AUC) to avoid potentia l toxic ity due to overdosing. Based on the Ca lve1tf01mula de scribed in 
the carboplatin label , the maxim um doses can be calculated as : 
Tota l Carboplatin Dose (mg) = (target AUC) x (GFR +25) [Calve 1t fo1m ula] 
Maximum Carboplatin Dose (mg) = target AUC (mg•min/mL ) x (150 mL/min)  
The maximum dose is based on a GFR estimate that i s capped at 125 mL/min for patient s with n01mal 
renal function. No higher estimated GFR values should be used.  
For a target AUC  = 6, the maximum  dose  is 6 x 150 = 900 mg 
For a target  AUC  = 5, the maximum  dose  is 5 x 150 = 750 mg 
For a target  AUC  = 4, the maximum  dose  is 4 x 150 = 600 mg 
8.1.10  Carboplatin  DoseMod ifications  
Carboplatin will only be given concmrnntly w ith radiation.  
• Carboplatin will be administered if platelets are 75,000 cells/llllll3 or above and ANC is 1000  
cells/tmn3 or above. Treatlnent will be delayed unt il the above c1ite1i a are  met.  
• No carboplatin dose adjustlnent s for grade 3 or less muco sitis/dysphag ia/den natiti s. Grade 4 
muco sitis/ dysphagia /de1mat itis that deve lops at any time  will require  a pe1manen t dose  reduct ion 
CTRC at UTHSCSA 
CTRC# 11-36 October 25.  2016  
-49 - CONFIDE NIATL  
  
 
of carboplat in to an AUC  of 1 on all subseq uent cycles.  If radiation  is given  in the setting  of grade 
4 mucositis/dysphagia/de1 matitis, carbo platin will be given  at a reduced  dose  of AUC of 1. 
• If in the previous  cycle  of carboplatin , patients  developed  grade  4 thrombocytopenia  or grade  4 
neutropenia or neutropenic  fever, or grade  3 or 4 non-hematologic  toxic ities with the except ion of 
mucositis /dysphagia/  de1mat itis, carboplatin  dose  will be reduced  to AUC  of 1 in all subsequen t 
administrations . 
• Ifneuropathy  worse ns to a grade  3 (impa ilment  of funct ion) after  treatment  with carboplatin,  then 
patients may discontin ue chemothera py for reasons o f toxic ity at the disc retion of the treating 
physician , based  on seve1i ty of function loss.  
• Patients  developi[INVESTIGATOR_744521]  [ADDRESS_1018546]  carboplatin  discontinued . 
8.2 Management of Cetuximab Adverse Reactions and Dose Modifi cation s 
Cetuxim ab will NOT be held for known docetax el, cisplatin  and bevacizum ab toxici ties. If 
docetaxel, cisplatin  and bevacizumab  are held to allow for the resolution  of known  toxiciti es to 
these drug s, cetuximab  will be allowed to be admini stered weekly 
Cetuximab  will be held or its dose  reduced to dose  level -1 or -2 (see below ) for the following  toxicities 
(see 8.2.2 to 8.2.4). 
Cetuximab w ill NOT be he ld or reduced for hematologic toxic ities. 
Dose levels fo r cetuxilnab are as follows : 
Cetux imab Dose Levels  
 
 
 
 
Staiting dose  Weel -dy Cetuxi mab dose  
250 mg/m2  
 
 
Dose  Level -1 200 mg/m2  
Dose  Level -2 150 mg/m2  
 
 
There will be no dose leve l reduct ions be low a weekly dose of 150 mg/m2. 
8.2.1 Manageme nt of Infusion Reactio ns 
Severe infusion reactions requil·ethe ilnmediate interruption o f cetuximab therapy and pe1manent 
disconti nuation from further trea tment. Appropriate medica l therapy including epi [INVESTIGATOR_238], 
c01ticos  teroids,  intravenous  antihistainines , bronchodilators , and oxygen  should  be available for use in the 
treatment of such reactions . Patients shou ld be caref ully obse1ved unti l the comp lete reso lution of all 
signs and  symptoms . 
In clinical trials, lnild to moderate infus ion react ions were managed by [CONTACT_744604]-medications  (eg, diphenhydrainine)  in subseq uent 
doses.  If the patient  experiences  a lnild  or moderate  (Grade  1 or 2) infus ion reaction , the infusion  rate 
should  be pe1manent ly reduced  by 50% . For grade  1 or 2 reactions  manifesting only  as delayed  drng 
fever , see below  in Section  8.2.2. 
CTRC  at UTHSCSA 
CTRC#  11-36 October 25,  2016  
- 50 - CONFI DENTIAL  
  
 
Cetuximab should be immediately and permanently discontinued in patients who experience severe 
(Grade 3 or 4) infusion reactions.  
8.2.[ADDRESS_1018547] use clinical  judgment  to detennine  if the fever  is 
related to the study dmg  or to an infectious  etiology . 
If a patient experiences isolated dmg fever , for the next dose, pre treat with acetaminophen or non­ 
steroidal anti-inflammat01y agent (investigator discretion ), repeat antipy:retic dose 6 and 12 hour s after 
cetuximab infusion. The infusion rate will remain unchanged for future doses . 
If a patient expe1i ences  recun:entiso lated dmg fever following  premedication  and post-dosing with an 
approp 1i ate antipy:retic,  the infusion  rate for subsequent  dosing should  be 505 of previous rate. If fever 
recurs  following  infusion  rate change , the investigator  should assess  the patient's  level of discomfo1t  with 
the event  and use clinical  judgment  to dete1ruine  if the patient  should  receive  further  cetuximab . 
8.2.3 Management of Pulmonary  Toxicity  
In the even t of acute onset  (grade 2:2) or wo rsening  pu lmona 1y symptom s whic h are not though t to be 
related to unde rlying cancer , cetuximab therapy should be intenupted and a prompt inve stigation of these 
symptoms should occur. If ILD is confirmed , cetuximab should be discontinued and the patient should be 
treated appropriately.  
8.2.4 Management of  Dermatologic Toxicity 
Patients developi[INVESTIGATOR_471773] 1m ato logic toxicities while receiving cetuximab should be monitored for the 
development of inflammatmy or infectious sequelae, and approp1iate treatmen t of these symptoms 
initiated . Dose modifications of any future cetux imab infu sions should be instituted in case of severe 
(grade 3) acneifonn rash. Treatment with topi[INVESTIGATOR_199]/or o ral antibiotics shou ld be considered ; topi[INVESTIGATOR_744522] t recommended.  
If a patient expe1iences  seve re acneifonn  rash, cetuximab  treatment  adjustments  should  be made 
according  to the following  table.  In patients  with mild  and moderate  skin toxicity , treatment  should 
continue without  dose modification. 
CTRC  at UTHSCSA 
CTRC#  11-[ADDRESS_1018548] occunence  Delay infusion 
1 to 2 weeks  Impro vement  Continue at 250 mg/m2 
  No Impro vement  Disconti nue cetuximab  
2nd occmTence  Delay infus ion 
1 to 2 weeks Impro vement  Reduce dose to 200 mg/m2 
  No Impro vement  Disconti nue cetuximab  
3rd occmTence  Delay infusion 
1 to 2 weeks  Impro vemen t Reduce dose to 150 mg/m2 
  No Impro vement  Discontinue cetuximab  
4th occmTence  Discontinue    
 cetuximab    
Intole rable Delay infusion Impro vement  Dose reduct ion by [CONTACT_744605]  2 1 to 2 weeks (only  during  No improvement  
maintenance ) 
 
8.2.5 In-field Toxicities DuringRadiation: Radiation Mucositis I Dysphagia I Dermatitis  
No cetuximab dose adjustme nts for grade 3 or less radiatio n muco sitis, dysphag ia, dennatiti s. 
Grade  4 radiation  mucositis /dysphagia  or de1matitis  that develops  at any time will require pe1manent  dose 
reduction  of cetuximab  by [CONTACT_744606].  If radiation  is given  in the setting of 
grade 4 radiation  mucositis/dysphagi a/de1m atitis, cetuximab  will be admin istered  with a dose reduction 
by [CONTACT_28633].  
IfRT  is held becauseof in-field toxicities, hold cispla tni and cetuxima b until  RT is resumed.  
8.2.6 Retreatme nt Criteria/or  Cetuximab  
Cetuximab  may only be admini stered  if all the following criteria  are met regardles s of cycle , providin g no 
criteria  for discont inuation are met:  
• Acne -like rash is grade  2 or less 
• All grade 3 or 4 non-hematologic out-of-field toxicities (except fatigue , anorex ,ia alopecia , and 
dianhea , and any cisplatin/carboplatin  or docetaxel -assoc iated toxici ties of any grade)  have 
resolved  to grade  1 or 0. 
• Patients with hypomagnesemia and other electrolyte abnormalitie s can be treated on sc hedu le and 
without a dose reduction if the abno1mal ity can be con -ected (e.g. intravenou s magne sium is given 
for con -ection of hypomagnese  mia). 
• Cetuximab can be administered  in the setting  of any grade  hematologic toxicities.  
• For in-field toxicit ies see 8.1.7.  Discontinue  
CT RC at UT H SCSA 
CTRC#  11-[ADDRESS_1018549]. 
Bevacizumab has a terminal ha lf-life of 21 days; therefore , its discont inuation results in slow elimination 
over severa l months . There is no available antidote for  bevacizumab.  
Subjects should be assessed clinically for toxic ity prior to, dming, and a fter each infus ion. If 
unmanageab le toxic ity occ urs beca use ofbevacizmnab at any time d uring the study , treatment with 
bevacizumab sho uld be discont inued.  
Anap hylaxis Preca utions : Anaphy laxis precaut ions shou ld be obse rved during bevac izumab 
administration . The pat ient' s blood pressure and heait rate should be monitored during the infusion. 
Eme rgency  agents  including  oxygen , oral and endotrachea l ailways , intubation  equipment , epi[INVESTIGATOR_238], 
antihistatninesand  co1t icosteroids  should be availab le. fu the event  of a suspected  anaphy lactic reaction 
dming bevac izumab in fusion, stop the bevac izumab in fusion and apply a tomniq uet proximal to the 
inject ion site, if possible, to slow systemic absor ption of bevac izumab. Administer antihistam ines, 
epi[INVESTIGATOR_238] , or other  medicatio ns at the investigatorsd iscretion.  
fufusion  Reaction:  fufus ion of bevac izumab  shou ld be inten upted for subjects who deve lop dyspnea  or 
clinica lly significant hypotension . Subjects  who expe rience  a NCI CTCAE  v. 4.0 Grade  3 or 4 allergic 
reaction  / hype rsensi tivity, adult respi[INVESTIGATOR_141876]1y  distress  syndrom e, or broncho spasm (regai· dless of grade) 
will be disco ntinued  from  bevaci zumab treatment. 
The infusion  shou ld be slowed  to 50%  or less or intenu pted for subjects  who expe1ience  any infusion ­ 
associated  symptoms  not specified  above.  When  the subject's  symptoms  have comp letely resolved, the 
infusion may be continued  at no  more  than 50%  of the rate prior to the react ion and increased  in 50% 
increments  eve1y  30 minutes  if well tolerated.  fufusions may be restaited  at the full rate dmi ng the next 
cycle . 
Adve rse events  requiling  delays or pennanent  disco ntinuatio n of bevacizumab  are listed in the table 
below. 
If bevacizumabi s held for any reason, the other study drug s will be given on time assuming 
param eters for their continuation ar e met and the patient will remain on study. 
Bevacizumab Do se Mana gement Du e to Adve1·seEve nts 
Eve nt Ac tion to be Taken 
Hypertension  
No dose modifications for grade 1/2 events  
Grade 3 If not controlled to 150/100 mmHg with medication, discon tinue be vacizuma b. 
Grade 4  
(includin ghyperten svi e 
encephalopath )y Discontinue bevacizumab  
CTRC at UTHSCSA 
CTRC# 11-36 October 25,  2016  
- 53 - CONF IDENTIAL  
  
 
Hemorrhage  
No dose modifications for grade 1/[ADDRESS_1018550] bevacizuma b held until  all of the following  criteria are 
met:  
The bleeding ha s resolved and hemoglobin is stable.  
There is no bleeding diathesi s that would increase the risk of the rapy. 
There  is no anatomic  or pathologic  cond  ition that significantly increa ses the risk of 
hemorrhage  recmTence . 
Subjec ts who experience  a repeat  Grade  [ADDRESS_1018551]  bevacizumabheld  until  all of the following  criteria are 
met:  
TI1e bleedingha s resolved and hemoglobin is stable.  
Ther e is no bleedin g diatl1e ssi  that woul d increas e the risk of therap y. 
There  is no anatomic  or pathologic  cond ition that significantlyincrea ses the risk of 
hemorrhage  recmTenc e. 
Grade 2 , 3, or 4 puhnonary or 
CNS hemoll"hage  Discontinue bevacizumab  
Venou s Tirrombosis  
No dose modifications for grade 1/2 events  
Grade 3 or 4  Hold  study  drug  treatmen t. If tlie planned  dura tion of full-dose  anticoag ulation  is < 2 
weeks , bevacizumab  should  be held until  the full-dose anticoagulati on period  is over. 
Iffue  planned  duration  of full-dose  anticoagula tion is > 2 weeks , bevacizumab  may be 
resmned  during tl1e period  of full-dose ru1ticoagulation  if all of tl1e following  c1iteria 
are met:  
The subject  must  have an in-range  INR (usually  between  2 and 3) if on warfarin; 
LMWH , warfarin , or other  anticoagulan t dosing must  be stable  prior to restarting 
bevacizumab  treatmen t. 
TI1esubject  must not have had a Grade  3 or 4 hemorrhagice vent while  on 
anticoagulation . 
Alteri.a l Tirromboembolic event 
(New onset, worsening , or unstable  angin, a  myocru -dial infru·ction , transie n t ischemi c  attack , cerebr o vascular  acciden t , and 
any oilier arteria l thromboembolic event ) 
Ally grade  Discontinue bevaciz umab  
BevaciZlllllab Dose Managemen t due to Ad verse Events 
Conges tive Hear t Failure (Left. ventriculru·systolic dysfi.mction ) 
No dose modifications for grade 1/2 events  
Grade 3  Hold bevacizumab un til resolution to Grade ::; 1 
Grade4  Discontinue bevacizumab  
Proteintlfia  
Nodose modifications for grade 1/2 events 
 [Proteinuria  should be monitored  by [CONTACT_744607]  (UPC) 
ratio  ptior  to every other dose of bevacizumab ] 
CTRC at UTHSCSA 
CTRC# 11-36 October 25,  2016  
- 54 - CONF IDENTIAL  
  
 
UPC Rat io 
<3.5 or 24-h mine protein <3.5 
gm Continue bevacizumab.  
UPC ratio;::3.5 or 24-h urine 
prote in 2:._3 . 5 gm  Hold bevacizumab until UPC recovers to< 3 .5, or 24 -h mine protein < 3.5 gm 
 
Discontinue  bevacizumab  if urine  protein does  not recover to < 3.5 after  8 weeks or 
bevacizumab  intem .1ption.  
 
Nephrotic syndrome   
Discontinue bevacizumab  
Fistula  
Any grade (TE fistula ) Discontinu e bevacizumab  
Grade 4 fistula Discontinue bevaciZll!nab  
Bowel Obstmction 
Grade 1 Continue patient on study for partial obstruction NOT requiring medical inte1ve ntion. 
Grade 2  Hold bevacizumab  for partial obstmction requiring medica l intervention.  Patient may 
restart upon comp lete resolution. 
Grade 3 /4 Hold  bevacizumab  for complete  obstmction . If surge 1y is necessaiy  , patient may restait 
bevacizumabaft.er  full recovery  from  surgery , and at investigator ' s discre tion. 
Wound dehiscence Any grade 
(requiring medical or smgical 
therapy)  Discontinue bevacizmnab  
Perforation (GI, or at1y other 
organ)  Discontinue bevacizmnab  
Revers ible Poste1i or Leukoe ncephalopathy 
Any grade 
(confirmed by [CONTACT_9268])  Discontinue bevaciztunab  
Other Unspecified Bevaci.Zll!nab -Rela ted Adverse Even ts 
Grade  3 
Grade4  Hold bevaciztunab until reco ve1y to :5Grade 1 
Discontinue bevaciztunab  
 
8.4 Docetaxel-Associa ted Hypersensitivity Reactions 
Treatment should be discontinued for Grade 3 or 4 hypersen sitivity reactions. 
There are no dose reductions for hypersensitiv ity reactions . 
Management of Acute Hyperse nsitivity 
Seve rity of Symptoms  Treatment Guidelines  
Mild symptoms: localized 
cutaneo us reactions such as mild 
pn ni tus, flushing , rash Consider decreasing the rate of infusion until recove 1y from 
symptoms , stay at bedside and monitor patien t then, complete 
Docetaxel infusion at the initia l planned rate  
Moderate symptoms: any symptom 
that is not listed above (mild 
symptoms) or below (severe 
symptoms) s uch as gene ralized 
pnni tus, flushing , rash, dyspn ,ea 
hypotens ion with systol ic • intem1p t Docetaxel  infusion  
• give diphenhydramine  50 mg IV with or without  
dexamethasone 10 mg IV ; monitor patient until 
resolution of symptoms  
• resmne Doce taxel infusion after recove1y of  symptoms ; 
depending on the phy sician ' s assessment of the patient , 
CTRC at UTHSCSA 
CTRC# 11-36 October 25,  2016  
- 55 - CONF IDENTIAL  
  
 
BP > 80 lllIIl Hg Doceatxel infusio n should be resumed  at a slowe r rate, 
then increased  incremental ly to the initia l planned  rate, 
(eg. infase  at a 8-hour  rate for 5 minutes,  then at a 4-h 
rate for 5 minutes,  then at a 2-h rate for 5 minutes,  then 
finall y, resume at the Ih infusion rate). 
• depending on the intensity of the reaction  observed,  
additiona l oral or N premedication with an 
antihistamine should also be given for the next cycle of 
treatment , and the rate of infusion should be decreased 
initially and then increased back to the recomm ended 1 - 
hour infusion, (eg. infuse at a 8 -hour rate for 5 minutes , 
then at a 4-h rate for 5 minutes, then at a 2 -h rate for  5 
minutes, and finall y, administer at thel -h infi,1sion rate ). 
Seve re symp toms: any reac tion 
such as bronchospasm, generalized 
urticaria , systolic  BP 80mm Hg, 
angioedema  • immediate ly discontinue Docetaxel  infusion  
• give diphenhydramine 50 mg N with or  without  
dexamethasone 10 mg N and/or epi[INVESTIGATOR_30481]; 
monitor patient until resolution of symptoms the same 
treatment guidelines outlined under  moderate  
symptoms (i .e. the third and fourth bullets) should be 
followed.  
Grade [ADDRESS_1018552] ions or alle rgic reactions  DISCONTINUE PROTOCOL TREATMENT*  
In the case of a severe life-threatening anaphylactic reaction , 
docetaxe l will not be re -administeredand hence docetaxe l will 
be discontinued.  
Following an infusion related reaction or allergic react ion, and 
depending on its sever ity, additiona l oral or N premedication 
with an antihistarnine shou ld be given p1ior to the next 
administration and the rate of the infusion should be increased 
gradua lly to the recommended I-hour infusion rate (e.g. at an 8 
hour rate for 5 rninutes , then a 4 hour rate for 5 minutes , then at 
a 2-hour infusion rate fo r 5 minutes , then finally , resume at the 
I-hour infusion rate) . 
 
*In case of prolonged or recmTent infusion reactions or allergic 
reactions, following initial imp rovement , or if hospi[INVESTIGATOR_744523] l sequelae, or if life-threaten ing 
consequences; urgent intervention is indicated . 
 
8.[ADDRESS_1018553] RC at UTHSCSA 
CTRC#  11-36 October 25. 2016  
- 56 - CONFIDE NIATL  
 )  
 
Patients developi[INVESTIGATOR_744524] , progress ion of existing edema , or another sign of fluid retention 
(eg. 2 pound weight gain) are to be treated with oral d iuretics. Regimens found to be e ffective in the 
management of fluid retent ion due to Docetaxe l are listed below. 
• Tliamterene/hydrochlorothiazi de one capsule po qd up to tid. 
• Furosemide 40 mg po da ily if edema progresses despi[INVESTIGATOR_30483]/hydrochlorothiazide therapy . 
Potassium  suppleme ntation shou ld be g iven as needed.  
• If afte r a two -week tlial , furosemide 40 mg po qd is ineffective , the patient may be t1·eated  with  
furosemide20  mg po daily plus meto lazone  2.5 mg po daily with potass ium supplementation as 
needed.  
Fmih er therapy sho uld be custo mized de pending upon the clin ical s ituation. The cl inical to lerance of the 
patient , the overa ll tumor response and the medical ju dgment of the inves tigator w ill detennine if it is in 
the patien t' s best interest to continue or discontinue treatmen t. 
8.6 Hyperlacrimation  
The excessive lacrimation (epi[INVESTIGATOR_744525]) seen in some patien ts receiving Doce taxel appears to be re lated to  
cumu lative dose (median 300 mg/m2 and reso lves rapi[INVESTIGATOR_335501] r treatmentcessa tion. 
 
Excessive lac1imat ion seems to be the res ult of a che mical conjunct ivitis and/or chemica l inflammation 
(with edema) o f the lac1imal duc t epi[INVESTIGATOR_111647] (produc ing a revers ible lac1ima l duct stenos is). 
Consequent ly, investigato rs in clinica l trials have treated such patien ts with (a) artific ial tears and/or (b) 
saline eyew ash and/or (c) stero id based eye drops.  
It is suggested t hat the following approach be taken fo r patients expe1ie ncing clinica lly significant 
hyperlaclimat ion: 
• Withho ld Docetaxe l treatment fo r 2 weeks , 
• Recommend frequent instillation of ait ificial teai·s, 
• Presc ribe a steroid ophthalmic solution (eg. p redniso lone acetate ) 2 gtts each eye b id for 3 days  
stai·ting the day before Docetaxe l adminis tration in patien ts without a hist01y of herpet ic eye 
disease  . 
9 DURATIO N OF THERAPY  / WITHDRA WAL FROM  STUDY 
Patients w ill rece ive a max imum o f [ADDRESS_1018554]  salvage  surge1yat  the discret ion of the multidisc iplina1yteain.  
 
10 DRUG FORM ULATIO N AND  PRO CUREMEN T 
 
10.1 Docetaxel  
 
10.1.1  Other Names 
Taxote re®, RP56976  
CTRC  at UTHSCSA 
CTRC#  11-[ADDRESS_1018555] other biological effects, including induc tion of apoptosis , and 
inhib ition of angiogenesis.  
10.1.4  Storage a11d  Stability  
Doceta xel vials shou ld be stored  between  2 and 25oc (36 and 77° F). Retain  in the 01iginal  package  to 
protect from  blight  light.  Freezing  does  not adversely affect  the product.  
Docetaxel infusion solution , if stored between 2 and 25°C (36 and 77°F) is stable for 4 hour s. Fully 
prepared docetaxe l infusion solution (in eithe r 0.9% Sodium Chl01ide solution or 5% Dextro se solution ) 
should  be used within  4 hours (includin g the 1 hour i.v. admin istration). 
10.1.5  Dose Specifics  
Docetaxel  will be administered  at a dose  as per 3.1. The BSA will be calculated  with the patient' s actual 
weight.  
10.1.[ADDRESS_1018556]  ions provided  below.  Note : Both  the docetaxel  for Injection  Concentrate  and the 
diluent vials contain an ove1ftl l. 
[IP_ADDRESS]  Preparation of the Initial Diluted  Solution  
• Gather  the appropriate  number  of vials of docetaxe l for Injection  Concentrate  and diluent (13% 
Ethano l in Water for Injection). If the vials were refrigerated, allow them to stand at room 
temperature for approximatel y 5 minutes. 
• Aseptically withdraw the contents of the approp1iate diluent vial into a syringe and tr·ans fer it to 
the appropriate via l of docetaxel for Inject ion Concentrate.  If the proce dure is followed as 
desc ribed, an initial dilut ed solution of 10mg docetaxel/mL wil l result. 
• Mix the initia l diluted  solution  by [CONTACT_744608] 45 seconds to assure  full 
mixture of the concentr·ate and diluent. Do not shake. 
CTRC at UTHSCSA 
CTRC# 11-36 October 25.  2016  
- 58 - CONFDI ENTIAL  
  
 
• The initial diluted docetaxel  solutio n (10 mg docetaxel/mL)  should  be clear;  howeve r, there  may 
be some  foam  on top of the solution due to the polyso rbate 80. Allow the solution  to stand for a 
few minutes to a llow any foam to dissipate. It is not required that a ll foam dissipates p1ior to 
contin uing the preparation  process.  The initial diluted solution  may be used  immediatelyor  stored  
either  in the refrigerator  or at room  temperature  for a maximum  of 8 hours. 
[IP_ADDRESS]  Preparation of the Final Dilution for  Infusion  
• Asept ically withdraw the required amo unt of initial di luted docetaxe l solution (10 mg 
docetaxel/ mL) with a calibrated  syringe and inject  into a 250 mL infus ion bag or bottle  of either 
0.9% Sodium Chlo1ide  solution or 5% Dextrose  solution to produce  a final conce ntration  of 0.3 to 
0.74 mg/mL.  If a dose  greater than 200 mg of docetaxel  is required, use a larger  volume of the 
infusion vehicle so that a conce ntration of 0.74 mg/mL docetaxe l is not exceeded.  
• Thoroughly  mix the infusion by [CONTACT_744609]. 
• As with all parenteral  products, docetaxel  should be inspected  visual ly for paiticulate  matter  or 
disco loration  p1ior  to administration  whenever  the solution and conta iner pennit. If the docetaxe l 
for Injection initial diluted solution or final d ilution for infus ion is not cleai· or appeai·s to have 
precipi [INVESTIGATOR_332] , these should be discai·ded . The fina l docetaxel dil ution for infusion should be 
administered intraveno usly as a I-hour infusion unde r ambient room temperat ure and lighting  
conditions . Contact  [CONTACT_744610] l concentrate  with plasticized  PVC  equipmen t or devices  used 
to prepai·e  solutions  for infusion is not recommended . In order  to minimize patient exposure  to the 
plasticizer  DEHP (di-2-ethylliexy l phthalate) , which  may be leached from  PVC infusion  bags  or 
sets, the final docetaxe l dilution for infus ion should  be stored  in bottles  (glass, polypropylene ) or 
plastic bags (po lypropylene , polyolefin) and adminis tered through polye thylene-lined 
adminis tration  sets. 
10.1.[ADDRESS_1018557] that is connected to t he patie nt's 
vasculai· access catheter.  
10.1.8  Incompatibilities/In teractions 
Contact  [CONTACT_744611] ·e solutions 
for infusion shou ld be avoided . Diluted docetaxel solution should be stored in bottles (glass , 
polypropy lene) or plastic bags  (polypropy lene, polyolefin)  and admi nistered through  polyethy lene-lined 
administration  sets. 
The metabo lism of docetaxel  may be modifie d by [CONTACT_744612] , inhibit, or are metabolized by [CONTACT_9058] P450 3A 4, such as cyclosp01ine , terfenad ine, 
ketoconazole  , e1y thromyc  in, and troleandomyc in. Caution should be exercised  with these  mugs  when 
treating  patients  receiving  docetaxel , as there  is a potent ial for a significant interaction . 
10.1.9  Availability 
Docetaxel (Taxotere®)is commercia lly available by [CONTACT_744613]. 
CTRC at UTHSCSA 
CTRC# 11-36 October 25.  2016  
- 59 - CONFDI ENTIAL  
  
 
Docetaxe l for Injection Concen trate is s upplied in a single -dose v ial as a steri le, pyrogen-free, non­ 
aqueous , viscous solution with an accompanying sterile , non-pyrogenic , diluent (13% ethanol in Water 
for Injection) vial. The fo llowing strnngths are availab le: 
DOCETAXEL  80 MG (NOC 0075-8001 -80) 
Docetaxel (doce taxel) 80 mg Concentrate for Infusion: 80 mg docetaxe l in 2 mL polysorbate 80 a nd 
diluent for docetaxe l 80 mg. 13% (w/w) ethano l in Water fo r Injection. Both items are in a b lister pack in 
one caiton.  
DOCETAXEL  20 MG (NOC 0075-8001 -20) 
 
Doceta xel (docetaxe l) 20 mg Concentrate for In fusion: 20 mg docetaxe l in 0.5 mL polysorba te 80 and 
diluent for docetaxe l 20 mg. 13% (w/w) ethano l in Water fo r Inject ion. Both items a re in a b lister pack in 
one caiton.  
Handling and Disposal: Procedures for proper handling and disposal of anticance r drugs should be 
cons idered.  Several  guidelines  on this subject have been  published. There  is no general  agree ment that all 
of the procedures  recom mended  in the guidelines ai·e necessa 1y or approp1iate  
10.1.JO Side Eff ects 
Cardiac:  a rrhythmi as, pe1icard ial effusions (d ue to fluid retent ion). Hypotension may occur in 3% of 
patients . Clinica lly meaning ful events such as hea1t fa i lure, sinus tachycai ·dia, atti al flu tter, dysrhythmia, 
unstab le angina, pulmona1y edema, and hyp e1tension occur rai·ely.8.1 % of metastatic  breast cancer 
patients receiving docetaxel 100 mg/m 2 in a rando 1nized trial and who had se1ia l left ventricu lar ejection 
fractions assessed  deve loped dete1i oration of LVE F by 2:_l 0%   assoc  i ated wit h a  drop below the 
institutional  lower  litnit of n01ma l. 
Hematolo gic: d ose -re lated neutropen ia , thro mbocytope n ia , and anetnia. Neutt ·openia (< 2000 
neutrophils/1Ilill3) occurs in virtually  all patients given  60-100 mg/m 2 of docetaxel  and  grade 4 
neutt·openia (< 500 cells/1Ilill3) occ urs in 85% of p atien ts given 100 mg/m 2 and 75% o f patients given 60 
mg/m2. Febri le neutt·o penia occurs in 12% of patie nts given 100 mg/m2 but is uncolilillon in patients given 
60 mg/m2. The median time to nadir is [ADDRESS_1018558] an increased 1isk for severe neutrope nia, and 
neutt·openic fever, as  well  as severe thrombocytopenia . Neutropenia and thrombocytope nia are 
significantly reduced with weekly schedu les of adtninistratio n. 
Gastrointestinal : nausea and votni  ting, diaiThea , and mucosi  tis, whic  h ai·e generally  tnild  to moderate. 
Severe  gastro intestina l react ions occur  in 5% of patients.  
Neurologic : severe neurosens01y symptoms (dysesthes ias, pai·esthes ias, or pain) occ ur in up to 6% of 
patients, whereas severe motor neuro pathy develops in 4% of patients.  
Hyperse nsitivity : Severe hypersensitivity reactions  chai·acte1i zed by [CONTACT_13199]/or broncho spasm, or 
generalized rash/e1ythe ma occurs  in 2% of patients  premedicated  with 3-day c01ticostero  ids. Patients  with 
a his to1yo f life-threatening hype rsensitivity react ions should not be rechalle nged with docetaxe l. 
CTRC  at UTHSCSA 
CTRC#  11-36 October 25. 20 16 
- 60 - CONFI DENTIAL  
  
 
Fluid retention : Severe fluid retention occurs in 7% of patient s desp ite use of a 3 -day dexamethasone 
premedicat ion regimen . It is characterized by [CONTACT_396474]: poo rly tolerated 
periphe ral edema , genera lized edema , pleural effus ion requiring mgent d rainage , dyspnea a t rest, cardiac 
tamponade , or pronounced a bdominal distention due to asc ites. Flu id retention may be cumulat ive and is 
less likely to develop with weekly reg imens. 
Derma tologic : alopec ia, reversib le rash, nail changes , and infus ion site reactions. Infusio n site reactions 
were generally mild and consisted of hyperp igmentation , inflamma tion, redness or drynes s of the skin, 
phlebitis, extravasa tion, or swelling of the vein.  Severe  nail changes  with hypo - or hype1pi[INVESTIGATOR_744526] . 
Hepatic:  In patien ts with normal l iver function tests a t baseline , an elevation in bilimbin occms in 9% of 
cases. Increases in AST or ALT > 1.[ADDRESS_1018559] , or alkaline phospha tase > 2.[ADDRESS_1018560] , are 
observed in 19% and 7% of patien ts, respectively.  
Other : asthen ia , dysgeusia , anorex ,ia conjunctivitis , epi[INVESTIGATOR_119230] , aithralgia , myalgias.  
 
 
 
Toxicities w ith 100 mg/ m2 of docetaxel 
(patients with normal L FTs) 
Adverse Eve nts % 
Neutrope nia <2000 cells /mm3  95.5  
<500 cells /mm3  75.4 
Thromb ocytopenia <100,000 cell s/mm3  8.0 
Anemia <8 g/dL  8.8 
Febrile Ne utropenia 11.0 
Septic Death 1.6 
Infections (Severe)  6.1 
Hype1·sensitivity rea ct. ion (An y) 21.0  
(Severe)  4.2 
With 3-day Premedication  (Severe)  2.2 
Fluid r etention (Any)  47.0 
(Severe)  6.9 
With 3-day Premedication  (Any)  64.1 
(Severe)  6.5 
Neurosensory (Any)  49.3 
(Severe)  4.3 
Cutaneous (Any)  47.6 
(Severe)  4.8 
Nail changes (Any)  30.6  
(Severe)  2.5 
Any Gastroint estinal (Severe)  4.7 
Nausea 38.8  
Vomitin g 22.3  
Diarrhea 38.7  
CTRC  at UTHSCSA 
CTRC#  11-[ADDRESS_1018561].omatit  is (Any)  41. 7 
(Severe)  5.5 
Alo pecia 75.8  
Asthenia (Any)  61.8  
(Severe)  12.8  
Mya lgia (Any)  18.9  
(Severe)  1.5 
Arthralgia 9.2 
Infusion Site Reactions 4.4 
(Table  modified  from  Doce taxel PrescribingInforma  tion (Aven tis). 
PDR 2000.) 
 
 
10.1.11  Nursing  Implications  
• Monito r CBC  with different ial and platelet count  p1i or to mug adininistration.  
• Symptom management of expected nausea , vomit ing, and muco sitis. 
• Advi se patient s of possible hair loss. 
• Patients  should  be obse rved closely for hype rsensitivity  reaction s, especially  during  the first and 
secon d infusion s. 
• Resuscitation  equipment  and medications  to treat hype rsensitiv ity reacti ons should be available 
dming docetaxe l administration . 
• Monitor liver function  tests. 
• Evaluate site regularly for signs of infiltration.  
• Monitor  for symptomsand  signs of fluid retention , and pe1iphera l neuropathy . 
 
10.1.12  References  
• Docetaxel presc1ibing information (Aventis). PDR  2003.  
• BmT si HA, hvin R, Kuhn  J, et al. Phase  I clinical trial of Taxotere  administered  as either  a 2-hour 
or 6-hour inti·a venous infusion. JCO 1993;11:950 -58. 
• Fossella FV, DeVore R, Ken- RN, et al. Randomized phase III ti·ial of docetaxe l  versus 
vinorelbine or ifosfamide in patient s with advanced non-small-cell lung cancer pre viously ti·eated 
with platinum-containing chemotherapy regimen s. The TAX 320 Non -Small Cell Lung Cancer  
Study Group. J Clin Oncol  2000 ; 18:2354 -62. 
• Pi[INVESTIGATOR_94899] M.J., Klijn J, Paridaen s R, et al. C01ticosteroids  signifi cantly delay the onset  of docetaxel­  
induce d fluid  retention:  final analysis  of a randomized  study of the European  Organizati on for 
Research and Treatment of Cance r Invest igational Dmg Branch for Breast Cancer. JCO 
1997;15:3149. 
• Tomiak , E., Pi[INVESTIGATOR_744527]  M.J., Kerger , S., et al. Phase I study of docetaxe l administered  as a I-hour 
inti·avenous infusion on a weekly  basis. JCO 1994 ;12:1458.  
• Hainswo1th JD, Buni s HA, Erland JB , Thomas M, Greco FA. Phase I trial of docetaxel 
adininistered  by [CONTACT_744614].  J Clin Oncol 1998 ; 
16:2164-8. 
• Hains wmth JD, Bm i s HA, Litch y, S. et al . Weekly docetaxel in the treatmentof elderly  patien ts 
CT RC at UTHSCSA  
- 62 - CONFIDE NITAL  
 CTRC#  11-36 October 25,  2016  
 
 
with advanced non-small -cell lung cancer : A M innie Pearl Cancer Research Network phase II 
trial, Cancer 2000;89:328 -33. 
10.1.13  Taxotere Reimbur sement Program  (PACT +) 
Website: http://www .taxotere .com/hcp /index .asp 
PACT + offers toll-free support at 1-800-996-ONCO (6626) Monday through Friday , from 8 :30 AM to 
6:[ADDRESS_1018562]+ 
Program at ePACT@access2 health.com.  
In addition  to calling The Aventis  Oncology  PACT+ Program , healthcare  profe ssionals  and patients can 
fax info1mat ion requests to the PACT+  Program  fax number:  [PHONE_15534] 
10.2 Cisplatin (Cis-diaminedi chloroplatinum , CDDP)  
 
10.2.1  Formulation  
Each  vial contai ns 10 mg or 50 mg of CDDP . Vialsa re recon stituted  with sterile  water.  The pH range  will 
be 3.5 to 4.5. Cisp latin is also commerc ially availab le in solution. 
10.2.2  Storage and  Preparation  
Vials of cisplatin are stored at room  temperature . When  reconstituted  as directed , the solution is stable  at 
room  temperature  for 20 hours. When  fmther  diluted  to 0.5 mg/ml with nom1alsaline, it is stable for 72 
hours  at room  temperature . Cisplatin  10 mg/vial and 50 mg/ml should be reconstitu ted with 10 and 50 ml 
of sterile water , respectively, resulting in a 1 mg/ml solution. The desired dose of cisplatin is fiuther 
diluted with 250 ml or more  of 0.45% -0.9% NaCl  and 5% dextrose , or n01mal  saline  . 
10.2.3  Administration  
Intravenou s over 1-2 hours (see treatment plan) 
 
10.2.[ADDRESS_1018563]  been  renal  toxicity  manifested  by [CONTACT_744615] , 
tinnitus  and audiologic  impailment  in the high  frequency  range  (4000  to 8000  Hz), nausea and vomiting, 
hypern 1i cemia, mild  to moderate  anemia,  peripheral  neuropathy , and electrolyte  abno 1malities.  
10.2.[ADDRESS_1018564] with aluminum which is found in some syiin ge needles or IV sets f01min g a black 
precipi[INVESTIGATOR_047]. C isplatin is less stable in solutions that do not contain chloride ions (e .g. 5% dextrose).  
CTRC at UTHSCSA 
CTRC# 11-[ADDRESS_1018565] ion, D5W , or 0.9% Sodium Chloride . Five mL o f the 
diluent should be added  to the 50 mg vial, 15 mL to the 150 mg vial and 45 mL to the 450 mg vial for a 
resulting concentration  of 10 mg/mL. Carbop latin can be further diluted to concentrations  as low as 0.5 
mg/mL with D5W  or 0.9% Sodium Chlo1ide . 
10.3.3  Storage and Stability 
Unopened via ls of carboplat in are stable for the life indicated on the package when stored at con trolled 
room temperat ure 15°-30°C (59° 86 ° F), and protected from l ight. When prepared as dire cted, carboplatin 
solution s are stable for 8 hour s at room temperature (25° C) or for 24 hours refrigerated (2 -8° C). 
10.3.[ADDRESS_1018566] nously (see Treatment plan ). 
 
10.3.6  Availa bility 
Commercially a vailable.  
 
10.3. 7 Side Effects  
Hematologic: Bone marrow suppre ssion i s the dose-limiting toxicity o f carbop latin. (1) 
Thrombocytopen ia, with platelet counts below 50,000/mm3, occur s in 25% of the patien ts (35% of 
pretreated  ovarian cancer  patients ), (2) neutropen ia, with granulocyte  count s below  1,000/mm3, occur s in 
16% of the patients  (21% of pretreated  ova1ian  cancer patients) and, (3) leuko  penia, with WBC  count s 
below, 2 000/mm3, occurs in 15% of the patients  (26% of pretreated  ova1i an cancer  patient s). The nadir 
usually occur s about day 21 in patient s receiv ing single agen t therapy . By [CONTACT_4475] 28, 90% of patient s have 
platelet count s above  100,000/mm3; 74% have  neutroph il count s above  2,000/mm3; 67% have leukocyte 
counts above 4,000/mm3. Mairn w suppression is usually more severe in patients with impa ired kidne y 
function. The hema tologic effect s, altho ugh usually reversible, have resulted in infectio us or hemorrha gic 
complications  in 5% of the patients treated  with cai·boplatin . Fever has also been  reported in patient s with 
neutropenia.  Anemia  with hemoglob in less than 11 g/dL has been  observed  in 71% of the patient s who 
staited therap y with a baseline above that va lue. The incidence of anemia increa ses with increa sing 
exposure to carboplatin. Transfusions have been admin istered to 26% of the patient s treated with 
carboplatin (44% of previou sly treated ovaiian cancer  patients). 
CTRC at UTHSCSA 
CTRC# 11-36 October 25. 2016  
- 64 - CONFIDENTIAL  
  
 
Gastrointe stinal : Vomi ting occurs in 65% of the patients (81% of previous ly treated ovarian cancer 
patients) and in about one -third of these patients it is severe. Nausea alone occurs in an additio nal 10 to 
15% of patients.  
Neurologic : Peripheral neuropathies have been observed in 4% of the patients receiving carboplatin (6% 
of pretreated ovarian cance r patients ) with mild paresthesias occun in g most frequently. Carboplatin 
therapy produces signific antly fewer and less severe neuro logic side effec ts than  does therap y with cisplatin. 
However, patients older than 65 years and/or previously treated with cisplatin appear to have an increased 
1isk (10%) for peripheral neuropathies . Clinical ototoxicity and other sens01y abn01malities  such as 
visual disturbances and change in taste have been rep01ted in only 1% of the patient. Although the overa ll 
incidence of peripheral neurologic side effects induced by [CONTACT_391411], prolonged treatme,nt 
particularly  in cisplatin-pretre ated patients, may result  in cumulative  neurotoxicity.  
Rena l: Developmen t of abno1ma l renal  function  test results is unco1mno n, despi[INVESTIGATOR_744528], unlike cisplatin, has usually been administered without high-volume fluid hydration and/or 
forced diuresis . The incidences of abn01mal renal function tests reported are 6% for serum creatinine and 
14% for blood urea nitrogen (10% and 22%, respectively , in pretreated ovarian cancer patients). Most of 
these repo1ted abnonnalities have been mild and about one half of them were revers ible. 
Hepa tic: The in cid ences  of abno nnal liver function  tests in patients with nonnal  baseline  values were 
repo1ted  as follows:  total bilirnbin,  5%; SGO T, 15%; and alkaline phosphatase , 24%; (5%, 19%, and 
37%, respectively , in pretreatedovar ian cance r patients) . These  abn01malities  have generally  been  mild 
and reversible in about one-half of the cases , although the role of metastatic tumor in the liver may 
complicate the assessment in many  patien ts. 
Electrolvtes : The in cidences  of abn 01ma lly decreased  serum electro lyte values reported  were as follows: 
sodium, 29% ; potassium , 20% ; calcium , 22%; and magne sium, 29%; (47% 28%, 31%, and 43%, 
respectively , in pretreated ovaiian cance r patients).  
Aller gic reactions:  Hypersensitivity to carboplatin has been reported in 2% o f the patients . These allergic 
reactions have been similar in nature and seve1ity to those rep01ted with other platinum -containing  
compound s, i.e., rash, mticaria, e1ythem, a  prnritu s, and rarely  bronchospasm  and hypotensio n. These  
reactions  have  been  successfu lly managed  with standard epi[INVESTIGATOR_744529] , co1ticostero id, and antihistam ine 
therapy . 
Other events : Pain and asthenia we re the most frequently repo1t ed miscellaneou s adve rse effects; their 
relationship to the tumor and to anemia was likely. Alopecia was repo1ted (3%). Card iovascular , 
respi[INVESTIGATOR_20325]01y , genitouri na1y , and mucosal side effects have occmrnd in 6% or less of the patients.  
10.3.[ADDRESS_1018567] w ith aluminium  
 
10.3.9  Nursing  Implication s 
Monito r CBC with differential  and platelet count  p1ior  to drng  admin istration. 
Sym ptom management  of expected  nausea  and vomiting.  
CTRC at UTHSCSA 
CTRC# 11-36 October 25. 2016  
- 65 - CONFIDENTIAL  
  
 
10.4 Cetuximab (C225, ERBIT UX) 
Cetuximab is an anti-EGFR human -to-murine chime1ic antibody. Ce tuximab is expre ssed in SP2 /0 
myeloma  cell line, grown  in large scale cell culture bioreactors  and pmi fied to a high  level  purity  using 
several pmi fication  steps including  protein  A chromatography , ion exchange  chromatography , low pH 
treatment  and nano filtration . Cetuximab  is not known  to be a vesicant.  
10.4.1  Supplier/How Supplied 
The product  is a sterile , clear,  color less liquid  of pH 7.0 to 7.4, which  may contain  a small amount  of 
eas ily visible, white, amorp hous cetuximab  pa1ticu lates. Each  single -use 50-mL vial contain s 100 mg of 
cetuximab at a concentrat ion of2 m g/mL and i s f01mu lated in a pre servative -free solution containing 8.48 
mg/mL sodium ch lo1ide , 1.88 m g/mL sodium phosphate diba sic heptahydrate , 0.42 mg/mL sodium 
phosphate monobas ic monohydrate , and Water for i njection, USP.  
10.4.2  Packag ing and Labeling  
Cetuximab fo r injectio n will be in single-use, ready -to-use 50-mL vials containing 2 m g/mL of prod uct. 
10.4.[ADDRESS_1018568] be dispensed only from  official  study sites by [CONTACT_744616] s. Cetuximab should be stored in a secme area according to local regulatio ns. It is the 
responsibility of the Investigator  to ensure that study dtug  is only dispensed to study patient s. 
10.4.4  Storage RequiremenVStab ility 
Store vials under refrigeration at 2 ° C to 8 ° C (36° F to 46 ° F). DO NOT FREEZE . Increased paiti culate 
fo1mation may occur at temperatures at or be low 0°C. This product contains no pre se1vati ves. 
Prepai·a itons of cen1xi mab in infu sion container s are chemically and physically stable for up to 12 hours at 
2° C to 8°  C (36° F to 46 ° F) or up to 8 hours at controlled room temperature (20° C to 25 ° C; 68° F to 
77° F). Discai·dan y remaining solution in the infusion container after 8 ho urs at controlled room 
temperature or afie r 12 hour s at 2° to 8° C. D iscai·dany unused po1tion of the vial. 
10.4.[ADDRESS_1018569]  be adtnini stered  with the use of a low protein  binding  0.22-micrometerin -line filter. 
Cetuximabi s supplied as a 50-mL, single -use vial containing  100 mg of cetuximab  at a concentration  of 
2 mg/mL in phosphate  buffered saline. The solution should be clear  and colorless and may contain  a small 
amount  of easily visible white  amo1phou s cetuximab  pa1ticula tes. DO NOT SHAKE  OR DILUT E. 
Cenlx.imab can be admini stered v ia infusion pump or syiinge pump.  
 
Infusion P ump: 
• Draw up the volume of a vial using a ste1ile syi·inge atta.ched to an appropr iate needle (a vented  
spi[INVESTIGATOR_744530]1iate tran sfer de vice m ay be used). 
• Fill cetuximab into a sterile evacuated container or ba g such as glass container s, polyolefin bag s 
(eg, Baxter Intravia), ethylene vin yl acetate bags (eg, Baxter Clintec), DEHP p lasticized  PVC 
CT RC at UTHSCSA 
CTRC#  11-36 October 25.  2016  
- 66 - CONFIDE NIATL  
  
 
bags (eg , Abbott L ifeca.re) , or PVC bags.  
• Repeat procedure until the calc ulated vo lume has been put in to the container. Use a new needle 
for each  vial.  
• Administer through a low protein b inding 0.22 -micrometer in -line filter (placed as proximal to 
the patien t as practical). 
• Affix  the infusion line and prime it with cetuximab  before  sta1ting the infusion.  
• Maximum infusion rate should not exceed 5 mL/min.  
• Use 0.9% saline solution to flush line at the end of infusion.  
SVIin  ge Pu m p : 
• Draw up the vo lume of a vial using a ste1ile sy ringe attached to an appropr iate need le (a vented 
spi[INVESTIGATOR_744531]). 
• Place the syringe into the syiinge  diiver  of a syiinge  pump  and set the rate.  
• Administer through a low prote in binding 0.22 -micrometer in -line filter rated for syringe pump 
use (p laced as proximal to the patient as pract ical). 
• Connect  up the infusion  line and strut  the infusion after  p1i ming  the line with  cetux imab. 
• Repeat procedure u ntil the calc ulated vohune has been  infused. 
• Use a new needle  and filter for each  vial. 
• Maximum in fusion rate should not exceed 5  mL/min.  
• Use 0.9%  saline solut ion to flush line at the end of infusion. 
• Cetuximab should be pi[INVESTIGATOR_744532] t' s infusion line. 
Follow ing the cetux imab infusion, a I -hour obse rvation pe1iod is recomm  ended.  
10.4.[ADDRESS_1018570] ion, gloves,  and Class II ve1tica l-lamina.r-air fl ow safety 
cabinets  are recommended  dming prepai·ation  and hand  ling . Opened  vials must be disposed  of at the 
investigat ional center as chemot herapy or biohazardo us waste provideddoc umented proceduresfor 
destmction ai·e in place.  
Cetuximab  therapy  should  be used with caution in patients  with  know n hypersensit ivity to Cetux imab, 
mmine  proteins , or any component  of this product.  
It is recommended  that patien ts weai· sunscreen  and hats and limit sun exposure while receiving 
cetuximab  as sunlight can exace rbate any skin reactions  that may occur.  
10.5 Bevacizumab  
 
10.5.1  Other  Names 
RhuMAb VEG F, Avas tin 
 
10.5.2  Class ification 
Recombinant h umanized monoclonal ant ibody  
CTRC  at UTHSCSA 
CTRC#  11-36 October 25.  2016  
- 67 - CONFI DENTIAL  
  
 
10.5.3  Molecular  Weight  
Approximate molecular weight is 149 ,000 daltons 
 
10.5.4  Mode of  Action  
Bevacizum ab blocks the binding of vascular endothe lial growth factor (VEGF) to its receptors result ing in 
inhibition of angiogenes is. 
10.5.5  Description  
Bevacizum ab is a recombinant humanized  anti-VEG F monoclonal  antibody , consisting  of93%  human 
and 7% murine  amino  acid sequences.  The agent  is composed  of human  IgG framework  and mmine 
antigen -binding complementar ity-detennini ng regions . 
10.5.6  How  Supplied  
Bevacizum ab is a clear to slightly opalescent , colorle ss to pa le brown, sterile liquid concentrate for 
solution for intra venous (IV) infusion. Bevacizumab may be supplied in 5-cc (I00-mg) and 20 -cc (400- 
mg), glass via ls containing 4 mL, and 16 mL, respectively (all at 25 mg/mL). Vials contain bevacizumab 
with phosphate , trehalose , polysorbate 20, and Sterile Water for Injection (SWF I), USP. Vials contain no 
preservative and are suitable for single use only. The monoclonal antibody (bevacizumab ) being 
admini stered is intended for use only in clinical trials . 
10.5.7  Preparation  
Vials contain no preservatives and are intended for single use only. The calculated dose should be placed 
in a s terile, empty IV bag and diluted with a sufficient amount of 0.9% sodium chloride for injection to 
obtain a final volume of I00 mL. 
10.5.8  Storage  
Upon receipt of the study dmg , vials  are to be refrigerated  at 2°C-8°C (36°F-46°F) and should remain 
refrigerated  until just ptior  to use. DO NOT  FREEZE.  DO NOT  SHAKE.  Vials should  be protected  from 
light.  
Opened  vials  must be used  within [ADDRESS_1018571]  be administered within  8 hours . 
10.5.9  Stability  
Shelf-life studies ofrhuMAb VEGF are ongoing . The ste1i le single use via ls contain no antibac te1ial 
preservatives. Therefore , vials should be discarded 8 hours after initial entty.  
Once diluted in 0.9% sodium chlor ide, solutions of bevac izumab mu st be administered within 8 hours . 
 
10.5.10  Rout e of Administration  
Intra venous 
All conventional chemotherapy dtugs, including Bevacizumab , are adtninistered according to institutional 
practices . It is the practice of the Cancer Therapy and Research Center (CTRC) and University Hospi[INVESTIGATOR_307] 
(UH) to give Bevacizumab in [ADDRESS_1018572] RC at UTHSCSA 
CTRC#  11-[ADDRESS_1018573] be flushed w ith 0.9% sodium 
chloride. The following are two recommended  methods  for flushing  the bevac izmnab  IV infusion line: 
• When the bevac izmnab infusion is complete , add an additiona l 50mL of 0.9% sod ium chl01ide  
for injection to the bevaci zumab infus ion bag. Contin ue the infusion un til a volume eq ual to that 
of the volume  contained  in the tubing has been  administered.  
• Replace the empty bevacizmnab  infusion  bag with a 50mL  bag of 0.9%  sodium  chlor ide for 
injec tion and infuse a vol ume equal to the volume conta ined in the tubing.  
NOTE : The flush is not included in the tota l recommended infusion times.  
 
10.5.[ADDRESS_1018574] public hea lth gu idelines 
is recommended fo r patients on treatme nt with or without bevacizumab. D iscontin uation of therapy 
shou ld be cons idered if the patient expe1iences uncontrolled hype1te nsion.  
Protein mi a will be mo nitored by [CONTACT_744617]: creatinine (UPC) ratio or dipstick at least eve1y [ADDRESS_1018575] patien t to monito r and re po1tsigns o f bleeding , increased cough , swelling. 
 
Treat  pain, aithralgias , etc. with acetaminophen , or other pain relief strateg ies that do not inte1fere with 
the clotting casca de. 
10.5.13  Side Effects 
Allergy/Immunology:  Allergic reaction/hypersens itivity. In fusion-related reactions. 
Blood/Bone Marrow : Leuko penia, neutrope nia, thrombocyto penia.  
 
Cardiac:  Hype1 t ension/hype rtensive  c1isis , cai·diac  ischelnia/  infarction , suprave ntriculai·an  hythlnia , left 
ventr iculai·dysfunction (congestive heait failure), hypote nsion, syncope . 
Constitutional symptoms : Asthe nia , fever , 1i gors/chills , weight loss. 
Dermatologylslan:  Exfo liative de1m atitis, comp lications w ith wound healing, rash, skin ulceration , 
urticai·ia  
CTRC at UTHSCSA 
CTRC# 11 -36 October 25.  2016  
-69- CONFIDENTIAL   
  
 
Gastrointestinal : GI perforation and wound dehiscence , somet imes complicated by [CONTACT_90169] -abdominal 
abscesses. Lru·ge bowel leakage , GI fistula , intestinal obstruction , intestina l necrosis, mesenter ic venous 
occlusion , colitis , mucositis /stomatit is, nausea, vomiting , anorexia , constipation , diruThea , 
hea1tbum /dyspepsia , dty mouth , taste disturbance.  
Hemorrhage /Bleeding : Life -threatenin g or  fatal puhnona1y hemotThage (primarily in lung cancer 
patients) , CNS bleedin g, GI hemotThage, subarachno id hemo tThage , hemotThagic stroke, epi[INVESTIGATOR_3940] (nose 
bleeds) , vaginal bleeding , gum bleeding . 
In fection : Infection with normal ANC.  
 
Metabolic/Laboratorv:  Increa sed: alkaline phosphatase , ALT (SGPT), AST (SOOT), Bilirnbin , senun 
creat inine. Hyponatremia and hypokalemia . 
Neurology:  Cerebrovasculru· ischemia, dizziness , abno nnal gait, confusion. 
 
Ocular:  Excessive lacrimation. 
Pain : Abdominal pain , chest/thoracic pain, headache , ruthralgias, myalgias, genera lized. 
Pulmonarv/Upper Respi[INVESTIGATOR_744533]:  Dyspnea , cough, bronchospasm/wheezing , voice changes (hoarse ness). 
 
Rena l/Genitourinar v: P ro tein mi, a   nephrotic  syndt·ome.  
 
Reversible Posterior Luekoen -cephalopathy Syndrome:  Possible blindness , stro ke sy mpt oms, stro ke . 
 
Vascular : Life-threatening and potenti ally fatal a1te1ial thromboembolic events: cerebral infarc tion, 
transient ischemic attacks, myocardial infru·cti on and angina. Venous thromboembolic events: deep vein 
thrombo sis, intra -abdominal thrombosis.  
11 CLINICAL AND LABORATORY  EVALUATIONS  
 
11.1 Evaluations at Screening / Baseline  
(Perfo1med within 4 weeks of registration unless othe1w ise indicated)  
• Histmy and physical examination , including vital signs, weight and perfo1mance status 
dete1mination (within 1 week ofr egistrat ion). 
• Complete  bloo d counts , including  platelets  and INR (within I  week of regist ration). 
• Blood chemi stty stud ies, includin g creatinine , electrolytes (K+, Na+ , CJ-, C O 2), calc ium , Mg 
(withi n 1 week of registration)  and liver function  tes,ts  including  bilirnbin, AST (SGO T, ) 
(SGPT) , and alkaline phosphatase (within I week ofr egistt·ation). ALT  
• If urine dipstick result is > 1+, a calc ulation of Utine Protein Creat inine (UPC) ratio is requ ired.  
Patients  must have a UPC  ratio  < 1.0 to pruticipate  in the study . 
• Pregnancy  test (when  applicab le, within  3 days  prior  to treatment initiati on) 
• PET/CT scans and CT of the chest and other imaging studies as indicated for staging and baseline 
tumor measurements . Any scans or x-rays used to document measurable disease should be done  
as close to study entty  as possible  and within  4 weeks p1ior  to registt·ation.  
• Dental evaluation (within 6 weeks of registration)  
• ENT evaluation/e ndoscopy (w ithin 6 weeks o fr egistration)  
CTRC at UTHSCSA 
CTRC# 11 -36 October 25.  2016  
-70- CONFIDENTIAL   
  
 
• Swallowing  assess ment (within  6 weeks  ofregistration)  
• Audiometly (within 6 weeks of registi·ation) 
• Quality of life questionnaire (complete FACTHN questionnaire in Appendix  F) 
• Blood samp les for research  purposes  
• Obtain  archival  tumor  sample  of unstained slides 
• Tumor  biopsies  at baseline  (optional ) for con elative  studies  
• EKG (All patients will have a baseline EKG. If abno nnaliti es cons istent w ith active coromuy 
a1tery  disease  are detected , the patient  will be refe1rnd  to a card iologist  for approp1iate  evaluation 
and management p1ior to treatlnent on study.)  
11.2 Evaluation During  Treatment  
 
11.2.1  Induction - Prior to Each Treatment Cycle, Day 1 
• Histo1y and physical examination, including vital signs, weigh t and perfo1man ce status 
dete1mination  
• Hype1tension will be monitored through routine evaluation of blood pressure prior to each  
bevacizumab treatlnent. Optimal control of blood pressure accord ing to standard public health  
guide lines is recommended for patients on treatment w ith or without bevacizumab.  
• Toxicity  assessment  
• Comp lete blood counts , including  platelets  
• Blood chemistty studies, includin g creatinine, electrolytes (K +, Na+, er-, CO 2), c a++ , Mg++, and 
liver function tests, including bilirnbin, AST (SGO T), ALT (SGPT) , and alkal ine phosphatase  
• Urine  for protein : creatinine  ratio  (and 24 hour collecti on if indicated).  Proteinuria  should  be 
monitored  by [CONTACT_744618]1y  othe r dose  of bevac izum ab. If urine dipstick  is > I+ 
then UPC  ratio  shou ld be dete1mined . 
• Blood  samples for con elatives  studies  (p1ior  to cycle  2) 
• Tumor  biopsies  on cycle  I, day 21 (plus /minus  2 days)  (optiona l) for correlat ive studies 
11.2.2  Indu ction- after cycle  3 
• Evaluations  as after  cycle  I and 2 (see above)  
• ENT  evaluation/endoscopy  
• PET/CT scan  
• CT scan of chest  
• Response  assessment  by [CONTACT_744619]  (repo1ted  separate  ly) in prima1y 
and lymph nodes  
• QOL  questionnaire  
• Swallowing  assess ment 
• Blood  samples for con elativesstudies  (p1ior  to staiting  radiation  therapy)  
• Urine for protein : creatinine ratio (and 24 hour collection if indicated) . Proteinuria should be 
monitored by [CONTACT_744620]1y other dose of bevacizumab. If urine dipstick is > I+ 
then UPC  ratio  should be dete1mined.  
11.2.3  Cllemoradiotherapy  - weekly  and 2 weeks  after  completion  
• Hist01y  and physical  examination.  A focused  evaluat ion of toxicities  on a weekly  basis  will be 
CTRC at UTHSCSA 
CTRC# [ADDRESS_1018576] eve1y 3 
weeks.  
• Hype1tension will be monitored through routine evaluation of blood pressure prior to each  
bevacizumab treatment. Optimal control of blood pressure accord ing to standard public health 
guidelin es is recommended for patients on treatment with or w ithout bevacizumab.  
• CBC , platelets  and creatinine /electrolytes will be pe1fo1med  at the time of cisplatin  administration  
at a lninimum.  
• Vitals signs w ill be checked eve1y time cetuximab is administered.  
 
• Urine  for protein : creatinine  ratio  (and 24 hour collection  if indicated).  Proteinuria  should be 
monitored  by [CONTACT_744621]1y  othe r dose  of bevac izum ab. If urine dipstick is > 1+ 
then UPC  ratio  shou ld be dete1min ed. 
11.2.4  Evaluation After Completion of Radiation (8 weeks  after)  
• Histmy and physical  examination  
• Comp lete blood counts , including  platelets  
• Blood  chemi stly studies, includin g creatinine , electrolytes  (K+, Na+ , er-, C O 2), c a++, Mg++  , and 
liver function tests, including bilirnbin , AST (SGO T), ALT (SGPT) , and alkaline phosphatase  
• ENT  evaluation/endoscopy  
• PET/CT scan  
• CT scan of  chest 
• Response  assessme nt by [CONTACT_744622]  (repo1ted  separate  ly) in prima1y 
and lymph nodes  
• Blood samples for co1Te lati ves s  tudi es 
• Urine  for protein : creatinine  ratio  (and 24 hour collecti on if indicated) . If urine dipstick is > 1+ 
then UPC  ratio  shou ld be dete1mined.  
11.3 Evaluations at Follow  Up 
Staiting 8 weeks a fter completion of radiation, patients will be followed eve1y 3 months for 2 yeai·s and 
then eve1y 6 months for 3 years , and subsequently ann ually for a total of 10 yeai·s. (Follow up evaluation 
will include assessment o f late tox icities , such as dysphagia , G-tube feedings r equirements , xerostomia , 
and others.) 
Quality of life assessments w ill be repeated at [ADDRESS_1018577] scan of neck/chest will be perfo1med eve1y [ADDRESS_1018578] 3 years. S ubsequent scans eve1y 6 months until the 5th year and then annually ai·e 
recommended but not required . 
Swallowing assess ments will be perfonned  as standard  practice  at baseline  and [ADDRESS_1018579] 
chemorad iotherap y and then as indicated.  
Blood samp les will be collected for co1Te lat ive s 6 m ont h s after comp letion of radiat ion. 
CTRC  at UTIISCSA 
CTRC#  11-36 Janua1y 14. 2015  
CONFIDENTIAL 7?  
  
STUDY PARA METERS TABL E 
  
Baseline  Prior to Each 
Treatment 
Cycle, Day [ADDRESS_1018580] RT 8 weeks after  
CRT  Off therapy 
Follow -Up 
History and physical exam  X X X x• X X 
Height  X      
Weight  X X X x• X  
Vital signs X X X x•   
T oxicity assessment   X X X X X 
Perfonnance Status  X X X x• X  
CB,C Differential, Platelets1 X X X x• X8  
Creat inine , Electrolytes (K'", Na • , er-, CO,,) Mg • +,c a++ X X X x• X8  
Liver enzymes ' X X X  X  
Chest X -ray (optional ) X      
 
Urine for pro tein (every 2 bevacizumab infusions ) [ADDRESS_1018581]' X      
PET/CTscan  X  X  X  
CT scan  of the neck/chest 
(can be part of PET/CT)  
X   
X   
X x• 
Bone scan, if clinically indicated  X      
Tumor measurements • X  X  X x• 
Swallowing assessment ' X  X   X 
Dental evaluation  X      
QOL assessment (FACT -HN)'  X  X   X 
Audiometry  X      
Pathology materials6  X      
Blood samples 7 X X X  X X 
ENT evaluation/endoscopy  X  X  X  
CTRC  at UTIISCSA 
CTRC#  11-[ADDRESS_1018582] RT 8 weeks after  
CRT  Off therapy 
Follow -Up 
EK<f  X      
Tumor biopsies (optional) '" X X     
All patients  should  be seen  by a Medical  Oncologist , an ENT  surgeon,  and a Radi ation Oncologis t prior  to initiating  therap y. Unresectabilityshould  be determined  by a multidisciplinary team. 
NOTE:  For H+P required  on every  cycle  day 1, patients  can be seen  the previousda y (due to long  duration  of druginfusions  on cycle  day 1). 
1 Complete  blood  counts  with  differential  and platelet  count  should  be performed < 24 hours  prior  to chemotherapy  administration(withthe  exception  of baseline  CBC ). ln the event  of grade  3 or 4 hematologic 
toxicity , follow -up CBC ,vithdifferential and platelet count willbe obtained every 1-3 daysuntil there is evidence of hematologic recovery . During CRT , CBC will be performed on the day of cisplatin 
administration at a  minimum . 
2 Liver  fimction  tests should  include:  Bilirubin,  AST  (SOOT),  ALT  (SGPT) , and alkaline  phosphatase  should be performed  <[ADDRESS_1018583] done  within  3 days  of initiation  of treatment  to rule out pregnancy  
4 Tumor measurements will be made usingphysical examination, including endoscopic examination (clinically) and PET/CT scans (radiographically) . Clinical and radiographic assessments wi ll be reported 
separately . Response  in the primary  and the neck  will be reported  separa tely as well. Tumor  assessments  willbeperformed  after  3 cycles  of induction  and 8 weeks  after  completion  of chemoradiotherap y using 
PET/CT. Subsequentl y, no specifi c tumo r measurement s are required. Patient s willbe categorize d as having  progression  of disease  or not. A repeat imagin g with CT scan of neck/chest  willbeperformed    every  
3 months  for 2 years , and then every  6 months  for 3 years . Subsequent  scans  every  6 months  until  the 5th year and then armually  are recommended  but not  required . 
5 QOL assessme nts (FAC T-H&N, version  4) will be performed  at baselin e, after completio n of inductio n therap y, at [ADDRESS_1018584]  at 12, 24, 3,6  48, and 60 month s follow  up. 
6 The following  materials  willbe submitted  (optional  studies):  paraffin -embedded  tumor  specimens  for i.nnnunohistochemistryand  molecular  studies . 
7 Blood samples  for DNA/RNA  and EGFR  studies  will be obtained  a) at baseline , b) prior  to cycle  2, c) after  3 cycles  of induction,  d) 8 weeks  aftercompletion  of chemora diotherap y (see section  13.0 for 
details ). Samples  will be forwarded  as specified  in the correlative  study  section  (13). 
8 During  chemoradiotherapy  and in the i.nnnediate  2 week  period  following  RT completion,  patients  needa  focused  evaluation  of toxicities  on a weekly  basis. However , a complete  history  and physical 
examination is onlyneeded every3 weeks . CBC and electrolyte s/creatini.ne willbeperformed at the timeof cisplatin administration at a minimum and willalso be repeated [ADDRESS_1018585] comple tion of 
radiation . Vitals  signs  willbechecked  everytimecetuximab  is administered . 
9 EKG (All patients  will have  a baseline  EKG . 1f abnormalities  consistent  with  active  coronary  artery  diseaseare  detected,  the patient  willbereferred  to a cardiologist  for appropriate  evaluation  and 
management  prior  to treatment  on study .) 
10 Tumor  biopsies  at baseline  (optional)  and on cycle  1, day 21 (plus/minus  2 days)(optional)  
11 UPC ra tio is requi red for patients with dipstick > 1+. 
CRT=chemoradiotherapy  
CTRC at UTHSCSA 
CTRC# 11-[ADDRESS_1018586] DISCONTINUATIO N 
Subjects  who canno t receive one of the drugs  will still remain on study  and be followed  per protoco l unless they  withdraw 
consen t. C1iteria for remova l from study  are: 
• Disease  progress ion 
• Study  closure  
• Unacceptable  adve rse event(s)  as defined in dose  mod ification  or other  unacceptab le AEs  
• Patient decis ion to withdraw  from  the study, or 
• In the judgmen t of the inves tigator , fmt her treatment wou ld not be in the best interest of the patien t. 
 
 
The following will r equire di scontinuationof b evacizumab : 
• If the patien t develo ps anaphy laxis to  bevacizumab  
• Grade  4 hype1t ension or Grade 3 hype1tens ion not controlled with medicatio n 
• Nephrotic syndrome  
• Grade 2 pulmonary o r CNS hemoIThage ; any Grade 4  hemorrhage  
• Sym ptomatic Grade 4 venous thromboe mbolic event requiring full dose warfru i n or eq uiva lent (i .e ., 
unfract ionated or low molec u lar we ight hepru"in)  
• Any grade rut erial thromboembo lic event  
• Grade 4 congestive  herut  failure 
• Gastro intestinal perforation  
• Trac heoesop hageal  fistula (any grade)  or Grade  4 fistula 
• Grade  [ADDRESS_1018587] ion that has not fully recove red despi[INVESTIGATOR_744534]  
• Wound dehiscence requit i ng med ical or surgical interven tion 
• Unw illingness or inability of sub ject to co mply with study  requil·ements 
• Determination by [CONTACT_20616] r that it is no longe r safe for the subject to contin ue therapy 
• All Grade  [ADDRESS_1018588] an ongoing  bevacizumab -relat ed Grad e 4 or se1iou  s ad ve 1·se event at the time  of discontinuation 
from study treatment will continue to be followed until re solution of the event o r until the e vent i s considered 
irreversible.  
NOTE: Pati ents will r emain and b e follow ed per proto col even if bevacizumabi s discontinu ed. 
 
13 STATI STICAL METHOD S 
 
13.1 Sample  Size 
The Simon's optimal two - stage design will be used to test whet her the admini stration of induction with cisplatin, 
docetaxel , cetux imab and bevac izumab followed by [CONTACT_181615], cetuximab , bevacizumab and radiation y ields a complete 
respo nse rate that is of clinical interest. The histo1ical contro l is our previous study (UPC I 05-003) in which the complete 
respo nse (CR)  rate after  TPE was 21% (by [CONTACT_10052]). We assume that the CR rate with  TPE  plus Avastin  will be significantly 
higher. This design will test the null hypot hesis that the trne CR rate is less than or equa l to 21% versus the alterna tive 
hypo thesis that it exceeds  40%. The samp le size of 30 response -evaluable patients  (Subjects  that complete  the induction 
phase  of the study  and at least have  staited  the concmTent chemo-radiation pa1t before  discont inuing therapy)  will provide 
81% power  to reject the null hypothes is when the hue response  rate is 40% , with the type I e1rn r rate at 7.6% . The 
CONFIDE NIATL  [ADDRESS_1018589] RC at UTHSCSA 
CTRC#  11-[ADDRESS_1018590]  if there are 10 or more  comp lete responders out of the total of 30 response ­ 
evaluable patien ts. 
The following  Simon's optimal  two-stage design  uses [ADDRESS_1018591] 
21% versus the alternative  hypothesis  that it exceeds  40%.  
Stage 1: Enrollment wi ll be placed on ho ld after the firs t [ADDRESS_1018592] a complete 
respo nse (CR) , the ttial will be tenninated  for insufficient efficacy and the accrnal  of patients will be stopped.  If [ADDRESS_1018593] a CR, then accrnal  will contin ue in the second  stage  oft his tt·ial. 
Stage 2: Enter an additional 17 evaluable patients to the tti al. Thus, a total of 30 patie nts will be studied. If the 
total number  responding  is less than or equal to 9 in the total 30 evaluable patients, the tt·ial tt·eatment  will be not 
concl uded effective. If 10 or more  CRs are observed  in the total 30 evaluable patients , then this treattnent  will be 
considered  protnising in this patient  population and will be evaluated futt her in future studies.  
A minimum of 2 cycles of induction i s required for re sponse assess ment. Response -Evaluable patients ru·e s tu dy ­ 
el i gible  patien  ts (i.e. , t hose  meeting  all of the protoco l inclusion/ex clusion c1ite1i a) who complete a tninim um of2 cycles 
of induction. Determination  of evaluabi lity will be done  by [CONTACT_744623]1y  and the study  principal inves tigator. It can be 
assumed  that some  patients will not be evaluable for response . Thus, more than 30 patients may need  to be enrolled to 
obtain  30 response -evaluab le patients.  Assutning  a 10%  ineva luability rate, a total of about  33 patients  will be enrolled. 
13.2 Anal yses 
The CR rate will be estimated  by [CONTACT_744624] f CR dividedby  [CONTACT_744625].  Confidence 
interva ls for the ttue CR rate will also be calculated.  
Smvival  data will be analyzed  using Kaplan-Meier analysis. The median, 2-ye,ar 3-year,  5-yeru·overa  ll smvival  and the 
c01Tespond  ing 95%  confidence  inte1val  will also be repmted . 
The maximum  grade for each type of toxic ity will be recorded  for each  patie nt, and frequency  tables  will be reviewed  to 
determine  toxici ty patterns.  Point estimation  and Confidence  Interva l estimation will be done  for toxicities.  
Statistical analyses wi ll also be done fo r the fo llowing: 1) local/region al and distant fa ilme rates , point estimation and 
Confidence Inte1val est imation; 2) acu te and late Q OL changes associated with tt·eattnent with induction 
docetaxel/cetux imab/cisplatin fo llowed by [CONTACT_744626] g iven conc mTen tly with stand ard rad iothera py. 
Longitudinal  QOL analysis will be pe1fom1  ed to compru· e FACT -HN  score s before  and after therapy . The first site of 
recurrence will be recorded and used  as the reference point for the calculation of the time to locoregional or distant 
progression.  
13.3 Definition of  response 
Respo nse c1iter ia will as previo usly used  by [CONTACT_744627] (Anna ls of Oncology  2010 ;21:2278 -83).79 CR by [CONTACT_744628]·ance of FDG activity attiibuta ble to ma lignancy, w ithout regard to the degree of CT response, 
assessed  on comb ined PET-C T. Patients  without  CR on PET (non-CR) will be catego rized as having  either abno nnal 
CTRC  at UTHSCSA 
CTRC#  11-[ADDRESS_1018594] tiss ue and blood samp les for potent ial future studies. A pane l of cand idate biomarker s including 
markers of proliferation , apoptosis and activation of EGFR and VEGF signaling pathways as well as HPV will be 
evaluated. Analysis ofbiomarkers will be explorato1y.  
14.2 Material Submi ssion 
 
14.2.1  Tissue Biomarker  Studies 
 
[IP_ADDRESS]  Sample Submission  Schedule  
Paraffin -embedded specimens will be used. 
These studies wi ll be perfo1med at baseline , p1ior to treatment initiation and after fir st cycle , day 21 (± 2 days as a n 
optional tumor biopsy for patient who prov ide info1med consent for it). Specimens that have been already collected for 
diagnosis will be generally used.  
[IP_ADDRESS]  Sample Prep aration  Guidelines  
A representat ive paraffin  block of the 01igina l diagnos is and all repeat  biopsies, if available , will be subtnitted . If blocks 
cannot  be submitted , [ADDRESS_1018595]:  
Jennifer  S. Carew,  PhD or Steffan  T. Nawrocki , Ph.D. 
Co-Director , Preclinica l Research  
CTRC Institute for Drng Deve lopment 
Assistant Professo r 
Depa 1t ment of Medicine/Division of Hematology and Medical Oncology 
University of [LOCATION_007] Health Science Center at San Anto nio 
[ADDRESS_1018596], MC 8232 
RoomG437  
San Antonio , TX [ZIP_CODE] 
Phone: [PHONE_15535]  
Emai l: Nawrocki @uthscsa.edu  
Emai l: Carew@ uthscsa.edu  
[IP_ADDRESS]  Shippi[INVESTIGATOR_744535]. DO NOT SHIP ON FRIDAY OR BEFORE A HOLIDAY. Ship to [CONTACT_744652] or 
[CONTACT_744653] at the above address.  
[IP_ADDRESS]  Methods  
CTRC  at UTHSCSA 
CTRC#  11-36 Januaiy  14. 2015  
- 77 - CONFIDENTIAL  
  
 
Methods will include but not limited to immunohistochemishy , FISH , and detection of HPV 16 using in-situ hyb ridization. 
Immunoh istoche mistiy for the determinatio n of biomarke rs will be perfo1med using commercial antibodies . Prin::taiy 
antibody incubation , secondaiy antibo dy detection comp lex using Dako Envi sion plus, followed by [CONTACT_744629] . Heat induced 
antigen rehieval will b e applied. Tissue microairny s will be consti u cted, if feasib le. 
14.2.2  Blood Biomar ker Studies  
Blood  samples (abou t 5mL  each) will be collected  for co1Telatives  at the following  tin::te  point  s (p1ior  to treatment  that day 
unless othe1wise indicated ): a) baseline pr ior to cycle 1, day 1, b) prior to cycle 2, c) cycle 3, p1i or radiation, d) 8 weeks 
after completion of radiation , e) 6 months after completion of  radiation . 
14.3 Bankin g 
The residual s and/o r derivatives of sample s collected and submitted for studies associated with this protocol will be 
retained  by [CONTACT_45822] [INVESTIGATOR_744536]. If future  use is denied  or withdrawn  by [CONTACT_102] , 
the samples will be removed  from  consideration  for use in any future study. 
14.4 Blood Correlatives for Lavender Top and Serum  Red Top Tubes 
Blood samples (34 cc) will be collected at each tin::te po int as li ste d above.  
 
Sample Collection Method s 
• Before venipuncture , the phlebotomist prepare s two ?ml lavender top tubes and two red top plastic 5 ml blood 
collection  tube (red top #1 and #2) and affixe s a label to each blood  collection  tube. Info1mation  to be encoded  
on the label include s the clinical tI"ial study n umber , subject's unique identification (ID) number and date. The 
tubes  ai·e placed  in a test tube rack, in order of  collection  (lavender tops, then red tops). 
• The phelobotomi st uses standard  venipuncturetechniq ues. Approxin::tate  blood volume to be collecte  d in each  
tube is as follows : 7 mL in each  lavender tube and 5 ml in each  red top tube. 
• The phlebotomist  affixes  the Subject  ID on to the blood  collection  f01m . 
• The phlebotomist  uses the blood  collec tion fo1m  to record  duration  of fast before  phleboto m, y  date and time of 
phlebotomy , approximate amount of blood collected into each tube, complications from phlebotom y, and staff 
initials. 
 
14.5 Methods 
 
Instructions for blood process ing protocols for lavender top tubes #1, #2 and r ed top tube #1 and #2 are 
outlin ed below. CTRC Pharmacokintetic laboratory personnel will can y out these procedures. 
Lavender Top Tube s (PBMC) 
 
• Samplesshouldbe processe d as soon as possi ble after receipt. 
• Allowblood to equilibrateto  room temperatur .e 
• Centrifuge  lavender  top tubes  #1 and #2. 
• Transfe r separated  plasmaand aliquotinto 1 ml volumesin1.8ml cryovials labeledwith specimennumb e,rcontents  of tube 
(plasma), volumeand date. 
• Freeze  plasma  at -80° C. 
• Replace  plasmaw ith an equal volumeof  PBS and mix bloodby [CONTACT_8536] . 
CT RC at UT HSCSA 
CTRC#  11-36 Januaiy  14. 2015 
- 78 - CONFIDE NIATL  
  
 
• Aliquotbloodmixtureinto 15 ml tubes contai ning1.5 ml per each tube. 
• Add 7.5 ml ELbufef r (Qiagen#7921 7,)vortex,and place on icefor 10 minute s. 
• After [ADDRESS_1018597] on ice for an addition10 minutes. 
• Centrifugetubes containing bloodat 1,300x g for 10 minutesat room  tempera true. 
• Aspi[INVESTIGATOR_744537]. 
• Resus pendthe pellet in 3mls of EL buffer, placein 3 ml cryovi al, and centrifugefor 10 minutesat 1,300 x g at room 
temperat uer. 
• Carefully aspi[INVESTIGATOR_744538]. 
• Add 0.6 ml RNA Later(Qiage n #[ZIP_CODE] ) to the pellet andlabelthe tube with the specimen  number , "1.5 ml bloodPBM C", and 
date.  
• Store samplesat -80°C. 
• RNA,DNA and protein will be subseqeuntlyisolate d using All PrepDNA/RNA/Protein mini kit (Qiage n #[ZIP_CODE]). 
• De live r to Steffan Nawroc ki ([EMAIL_14208] ) or Claudia Espi[INVESTIGATOR_744539] (Espi[INVESTIGATOR_54604]@uth scsa.e du). 
 
 
Red Top Tub es (Se rum) 
• To allow  clot fmmation , red top tubes sit at room  temperature  (22° to 25° C) for at least  30 to 45 minutes. 
• If futther  processing  cannot  be accomp lished immed iately after  clot retract ion, red top tubes  should be placed  at 
40 C. 
• Centr  ifuge r ed t op tu bes. If futt her process ing can not be accompl ished within 5 minutes after co mpleting 
centrifugatio  n, red top tubes  should  be placed at 4° C. 
• Inspect and record if serum shows  signs  of hemolys is, ictems, and/or  turbidityTransfer  serum into labeled freezer 
tubes. Aliquot 1ml of sera per 1.8 ml c1yov ial. 
• Info1mation  to be encoded  on each  tube includes the specimen  number  con esponding  to the sample collection , the 
contents of the freezer  tube (sernm), volume and date. 
• Freeze and store at -80° C until shipment  to [CONTACT_744653]  or [CONTACT_744652]. 
 
Anticipat ed aliquot di stribution  
 
Collection  tube Conten ts of fre.ezer tube   
Number of aliquots per 
tube  
 
 
Lavender  #1 & #2 PBMC 
Red top #1 & #2 Serum 4-5 
Tota l 11 
 
 
14.6 SWppi[INVESTIGATOR_744540] c1yov ials are to be delivered to:  
Jennifer S . Carew , PhD, 
Steffan T. Nawroc ki, Ph.D. (or Claudia Esp itia Olaya) 
Co-Directo r, Preclinica l Research  
CT RC at UTHSCSA 
CTRC#  11-36 Januaiy  14. 2015  
- 79 - CONFI DENTIAL  
  
 
CTRC Institute for Dmg Development 
Assistant [CONTACT_3348] of Med icine /Division of Hematology and Medical Oncology 
Univers ity of Texa s Health Science Center at San Antonio  
[ADDRESS_1018598] , MC 8232 
Room G437  
San Antonio , TX [ZIP_CODE] 
Phone: [PHONE_15535] 
Email: Nawrocki @uthscsa.edu  
Email: Carew @uthscsa.edu 
Email: espi[INVESTIGATOR_54604]@uthscsa .edu 
 
Please  send  e-mail notification  to the above  laborat01y  contacts  to ensure someone  is there  to receive  samp les. Include 
patient's  initials, date and cycle drawn  and time sample drawn.  
15 DATA SAFETY  MONITORING  
Data and Safety Monitoring Oversight  
 
A Data and Safety Monit01ing Plan i s required for all an individual protocols cond ucted at CTRC. All protocols 
cond ucted at CTRC are covered under the a uspi[INVESTIGATOR_744541]01ing Plan (DSMP).  
 
The CTRC Institutional DSMP global policies provide individual ttials with:  
 
• Institutional  policies  and procedures  for institutiona l data safety  and monitoring , 
• An institut ional guide  to follow , 
• Monitoring  of protocol  accmal  by [CONTACT_744630] , 
• Review  of study  forms  and orders  by [CONTACT_744631], 
• Independent  monitoring  and source data ve1ification  by [CONTACT_744632] /Auditor 
• Tools for monito ring safety  events , 
• Monitoring of UPI[INVESTIGATOR_9961] 's by [CONTACT_744633] , 
• Deten ninin g level of 1isk (Prio1ity  of Audit  Level Score - PAL S), 
• Oversight  by [CONTACT_744634]01ing  Committee  (DSMC) , and 
• Ve1ification of protoco l adherence via annual audit for all Investigator Initiated Stud ies by [CONTACT_744635]. 
 
 
Monitoring Safety  
 
Due to the risks assoc iated w ith partic ipation in this protocol , the CTRC Data Safety Monito ring Board (DSMB ) #2 in 
conjunction with the Plincipal Investigator will pelf01m assessme nt of adverse events, adverse event trends and tt ·eatment 
effects on this study. The CTRC DSMB #2 acts as an independent DSMB for Investigator Initiated Studie s (ITS)  
cond u cted at CTRC. The CTRC DSMB #2 w ill monitor data throughout the duration of a study to dete1mine if 
contin uation o f the study is approp1iate scie ntifically and ethically. The CTRC DSMC who w ill review the DSMB's 
qua1terly rep01ts provides an additional layer of review. 
 
Baseline eve nts and adverse even ts will be captured using the CTRC Master Adverse Events Document for each patient 
using CTCAE V4 .0 for the grading and atttibution of adverse events. Usage of the CTRC Master Adverse Events 
Docl.lIIlent centt·ally docl.lIIlents:  
 
• Th e event  and grades  the seriousness  of the event, 
CT RC at UTHSCSA 
CTRC#  11-36 Januaiy  14. 2015  
- 80 - CONFI DENTIAL  
  
 
• If the event  was a change  from  baseline,  
• The detennination  of the relationship  between  the event  and study  intervention,  
• If the event  was pait of the nom1al  disease  process , and 
• What  actions  were  taken  as a result  of the event?  
 
 
 
Reporting Requirements  
 
For this stud, y  the Maste r Advers e Event s Document s collecte d on patients  for this protocol  will be reviewed  by [CONTACT_364828] r on a monthly basis to determine if a serious safety problem has emerged that result in a change or 
eai·ly tennination of a protocol such as: 
 
• Dose modification , 
• Suspending  enrollment  due to safety  or efficacy, or  
• Termination  of the study  due to a significant  change  in risks  or benefits . 
 
The PI [INVESTIGATOR_16588] #2 with the monthly findings for discussion and review dming their meetings.  
 
As per the CTRC DSMP , any protoco l modifications, problematic safety repo1ts , unanticipa ted problelllS , and suspension 
or eai·ly tennination of a tiial must be rep01ted to the DSMB #2 and all members of the reseai·ch team . Suspension and 
early termination of a ti·ial must also be rep01ted immediatel y to the Director of Quality Assmance who will promptly 
notify the sponsor  and the UTHSCSA IRB. 
 
The PI [INVESTIGATOR_744542] s documents  to detemline  the significance  of the reported  events  and will 
provide  finding s to the DSMB  #[ADDRESS_1018599]  patient  completes  ti·eatment  for which  toxicity  analyses  will also be 
performed , after  an additional  10 patients  are accmed  and completed  ti·eatment , eve1y  6 months  , at the end of study , and 
as necessaiy  should  signi ficant  adverse  events  ai·ise . The DSMB  #2 will review the infonnation  provided  by [CONTACT_978] [INVESTIGATOR_744543]1t to the CTRC  DSMC  on a bi-annual  basis  unless  an emergent  issue has been  identified . The Investigator  Initiated 
Study  DSMC  Repo1t  F01m  includes  infonnation  on adverse  events,  cunent  dose  levels , number  of patien ts enrolled , 
significant  toxicities  per the protocol , patient  status  (morbidity  and mortality ), dose  adjustments  with observed  response , 
and any intelim  findings . Any trend  consisting  of three  or more  of the same event  will be repo1ted  to the CTRC  DSMC 
for independent  revie w outside  of the bi-annual  reporting  cycle , which  begins  three  months  following  protocol  sta1t up. 
DSMB #2 will also provide its findings to the CTRC's Regulato1y Affairs Division so that it may be provided to the 
UTHSCSA  IRB with the protocol's  annua l progress  repo1t.  Conflict  of interest  is avoided  by [CONTACT_744636] #2, CTRC DSMC and by [CONTACT_744637][INVESTIGATOR_9961]'s by [CONTACT_744638] . 
 
All SAE and UPRISO ' s will be rep01ted following CTRC and UTHSCSA institutiona l guidelines.  
 
UTHSCSA SAE/UPRISO REPORTING REQUIREMENTS  
Type Event  Report to  Timeframe  
 
All AE , SAE and UPI[INVESTIGATOR_744544]1y Affairs and DQA  Same as other notification timeframes 
except for SAE /AE whic h shou ld be 
reported on Monday for tl1e prior week  
SAE  Clinical Trial Sponsor Within [ADDRESS_1018600] RC at UTHSCSA 
CTRC#  11-36 Januaiy  14. 2015  
- 81 - CONFI DENTIAL  
  
 
AE/SAE  UTHSCSA IRB Annually  
 
UPI[INVESTIGATOR_9961] - all  
Clinical Trial Sponsor  Within 24 ho urs of the PI [INVESTIGATOR_16598] a  
UPI[INVESTIGATOR_744545] - life t hreatening   
UTHSCSA IRB Within 48 hours of the PI [INVESTIGATOR_16598] a 
UPI[INVESTIGATOR_744545] - non-life threa tening  
UTHSCSA IRB Within 7 days of the P I determininga  
UPI[INVESTIGATOR_744546] g for Ph ase II and III Studies (includin g hospi[INVESTIGATOR_059] .:. 
 
U NE XPECTED EVENT EXP ECTED EVEN T 
GRAD ES2 - 3 
Attribution of 
Possible, Probab le 
or Definite GRAD ES4 - 5 Regardless of 
Attribution GRADE S 1 - 3 GRADE S 4 - 5 Regardless of 
Attri bution 
Expedited report 
within 10 working 
days  Rep011 by [CONTACT_744639] B 
within 24 hrs. Expedited 
rep011 to follow within 10 
working days.  Adve rse Event 
Expedi ted Expedite d repo1 1, includin g Grad e 5 
Aplasia in leukemia patients , within 10 
working days.  
Grade 1 - Adverse 
Event Expedited 
Reporting NOT 
required.) This  includes  all deaths  within 
[ADDRESS_1018601] dose of 
treatment with an 
investigat ional agent 
regardless of  attribution.  
Any late deat h attrib uted to  
the agent (poss ible, probable , 
or definite) should be rep011ed 
within 10 working days.  Reporting N OT 
requi red. This  include s all deaths  within  30 days  of 
the las t dose of treatme nt with an 
investigationa l agent regardless of 
attribution.  
 
Any late death attributed to the agent 
(possi ble, probab le, or definite) should be 
rep011ed within 10 working days.  
   Grade 4 Mye losuppression or other Grade 
4 events that do not require expedited 
rep011ing  will be spec ified  in the protocol.  
 
* For Hospi[INVESTIGATOR_16601] - Any medical event equivalent to CTC Grade 3 , 4, 5 which precipi[INVESTIGATOR_744547] (or 
prolongat ion of existing hospi[INVESTIGATOR_059]) must be repmted regardless of requirements for Phase of study, expected o r 
unex pected and attrib ution.  
 
Expedited  repo1t ing may not be appropriate  for specific expected  adverse  events  for ce1ta in later Phase II and Phase III 
protocols.  In those  situations  the adve rse events  that will not have  expedited  repo1t ing must be specified  in the text of the 
approved  protocol.  An expected  Grade  3 event  that is definitely  related  to the investiga tional agent  is only to be repo1ted  if 
the patient is hospi[INVESTIGATOR_744548]1ting criter ia. For instance , in a trial of an investigationa l agent where 
Grade  3 dianhea  requiring hospi[INVESTIGATOR_744549],  only dian hea requiring ICU care (Grade  4) might be designated  for 
expedited  repo1ting.  
 
Setio us adve rse events  on NCI sponsore d trials utilizing a commercially available agent  (with no IND's  involved)w ill 
additionally be rep01ted via the FDA's Medwatc h program . 
CTRC  at UTHSCSA 
CTRC#  11-36 Januaiy  14. 2015  
- 82 - CONFIDE NIATL  
  
 
AssU1ing Com pli ance with Protocol and Data Accuracy  
As with a ll studies cond ucted at CTRC , the PI [INVESTIGATOR_16884] u ltimate responsibility for ensur ing protoco l comp liance and data 
accuracy /integrity. Protocol comp liance, data accuracy and repo1ting o f events is finthe r ensured by [CONTACT_744640] , whose a udit report is shared with the PI, the research team and will be reviewed by 
[CONTACT_744641].  
 
 
CTRC DSMB Membership  
 
The CTRC  has two DSMB 's with a prima1yset of member s specific to the histology of the study consisting  ofUTHSCSA 
faculty  and staff. This Protocol  will utilize DSMB#2.  
 
DSMB # 2 (for Solid Tumors ) 
C. Richard Meier , MD 
Melissa Nashawati , MPA  
YuanYuan Liang  
 
As per NCI guidelines and to e liminate conflict of interest (financ ial, intellectual , professiona l, or regulato1y in nature ), 
the CTRC DSMB specific to this st udy will not treat patient s on this protocol. Usage of the DSMB specific to the 
histology has been created to ensure that expe1ts in that histology are represented o n the DSMB assembled for this 
protocol, but may be expanded, at the PI's discretion , to include other members which may include:  
 
• Expe1ts  in the fields of medicine  and science that are applicable  to the study (if not CU1Tent ly represented  on the 
DSMB) , 
• Statist ical expe1t s, 
• Lay repre sentat ives, 
• Multidisciplina1y  representation , from  relevant  specialties  includin g expe1ts  such as bioethicists  , biostat  istic ians 
and basic scientists , and 
• Others  who can offer an unbia sed assessment of  the study progi·e ss. 
 
Additional or alternate member ship of in the DSMB is selected by [CONTACT_16676], in conjunction with the PI [INVESTIGATOR_744550].  
 
CTRC DSMB Chaiter and Responsibilitie s 
 
The CTRC  DSMB  will provide  inf01mation  on the membership  composition , including  qualification s and expe1ience  to 
both the UTHSCSA IRB and CTRC PRC for revie w. The C TRC DSMB for this study will act as an independent 
adviso1y  board  to the PI [INVESTIGATOR_744551]1t  its finding  s and recommendationsto  the PI, the UTHSCSA  IRB and the CTRC 
DSMC.  CTRC  DSMB  repo1 ts will utilize  the Investigator  Initiated  Study  DSMC  Rep01t  F01m and meet ings will occur 
on a monthly  basis  to review any updates  from the p1ior  mee ting. 
 
Once  the protoco l is activated , if not afready  established  elsewhe re in the protocol  the CTRC  DSMB  will estab lish and 
provide: 
CTRC at UT HSCSA 
CTRC# 11 -36 Januaiy  14. 2015   
  
 
• Proced ures for maintaining  confidentiality;  
• Statistical proced ures includ ing mon itoring g uidelines, which will be used to mo nitor the identi fied prim.my, 
seconda1y , and safety outcome  valiables;  
• Cons ider factors externa l to the study whe n relevant infonnation beco mes ava ilable, such as scientific or 
therape utic developments  that may have  an impact  on the safety  of the participants or the ethics  of the study;  
• Plans for changing  frequency  of interim analysis as well as proced ures for recommending  protoco l changes;  
• Recommendation of dose escalation, MTD recommendation of eat"ly terminat ion based on efficacy results;  
• Recommendation  of tennination  due to unfavorab le bene fit-to-risk or inability to answe r study questions;  
• Recommendation  of continuation  of ongo ing studies; 
• Recommend  modification  of sample  sizes based  on ongoing  assessme nt of event  rates;  and 
• Review of final results and  publications. 
 
 
[ADDRESS_1018602] S 
• In additio n to the regulat·  hosp ital chatt,  a sepat ·ate patient  folder  will be kept which  includes: 
o The patient's signed , dated and witnessed  consent  
o Pathologic  documentatio n of squamo us cell cat·cinoma  of the head  and neck  
o The Com pleted Patient Reg istration Fo1m and all other study fo1ms  
o Comp leted Patient Regist ration Fo1m . Eligibility c1i te1ia will be cleat·ly stated.  
o Base line info1mation will include: age, gende r, race, feeding tube placement, smo king and alcohol 
hist01y,  pe1f01mance sta tus, TNM  staging , sites of disease  involvement, and quality of life assess ments.  
o Flow Sheet  (see Appendix)re flectingpretreatme nt test  results and the first therapy.  
o Meas urement Fonn showing  baseline measurement (measurab le disease  patients).  
o Pathology Repo1t (pathologic confum at ion of disease.)  
o Signed, date, d  and witnesse d Patien t Info1mation and Consent Fo1m.  
o Evaluat ion f01ms after inductio n therapy (3 cycles) and after completion of che moradiotherapy. C linical 
and radiograp hic response w ill be repo1t ed. Also , respo nse in the prima1yand lymph nodes will be 
reported sepat·ately.Meas urement Fo1ms: after each lesion meas urement or evaluation , whichever is less 
freque nt. Measurement fo1m s must g ive se1ial measurements or evaluatio ns as re quired by [CONTACT_567745] l to 
assess disease response to therapy. Follow-up fo1m s will repo1t the presence of feeding tube and late 
toxic ities.  
o A final Treatmen t Summaty  Form is to be sublnitted when the patient  progresses,  dies,  or goes  off study  
for any other reason.  Any subseque nt head  and neck  surge 1y will be rep01ted.  
o Follow -Up Fo1m is sublnitted at the time the patie nt goes off study at any time p1i or to treatment 
comp letion as schedu led and thereafter , eve1y [ADDRESS_1018603] 2 years , then eve1y 6 months for the 
next 3 yem· ,sand subseq  uently ann ually for a total of [ADDRESS_1018604] be rep01ted , using the Follow-Up F01m  
 
 
 
 
 
 
 
 
 
CONFIDE NIATL - 83 - 
CTRC at UT HSCSA 
CTRC# 11-[ADDRESS_1018605]  E, Hao Y, Xu J, Munay  T, Thun  MJ. Cancer  statistics, 2008 . CA Cancer  J Clin 2008; 
58:71-96. 
 
2. Zbae ren P, LehmannW . Frequency  and sites of distan t metastases  in head  and neck  squamous  cell carcinoma . 
Arch  Otolaryngo l Head Neck  Surg 1987; 113:762-764. 
 
3. Kotwa ll C, Sako  K, Razack  M, et al. Metastat ic patterns  in squamous  cell cancer  of the head and neck. Am J Surg 
1987;  154:439 . 
4. Vokes EE , Weichselba um RR, Lippman S , Hong WK. Head and neck cancer. N Eng l J Med 1993; 328:184-194. 
 
5. Hong W, Lippman S, Itri M, et al . Preve ntion of second prima1ytumo rs with isotretinoin in squamo us-cell 
carcinoma  of the head  and neck.  N Engl J Med  1990;  3223:795 -801. 
 
6. Lefebvre  JL, Cheva lier D, Luboins ki B, Kirkpatr ick A, Collette  L, Sahmo ud T. La1ynxpreservat ion in pyrifonn  
sinus cancer:  prelimina1yresults  of a European  Organization  for Research  and Treatment  of Cancer  phase  III trial 
EORTC Head  and Neck  Cancer  Cooperative  Group.  J Natl Cancer  Inst 1996; 88:890 -9. 
7. Induction  chemotherapy  plus radiation  compared with surge1y  plus radiation  in patients with advanced  laiyngea l 
cancer.  The Depa1tment  of Vete rans Affairs Laiyngea l Cancer  Study  Group. N Engl J Med  1991; 324:1685 -90. 
 
8. Forastiere AA, Berkey B, Maor M, Weber R, Goepfe1t H, Moni so n WH, et al. Phase III T1ial to Preserve the 
La1ynx: Induction Chemotherapy and Radiotherapy Versus Concomitant Chemoradiotherapy Versus  
Radiotherapy Alone, Intergro up Trial R91-11. Proc Am Soc Clin Onco l 2001; 20:A4.  
 
9. Vokes EE, Weichselbau m RR. Concomitant chemoradiotherapy: rationale and c linical expe1ie nce in patients w ith 
solid tumors . J Clin Oncol 1990;  8:911-34. 
10. Vokes E . The interact ion of che motherapy and radiation . Semin Onco l 1993;  20:70-79. 
 
11. By[CONTACT_78925] J, Shai-p T, Fran kel S, et al. Phase I and II trial of five-day infused 5-fluorouraci l and rad iation in 
advanced  cancer  of the head  and neck.  J Clin Oncol  1984; 2:406 -413. 
 
12. Adelstein  D, Sharah  V, Eai-Ie A, et al. Long-tenn results  after  chemo -radiotherapyfo r locally  confined squamo us­ 
cell head  and neck cancer. Am J Clin Oncol  1990; 13:440 -447.  
13. Taylor  SI, Murthy  A, Caldat·e lli D, et al Combined  simultaneous  cisplatin/ fluorourac il chemotherapyand  split 
course  radiation  in head  and neck  cancer.  J Clin Onco l 1989;  7:846-856. 
 
14. Wendt  T, Ha11enst ien R, Wustrow  T, et al. Cisplatin, fluorourac il with leucovo1in  calcium enhancement  , and 
synchrono us accelera ted radiotherapy in the management  of locally advance d head and neck cancer : a phase II 
study . J Clin  Onco l 1989; 7:471-476. 
15. Weppe lmann B, Whee ler RH, Peters GE, Kim RY, Spencer  SA, Meredith RF, et al. Treatme nt of recun ent head  
and neck cancer  with 5-fluorouraci l, hydroxyurea , and rein adiation.  Int J Radiat Oncol  Biol Phys  1992;  22:1051- 
6. 
CTRC at UT HSCSA 
CTRC# 11-36 Januaiy  14. 2015  
- 85 - CONFIDE NIATL  
  
 
16. Vokes EE , Panje WR, Schilsky RL, Mick R, Awan AM, Mora n WJ, et al. Hyclroxy urea, fluorouracil, and 
concomitant  radiot herapy  in poor- prognos is head and neck  cancer: a phase  I-II study. J Clin Onco l 1989; 7:761- 
8. 
 
17. Merlano  M, Vitale V, Rosso  R, et al. Treatment of advanced  squamous -cell carcinoma of the head  and neck with 
alternat ing chemotherapy  and radiotherapy.  N Engl J Med  1992; 327:1151-1121. 
 
18. Pi[INVESTIGATOR_156776], Bourhis J, Domenge  C, Designe L. Chemotherapy  added  to locoregiona l treatment  for head  and neck 
squamous- cell carcinoma:  three meta-analyses of updated  individual data. MAC H-NC Collaborative  Group. 
Meta -Analysis  of Chemotherapy on Head and Neck Cancer. Lancet  2000; 355:949-55. 
 
19. Brizel D, Albe rs M, Fisher S, et al. Hyperfractionated in adiatio n with or without concmrnnt c hemotherapy for  
locally advance d head and neck cancer. N Engl J Med 1998; 338:1798-1804. 
20. Calais G, Alfonsi M, Bartlet E , Sire C, Germain T, Bergerot P, et a l. Randomized trial of radiat ion therapy versus  
concomitant chemotherapy and rad iation therapy for advance d-stage orophaynx carcino ma. J Natl Cancer Inst  
1999; 91:2081-2086 . 
 
21. Wendt TG, Grabenbaue r GG, Rodel CM , Thiel HJ, Aydin H, Rohloff R, et al. Simu ltaneous radioc hemothera py 
versus rad iotherapy alone in advanced head and neck cancer: a randomized multicente r study . J Clin Onco l 1998; 
16:1318-24. 
 
22. Al-San af M, LeBlanc M, Gili PG, Fu KK, Cooper  J, Vuong T, et al. Chemoradiotherapy  versus radiotherapy in 
patients  with advanced  nasophaiyngeal  cancer: phase  III randomized  Intergroup  study  0099.  J Clin Oncol  1998; 
16:1310-7. 
23. Adelstein DJ , Li Y, Adams GL, Wagner H, Jr., Kish JA, E nsley JF , et al. An intergroup phase III compar ison of 
standai·d radiation therapy and two sched ules of concurrent c hemora diotherapy in patients with unresectab le 
squamous cell head and neck cancer. J Clin Onco l 2003 ; 21:92-8. 
24. Forastiere  AA, Goepfert H, Maor  M, Pajak TF, Webe r R, MoITison W , G li sso n B, T rotti A , Ridge  JA, Chao  C, 
Peters G, Lee DJ, Leaf A, Ensley J, Cooper J . ConcmTent c hemotherapy and rad iotherapy for organ preservatio n 
in advanced  lruyn gea l cancer.  N Engl J Med. 2003  Nov 27;349(22) :2091-8. 
 
25. Al-Sarraf  M, LeBlanc M, Gili P, al e. Supe1io rity of chemo -radiotherapy vs radiotherapy  in patients  with locally 
advanced  nasophruyn  gea l cancer  prelimin aiy results  of intergro up (0099)  (SWOG  8892 , RTOG  8817, ECOG 
2388)  randomized  study . Proc Am Soc Clin Onco l 1996; 15:313 (Abstr  882).  
 
26. Al-Sa1rnf M, LeBlanc M, Gili P, Fu F , Cooper J , Vuong T, et al. Superi01ity of Five Yeru · Surv ival with Chemo ­ 
Radiothera py vs Radiotherapy in Patients w ith Loca lly Advanced Nasopha1yngeal Cancer. Intergroup (0099 ) 
(SWOG 8892 , RTOG 8817, ECOG 2388 ) Phase III Study: Final Rep01t. Proc Am Soc Clin Oncol 2001; 20:A905.  
27. Vokes  EE, Athanas iadis I. Chemotherapy  of squamo us cell carcino ma of head  and neck: the ftlture is now. Ann 
Onco l 1996; 7:15-29. 
 
28. Dimery I, Hong W. Ove1view  of combined  modality therap ies for head  and neck cancer.  J Natl Cancer  Inst 1993; 
85:95-111. 
CTRC at UTHSCSA 
CTRC# 11-36 Januaiy  14. 2015 
- 86 - CONFDI ENTIAL  
  
 
29. Ervin TJ, Clark JR, Weichselbaum RR, Fallon BG , Miller D, Fabian RL, et al An analysis o f induction and 
adjuvant chemothera py in the multidisciplina1y  ti-eatment  of squamous  -cell carcinoma  of the head  and neck. J 
Clin Onco l 1987; 5:10-20. 
 
30. Rooney  M, Kish  J, Jacobs  J, et al. Improved  complete  response  rate and survival in advanced  head  and neck 
cancer  after  three -course induc tion therapy  with 120-hour  5-FU infusion and cisplatin. Cancer  1985; 55:1123- 
1128. 
31. Kies M, Gordon  L, Hauck W, Krespi  Y, Osso:ff  R, Pecaro  B, et al. Analysis of complete  responders  after initial 
treatment w ith chemo therapy in head and neck cancer. La1yngo l Head Neck Surg 1985; 93:199-205. 
 
32. Thyss  A, Schne ider M, Santini  J, Caldani  C, Vallicioni  J, Chauvel P, et al. Induction  chemotherapy  with cis­ 
platinum  and 5-fluoro uracil for squamo us cell carcinoma  of the head and neck.  Br J Cance r 1986; 54:755 -760. 
33. Vokes  E, Mick  R, Lester  E, Panje W, Weichselbaum R. Cisplatin and 5-fluorouracil  does  not yield long-te1m 
benefit in locally  advanced  head  and neck  cancer : results from  a single  institution.  J Clin Onco l 1991; 9:1376- 
1384.  
 
34. Tannock  I, Cummings  B, S01rn nti V, Group  E. Comb ination chemothera py used  prior  to radiat ion therapy  for 
locally advance d squamous cell carcino ma of the head and neck. Cancer Treat Rep 1982; 66:1421-1424. 
 
35. Schantz SP, Hani son BR, Forastiere A. Tumors of the nasa l cavity and paranasa l sinuses, nasopha1ynx , oral 
cavity , and oropha1ynx. In: DeVita VT, Hellman S, Rosenberg SA, eds . Cancer. Pli ncipals and prac tice of 
Oncology: Lippi[INVESTIGATOR_744552] W ilkin s, 2001:797-860. 
36. Domenge C, Hill C, Lefebvre JL , De Raucomt D, Rhein B, Wiba ult P, et al. Randolnized t rial of neoadj uvant 
chemotherapy in oro phaiyngeal ca rcinoma. French Groupe d'Etude des Tumeurs de la Tete et du Cou (GETTEC). 
Br J Cance r 2000;  83:1594-8. 
 
37. Paccagne lla A, Orlando A, Mai·chi01i C, Zorat PL, Cavan iglia G, Sileni VC, et al. Phase III trial of initial 
chemotherapy in stage III or IV head and neck cancers : a study by [CONTACT_744642] s ui Tum01i della Testa e 
del Collo. J Natl Cancer Inst 1994; 86:265 -72. 
 
38. Richai·d  JM, Kramai·  A, Molina1i,R Lefebvre  JL, Blanchet  F, Jo1tay ,A et al. Randolnised EO RTC head and nec k 
cooperat ive group trial of preoperat ive int:ra-a1terial chemotherapy in oral cavity and oropha1ynxcai ·cinoma . Eur J 
Cancer 1991; 27:[ADDRESS_1018606]·inciples and Pl·acitce of 
Oncology Update 1993;  6:1-2. 
 
40. Schu ller D, Metch  B, Mattox  D, Stein  D, McCracke n J. Pl·eopera itve chemotherapy  in advanced  resectable  head 
and neck cancer:  final repo1t of the Southwest  Onco logy Group.  Laiyngosco pe 1988;  98:1205-1211. 
41. Laramore GE, Scott CB, al-Sa1Taf M, Haselow RE, Ervin TJ, Wheeler R, et al. Adj uvant chemotherapy for 
resectab le squamous cell carcinomas of the head and neck : rep01t on Intergroup Study 0034. Int J Radiat Oncol  
Biol Phys 1992; 23:705-13. 
 
42. Jacobs C, Makuch R. Efficacy of adjuvant chemotherapy fo r patients with resectab le head and neck cancer: a  
subset  analysis of the head  and neck  contracts  program.  J Clin Onco l 1990; 8:838 -847. 
CTRC at UTHSCSA 
CTRC# 11 -36 Januaiy  14. 2015  
- 87 - CONFIDENTIAL   
  
 
43. Specht L, Larsen SK, Hansen HS. Phase II study of docetaxel and cisplatin in patients with reclment or 
disseminated squamous -cell carcinoma of the head and neck. Ann Oncol 2000 ; 11:845-9. 
 
44. Schoffski P, Catimel G , Planting AS, Droz JP, Ve1we ij J, Schrijvers D, et al. Docet axel and cisplatin: an active 
regimen in patients with loc ally advanced , recunent or metastatic squamous cell carcinoma of the head and neck. 
Results of a phase  II study of the EORTC  Early  Clinical  Studies  Group.  Ann Oncol  1999; 10:119-22. 
 
45. Glisson BS, Mmphy BA, Frenette G, Khuri FR, Forastiere AA. Phas e II Trial of docetaxel and cisplatin 
combi nation chemotherapy  in patients  with squamous  cell carcinoma  of the head  and neck.  J Clin Oncol  2002; 
20:1593-9. 
46. Mel JR Rodriguez R, Constela M, Davila A, Femandez -Pi[INVESTIGATOR_53074] M, Gonzalez -Lama J. Phase II study of docetaxel 
and cisplatin as induction chemotherapy in locally advanced squamous ce ll cacinoma of the head and neck : 
prelimina1y  results. Proc Am Soc Clin Oncol  1999; 18:A1549. 
47. Vem1orken JB, Mesia R, Rivera F, Remen ar E, Kawecki A, Rottey S, Erfan J, Zabolotnyy D , Kienzer HR, 
Cupi[INVESTIGATOR_245355] D, Peyrade F, Benasso M, Vynnychenko I, De Rancourt D, Bokemeyer C, Schuele r A, Amellal N , Hitt 
R. Platinum - based chemothera py plus cetuximab  in head  and neck  cancer.  N Engl J Med . 2008  Sep 
11;359(11):1116 -27. 
48. Baselga J, Trigo JM, Bourhis J, et al. Phase II multicenter study of the antiepi[INVESTIGATOR_744553] l growth factor recept or 
monoclonal antibody cetuxi mab in combination with platinum -based chemotherapy in patients with platinum­ 
refract01y metastatic and/or recmTent squ amous cell carcinoma of the head and neck. J Clin Oncol  
2005;23(24) :[ADDRESS_1018607] radiotherapy for  
locoregionally  advanced , squamous  cell head  and neck  cancer: a pi[INVESTIGATOR_744554] a new combined -modality 
paradigm. J Clin Oncol  2006;24(7) :1072 -8. 
50. Lacouture ME. Mechanisms of cutaneous toxicities to EGFR inhibi tors. Nat Rev Cancer  2006;6(10) :803-12. 
51. Taylor  SGt.  Why  has so much  chemotherapy  done  so little  in head  and neck  cancer?  J Clin Oncol  1987 ; 5:1-3. 
52. Tannock  IF, Browman  G. Lack of evidence  for a role of chemotherapy  in the routine  manageme nt ofl ocally  
advanced  head  and neck  cancer.  J Clin Oncol  1986; 4:1121-6. 
53. Rosen thal DI, Pi[INVESTIGATOR_744555], Glatstein E. A review of neoa djuvant chemotherapy for head and neck cancer : 
pa1tia1ly  shm nken tumors  may be both leaner and meaner. Int J Radiat  Oncol  Biol Phys  1994; 28:315-20. 
 
54. Taylor SGt, Mmthy AK, Vannetzel JM, Colin P, Dray M , Caldarelli DD, et al. Randomized compa1ison of  
neoadjuvant cisplatin and fluorouracil infusion followed by [CONTACT_744643]. J Clin Oncol  1994 ; 12:385-95. 
 
55. De Andres L, Bnmet , J Lopez -Pousa A, Burgues , J Vega M, Tabemero JM , et al. Randomized tiial of 
neoadjuvant cisplatin and fluorouraci l versus carboplatin and flu orouraci l in patients with stage IV -MO head and 
neck cancer. J Clin Oncol 1995 ; 13:[ADDRESS_1018608] R C at UT H SCSA 
CTRC#  11-36 Januaiy  14. 2015 
-88 - CONFIDE NIATL  
  
 
carcinoma o f the head and neck: a So uthwest Onco logy Group study . Journa l of Clinical Oncology 1992; 
10:1245-51. 
 
57. Vokes EE, Stenson K , Rosen FR, K ies MS, Rademaker AW , Witt ME, et al. Weekly Carbop latin and Paclitaxe l 
followed by [CONTACT_744644], Fluorourac il, and hydroxyurea chemoradiotherapy: curative and organ­ 
preserving therapy for advanced head and neck cance r. J Clin Oncol 2003 ; 21:320-6. 
 
58. Machtay M, Rosenthal D I, Hershock D, Jones H, Williamson S, Greenberg MJ, et al Organ p reservation t herapy 
using inductio n plus concmTent  che moradiation  for advanced  resectable  oropharyngeal  carcinoma: a Univers ity of 
Pennsylvania Phase II Trial J Clin Onco l 2002;  20:3964 -71. 
 
59. Gaspar C, Pesudo C , An ibas L, Climent MA, Mengua l JL, Molinas C, et a l. Induction chemot herapy (ICT) 
followed  by [CONTACT_744645]  (CT/RT)  for advanced  squamous  cell carcinomas  of head  and neck  
(SCCHN) . Ann Onco l 2002; 13 (Suppl.  5):152. 
60. Weave r A, Fleming  S, Ensley J, Kish  JA, Jacobs  J, Kinzie  J, et al. Super ior clinical  response  and surviva l rates 
with initial bolus of cisplatin and 120 hour infusion of 5-fluorouracil before de finitive therapy for locally 
advanced  head and neck  cancer.  American  Journal of Surge1y  1984;  148:525-9. 
61. Di Blasio B, Barbie1iW , Bozzett i A. A prospec tive rando mized trial in resectab le head  and neck  carcinoma : loco­ 
regional treatment with and without  neoadj uvant chemotherapy . Proc  Am Soc Clin Oncol 1994; 13:279(abstract).  
 
62. Shin DM, Glisson BS, Khmi FR, Lippman SM , Ginsberg L, Diaz E, Jr., et al. Phase II study of induction 
chemotherapy  with paclitaxel, ifosfamide , and carbop latin (TIC) for patients with locally advanced  squamous cell 
carcinoma of the head  and neck.  Cancer 2002;  95:[ADDRESS_1018609] M . Goldberg, Daniel J. Sargent. Response -Independent Surv ival Benefit in Metastat ic 
Colorecta l Cancer : A Com parative Analysis ofN974 1 and AVF2 l 07. Journal of Clinical Oncol ogy, Vol 26, No 2  
(Janua1y  10), 2008  : pp. 183-[ADDRESS_1018610]; 
Eastern Cooperative  Oncology Group  Study  E3200.  Bevac iZUlllab  in comb  inat ion w ith ox aliplatin, fluorouracil, 
and leucovor in (FO LFOX4) for previously treated metastat ic colorectal cancer: results from the Eastern 
Cooperat ive Onco logy Group  Study  E3200 . J Clin Onco l. 2007  Apr 20;25 (12):1539-44. 
 
65. Sand ler AB, GrayR  , Peny MC, et al. Paclitaxelcarbop latin alone  or with bevaciZUlllab  for non -small  cell lung 
cancer. NEng l JMed 2006 ;355:2542 A50 . 
 
66 . Miller KD. E2100: a phase III trial of paclitaxel versus paclitaxel/bevacizu mab fo r metastatic breast cancer. Clin 
Breast Cancer . 2003 Feb ;3(6):421-2. 
 
67. Ozcan  C, Wong  SJ, Ha1i  P. Reve rsible poste1i or leukoencepha lopathy  syndro  me and  bevacizu mab. N Engl J Med. 
2006 Mar 2;354(9 ):980-2; discussion  980-2. 
68. Glusker  P, Recht  L, Lane  B. Reversible poste 1i or leukoence phalopathy  syndrome  and bevaci zumab. N Engl J 
Med. 2006 Mar 2;354(9):980 -2; discussion  980-2. 
CT R C at UT H SCSA 
CTRC#  11-36 Januaiy  14. 2015 
-89 - CONFIDE NIATL  
  
 
69. Scappaticc i FA, Fehrenbacher L, Cartwright T, Hainswo1th JD, Heim W, Berlin J, Kabbinava r F, Novotny W , 
Sarkar S, Hmwitz H. Surgical wound hea ling complications in metastatic colorectal cance r patients t reated with 
bevacizumab . J Surg Onco l. 2005 Sep  1;91(3):173-80. 
70. Karp JE, Gojo I, Pi[INVESTIGATOR_45769] R, Gocke CD, Greer J, Guo C, Qian D, Monis L, TidwellM, Chen H, Zwiebel J. Target ing 
vascular endo thelial growth  factor  for relapsed  and refracto1y  adult acute myelogeno us leukemias  : therapy  with 
sequential 1-beta-d-arabinofuranosylcytos ine, mitoxantrone , and bevac izumab . Clin Cancer Res. 2004 Jun 
1;10(11):[ADDRESS_1018611]  cancer.  J Clin Oncol.  2006  Feb 10;24(5) :769-77. Epub  2006 Jan 3. 
72. D'Adamo DR, Ande rson SE, Albr itton  K, Yamada  J, Riedel E, Sche u K, Schwai tz GK, Chen H, Maki  RG. Phase 
II study  of doxornb icin and bevac izumab for patien ts with metastatic  soft-tissue sarcomas.  J Clin Onco l. [ADDRESS_1018612] 
1;23(28) :[ADDRESS_1018613] E, Gorbounova Vet al; Cisp latin and  
Fluoroura cil Alone or with Docetaxe l in Head and Neck Cancer. NEJM Volume 357:1705-1715, 2007.  
 
74. Veimo rken JB , Remenar E , van Herpen C, e t al. Cisp latin, fluoro uracil, and docetaxe l in unresecta ble head and 
neck cancer.  N Engl  J Med. 2007;357: 1695-1704. 
 
75. Lindel K, Beer KT, Laissue J, Greiner R.H, Aeberso ld D.M . Hum an papi[INVESTIGATOR_744556] o f the oropha 1ynx. A radiosens itive subgrou p of head and neck carcinoma. Cance r 2001;92:805-13. 
 
76. Mork J, Lie A K, Glattre E,Clark S,Phil D, Hallmans  G, Jellum E, Koskela P, Moller  B, Pukkala E, Schiller J.T, 
Wang  Z, Youngman  L, Lehtinen M, Dillner J. Human  Papi[INVESTIGATOR_744557] a Risk  Factor  for Squamous ­ 
Cell Cai·cni oma of the Head and Neck . NEJM 2001 (15) 344:1125-1131 
77. Licitra L, Pe1rnne F, Boss i P, Suai·diS , Mai·iani L, Altusi R, Oggionni M, Rossini C, Cann) G, Sq uadrelli M, 
Quattrone P, Locati L.D, Bergamini  C, Olmi  P, Pi[INVESTIGATOR_744558] i M.A, Pi[INVESTIGATOR_068] S. High-Risk Human Papi[INVESTIGATOR_744559]. JCO  2006 , Vol 24, No 
36: 5630 -5636 . 
78.Hui E.P, Ma B.B, Leung S.F, King A D, Mo F, Kam M.K, Yu B.K, Chiu S.K, Kwan W.H , Ho R, Chan I,  Ahuja  A 
T, Zee B.C , Chan A T. Rando mized Phase II Tr ial of Conc mTent Cis platin-Radio therapy Wi th or Without 
Neoadj uvant Docetaxe l and Cisplatin in Advanced Nasopha 1yngeal Carc inoma. J Clin Oncol. 2009 Jan 
10;27(2) :242-9. 
79.V. A Passero,  B. F. Bra11Stetter  , Y. S hu ai , D . E . H eron , M . K . Gi b son , S . Y. L a i , S . W . Kim, R. L. Fenis,  J. T. 
Johnson , A Argiris.  "Res ponse  assessme nt  by  [CONTACT_744646] t reated with  chemoradiotherapy "  Annals o f 
Onco logy 2010;21:2278 -83 
 
80. L. H. Dohn, B. V. Jensen, F.0 Lai·sen . "Sho1t time infusion of bevacizumabin combination with 5F U-based 
chemotherapy as first-line therapy in a non -selective patient group with metastatic co lorecta l cancer. " Acta Onco l, 
2010; 49 : 395-396. 
CTRC  at UTHSCSA 
CTRC#  11-36 Januaiy  14. 2015  
- 90 - CONFDI ENTIAL  
  
 
81. D. L. Reidy , K. Y. Chung , J. P. Timoney , V. J. Park, E. Hollywood , N. T Sklarin , R. J. Muller, L.B. Saltz. 
"Bevacizmnab  5mg/kg  can be infused  safely over 10 minutes."  JCO 2007 ; 25 (19): 2691-2695.  
CTRC  at UTHSCSA 
CTRC#  11-36 Januaiy  14. 2015  
- 91 - CONFIDENTIAL  
  
 
APPENDIX A: EC OG PERFORMANCE S TATUS 
 
 
 
 
Grade  
ECOG 
0 Fully active, able to canyon allp re-diseasepe1fo1mance without restiiction  
1 Restiicted  in physically  strenuo us activ ity but ambulat01y and ab le to cany  out work  of a light or 
sedentaiy nature , e.g., light house work, office  work  
2 Amb ulato1y and capable  of all selfcare but unab le to cany  out any work  activities.  Up and about 
more  than 50%  of waking  hours 
3 Capable of only limited selfcare, confined to bed or chai r more than 50% of waking hours  
[ADDRESS_1018614] RC at UT HSCSA 
CTRC#  11-36 Januaiy  14. 2015  
- 92 - CONFIDE NIATL  
  
 
APPENDIX B : PROCED URE FOR OBTAI NING A URI NE PROTE IN / CREATINI NE RATIO  
 
 
1) Obtain  at least 4 mL of a random  urine  sample  (does  not have to be a 24 hour  urine) 
2) Determine protein concentration  (mg/d L) 
3) Determine c reatinine concentrat ion (mg/dL) 
4) Divide #2 by #3 above : urine protein / creatinine ratio  = prote in concentration (mg /dL) / creatinine  concentra tion 
(mg /dL) 
The UPC  directly con elates with the amount of protein  excreted  in the urine per 24 hrs (i.e. a UPC  of 1 should be 
equivalent  to 1 g protein  in a 24 hr urine collection)  
Protein  and creat inine concentrat ions shou ld be available  on standard reports of urinalyses, not dipstic ks. If prote in and 
creatinine  concentrations  are not routinely repo1ted  at an Institution , their  meas urements and repo1t s may need  to be 
requested.  
CT RC at UT HSCSA 
CTRC#  11-36 Januaiy  14. 2015  
- 93 - CONFIDE NIATL  
  
 
 
 
 
APP ENDIX C : NC I COMMO N TOXI CITY CRITERIA (CTCAE V 4 .0) 
 
 
See: http: //evs.nci.ni h.gov/ftp1/CTCAE /About.html  
CTR C at UTHSCSA 
CTRC# 11-36 Januaiy  14. 2015  
- 94 - CONFIDENTIAL  
  
 
APPENDIX D: FDA ME DWATCH 3500A FORM 
 
 
See: www .fda.gov/medwatch/sa fety/FDA-3500A fillable .pdf 
CTR C at UTHSCSA 
CTRC# 11-36 Januaiy  14. 2015  
- 95 - CONFIDENTIAL  
  
 
APPENDIX E: NEW YO RK H EART ASS OCIATION (NYHA) GUI DELINES  
 
NYHA Classification 
Excerpted from Oxford Textbook of Medic ine. Vol [ADDRESS_1018615] Pre ss.1997 . 
 
Class Description 
 
I Subjects wit h cardiac disease but without res ulting limitat ions 
of physical activity. Ordinruy physical activity does not cause 
undue fatigue , palpi[INVESTIGATOR_332], dyspnea , or angina }pain.  
 
 
II Subjects wit h cru·d iac disease result ing in slight limitation of 
physic al activity. They ru·e comfortable at rest. Ordinruy 
physical activity resu lts in fatigue , palpi[INVESTIGATOR_3116], dyspnea, or 
angina} pain.  
 
 
III Subjects  with cru·diac  disease  resulting in mru·ked  limitat ion of 
physical activity. They are comfo rtable at rest. Less than 
ordina1y physical activity ca uses fatigue, palpi[INVESTIGATOR_332] , dyspnea , 
or anginal  pain. 
 
 
IV Subjects  with cru·d iac di seas e re sult ing in inability  to canyon 
physical activity without discomf01t. Symptoms of cardiac 
insufficiency or of the angina}syndro me may be p resent even t 
at rest. If any physical activity is unde1taken , discomfo 1t is 
increased. 
CTR C at UTHSCSA 
CTRC# 11-36 Januaiy  14. 2015  
- 96 - CONFIDENTIAL  
  
 
APPENDIX F: FACT - H&N 
 
 
Quality of Life , Pe1fo1mance and Patient P rio1ities  
 
 
1) Patient  Name:     
 
 
2P)atien t ID #:  /_  / _/   -/_  /_  /_  / 
 
 
3) Date : /_ /_ /_ /_ /_ /_ / 
 
 
4) Assess ment  Point: / / 
1 = baseline  
2 = post induction  
3 = 3 months follow -up 
4 = [ADDRESS_1018616] - H&N (Versio n 4) 
 
Below is a list of statements that other people w ith yo ur illne ss have said are imp01 t ant. By [CONTACT_744647] , 
please indicate how true each statement ha s been for you during the past [ADDRESS_1018617] pain 
 
 
GP5 I am bothe red by [CONTACT_744648] a little 
bit some- 
what  quite 
a bit very 
much  
0 1 2 3 4 
 
0  
1  
2  
3  
4 
 
0  
1  
2  
3  
4 
 
0  
1  
2  
3  
4 
 
0  
1  
2  
3  
4 
 
CTR C at UTHSCSA 
CTRC# 11-36 Januaiy  14. 2015  
- 97 - CONFIDENTIAL  
  
 
 
GP6 I feel ill 0 1 2 3 4 
 
GP7 I am forced to spend time in bed   
0  
1  
2  
3  
4 
 
not at a little some- quite very 
  SOC IAL/FAMIL Y WELL-BEING  all bit what a bit much 
GSI  I feel close to  my fiiends  0 1 2 3 4 
GS2  I get emotiona l support from  my family  0 1 2 3 4 
GS3   I get suppo11 from  my fiiends  0 1 2 3 4 
GS4 My family has accepted my  illness  0 1 2 3 4 
GS5  I am satisfied with family comm unication  about  my 0 1 2 3 4 
illness  
GS6  I feel close  to my partne r (or the person  who is my 0 1 2 3 4 
main supp01t)  
 
Regardless o f your ClllTent level of sexual activity, please 
answer the following question. If you prefer not to answer 
it, please check the box below and go to the next section.  
□ 
GS7  I am satisfied with my sex life [ADDRESS_1018618] my illness   
0  
1  
2  
3  
4 
 
GE4 I feel nervous   
0  
1  
2  
3  
4 
 
CTR C at UTHSCSA 
CTRC# 11-36 Januaiy  14. 2015  
- 98 - CONFIDENTIAL  
  
 
 
GE5 I wony about dying  0 I 2 3 4 
 
GE6 I wony that my condit ion will get worse   
0  
I  
2  
3  
4 
 
 
  FUNC TIONAL WELL-BEING  not at a little some- quite very 
 all bit what a bit much 
GFI I am ab le to work (include work at home)   
0 I 2 3 4 
 
GF2   
My work (include work at home) is fulfilling   
[ADDRESS_1018619] accepted my i llness   
0  
I  
2  
3  
4 
 
GF5   
I am sleep ing well   
0  
I  
2  
3  
4 
 
GF6   
I am enjoying the things I usually do for fun   
0  
I  
2  
3  
4 
 
GF7   
I am content with the quality of my life right now   
0  
I  
2  
3  
4 
not at a little some- quite very 
  ADDITIO NAL CONCERNS   all bit what a bit much 
 
H&Nl   
I am able to eat the foods that I like  
0  
I  
2  
3  
4 
 
H&N2   
My mouth is dty  
0  
I  
2  
3  
4 
 
H&N3   
I have troub le breathing   
0  
I  
2  
3  
4 
 
H&N4   
My voice has its usual qua lity and strength  
0  
I  
2  
3  
4 
 
H&N5   
I am able to eat as much food as I want   
0  
I  
2  
3  
4 
 
CTR C at UTHSCSA 
CTRC# 11-36 Januaiy  14. 2015  
- 99 - CONFIDENTIAL  
  
 
 
H&N6  I am unhappy with how my face and neck look 0 I 2 3 4 
 
H&N7   
I can swallow naturally and easily   
0  
I  
2  
3  
4 
 
H&N8   
I smoke c igarettes or other tobacco products   
0  
I  
2  
3  
4 
 
H&N9   
I drink alcohol (e.g. beer, wine , etc.)  
0  
I  
2  
3  
4 
 
H&N IO  
I am ab le to communicate with others   
0  
I  
2  
3  
4 
 
H&N l I  
I can eat solid foods   
0  
I  
2  
3  
4 
 
H&N l [ADDRESS_1018620] pain in my mouth , throat o r neck   
0  
I  
2  
3  
4 
CTRC  at UTHSCSA 
CTRC#  11-36 Januaiy  14. 2015  
-100- CONFIDENTIAL   
  
 
APPENDIX G: AJCC S TAGING SYSTEM, 7TH E DITIO N 
 
 
1) LIP AND ORAL CAVI TY 
 
Patient  Name /Information     
 p   e c  _ 
 
Tumor  Size     
 His topaTytpe  olo g   _ 
Laterality  Bilateral  Left Righ t 
 
 
DEFIN ITIONS: 
 
Ptimaiy Tumor (T) 
 
TX Ptima1y tumor cannot  be assessed 
TO No  evidence of prima1y tumor 
Tis Carcinoma in situ 
Tl Tumor [ADDRESS_1018621]  dimension  
T4a (Lip) Tumor  invades  throu gh co1t ical bone , infe1ior  alveolai·nerve  , floor  of mouth , or skin of face, i.e., chin or 
nose(l)  
T4a (Oral Cavity) Tumor  invades through co1tical  bone , into deep  [extlinsic]  muscle  of tongue (genioglossus , 
hyoglossus , palatoglo ssus, and styloglossus) , maxilla1y  sinus, or skin of face 
T4b Tumo r involves masticato r space, pte1ygoid plates,  or skull base  and/o r encase s intern al cai·o tdi  ait e1y 
 
 
Regional Lymph Nodes (N)  
 
NX Regional lymph  nodes  cannot  be assessed 
NO No regional lymph node  meta stasis 
NI Metas tasis in a single ipsilateral  lymph  node , [ADDRESS_1018622]  dnnen sion; or in 
multiple ipsilateral  lymph  node s, none  more  than [ADDRESS_1018623]  dimension ; or in bilateral  or conti ·alateral  lymph 
nodes , none more  than [ADDRESS_1018624]  dnnens ion 
CTRC  at UTHSCSA 
CTRC#  11-[ADDRESS_1018625] dimension  
 
 
 
Distant Metastasis (M) 
 
MX Distant metastasis cann ot be assessed 
MO No distant  metastasis  
M1 Distant  meta stasis 
 
Biopsy  of meta static site perfo1med  y N 
 
Source of pathologic metastatic specimen  
 
 
 
Stage Groupi[INVESTIGATOR_007]  
 
0 Tis NO MO 
I Tl NO MO 
II T2 NO MO 
III T3 NO MO 
 Tl Nl MO 
 T2 Nl MO 
 T3 Nl MO 
IVA T4a NO MO 
 T4a Nl MO 
 Tl N2 MO 
 T2 N2 MO 
 T 3 N2 MO 
 T4a N2 MO 
IVB AnyT  N3 MO 
 
IVC T4b 
AnyT  AnyN  
AnyN  MO 
Ml 
 
 
Histologic Grade (G) 
 
GX Grade cannot be assessed 
Gl Well  differentiated  
G2 Moderately differentiated 
G3 Poorly differentiated  
G4 Undiffer entiated  
 
 
Residual Tum or (R) 
RX Presence  of residual  tumor  cannot  be assessed  
CTRC  at UTHSCSA 
CTRC#  11-36 Januaiy  14. 2015  
-102- CONFIDENTIAL   
  
 
RO No resid ual tumor 
RI Microscopic residual  tumor  
R2 Macroscopic residual tumor (continued ) 
 
 
Additional Descriptor s 
 
For identification of special cases of TNM or pTNM class ifications, the "m" suffix and "y ," "r," and "a" prefixe s are used. 
Although they do not affect the stage group ing, they indicate c ases needing separate analys is. 
 
m suffix  indicate s the presence of multiple  prima1y  tumor s in a single site and is recorded in parenthe ses: pT(m )NM. 
y prefix  indicate s those  cases  in which classification  is perfo1med  dmi ng or following  initial  multimoda lity therap y. 
The cTNM or pTNM categ01y is identified by a "y" prefix . The ycTNM or ypTNM categ01izes the extent of tumor 
actually  present at the time of that examinat ion. The "y" catego rization  is not an estimate  of tumor  p1i or to multimodality 
therapy . 
r prefix indicate s a recmTen t tumor when staged after a disease -free in terval and is identified by [CONTACT_941] "r" prefix : rTNM . 
 
a prefix designates the stage dete 1mined at autopsy: aTNM. 
Progno stic Indicator s (if applicable)  
Note s 
 
Superficia l erosion alone of bone /tooth socket by [CONTACT_744649] i s not sufficient to classify as T4. 
 
Additional Desc1iptor s 
o Lymph -Vascular Invasion (LVI)  
o Lymph-Vascular Invasion Not Present (abse nt)/No t Identified  
o Lymph -Vasc ulai·In vasio n Present/Identified  
o Not Applicab le 
o Unknown/Inde te1min ate 
 
 
 
 
Physician's  Signatme     Date ------------ 
CTRC  at UTHSCSA 
CTRC#  11-36 Januaiy  14. 2015  
-103- CONFIDENTIAL   
  
 
2. PHARYNX (INCLUDING BASE OF TONGUE, SOFT PALA TE, AND UVULA)  
Patient  Name/Information     
Type  of Specimen       
Tumo r Size     
Histopatholo gic Type  _ 
 
Lartilty Bilatera l Left Right  
 
DEFINITIONS : 
Prima1y T umor (T) 
TX Primaiy tumor cannot be assessed 
TO No evidence of  prima1ytumor 
Tis Carcinoma in situ 
 
Nasophaiynx  
Tl Tmn or confine d to the nasophaiynx  or tumo r extend s to orophaiynx  and/o r nasal  cavit y withou t pai·apha1yngeal 
extension  
T2 Tumo r with pai·aphaiyngeal  extension  
T3 Tumor  involves bony  stmctmes of skullba se and/orpai·an saal sinuses  
T4 Tmno r with intracran ial extension  and/or  involvement  of crania l nerves , hypoprhaiynx , orbit, or with extension  to 
the infratempora l fossa/masticator  space  
 
 
Orophatynx  
 
Tl Tmno r [ADDRESS_1018626]  dimension  
T4a Moderately Advanced  Disease  
Tumor invade s the la1ynx , extrins ic muscle of tongue, medial pte1y goid, hai·d palate , or mandible 
T4b Vety Advanced  Disease 
Tumor invade s lateral pte1ygoid muscle, pte1ygoid  plates, latera l nasophaiynx,  or skull base or encase s cai·otid 
a1tery  
 
Hypopha1ynx  
Tl Tumo r limited  to onesubsite of hypo phaiynx  and [ADDRESS_1018627] RC at UTHSCSA 
CTRC#  11-36 Januaiy  14. 2015  
-104- CONFIDE NIATL  
  
 
Tumo r invades thyroid /cricoid cru.tilage , hyoid bone , thyroid gl and, esophagus o r central compru. tm ent soft 
tissue(2)  
T4b Ve1y Advanced Disease  
Tmnor invades prevertebral fascia , encases carotid ru.te1y , o r in vo lves mediastinal strnctures 
Regio nal Lymph No des (N)  
Nasophru.ynx  
NX Regiona l lymph nodes caJ.lllo t be assessed 
NO No regional lymph node  metastasis  
Nl  Unilateral metastasis  in ce1v ical lymph  node(s), [ADDRESS_1018628]  dimens ion, above  the supraclav icular 
fossa(3) (conti nued) 
 
2. PHARYNX (INC LUDING BASE OF TONGUE , SOFT PALA TE, AND UVULA) (con tinued) 
N2  Bilateral metastasis in cervical lymph node(s) , [ADDRESS_1018629] d imens ion, above the supraclaviculru.· 
fossa (3) 
N3 Metastasis  in a lymphnode(s)  >6 cm and/or  to supraclav iculru·. fossa 
N3a Grea ter than 6 cm in dimension  
N3b Extens ion to the  supraclavicular fossa (3) 
 
 
Orophru.ynx and H ypop h a1ynx  
 
NX Regio nal lymph nodes  cannot  be assessed 
NO No regional lymph  node  metastas is 
NI Metastasis  in a single ipsilatera l lymph node , [ADDRESS_1018630] dime nsion 
 
Distant Metastas is (M) 
MX Distant metastas is cannot be assessed 
MO No distant  metastasis  
Ml Distant metastas is 
Biopsy of metastatic site perfonned y N 
Source of patho logic metas tatic specimen 
CTRC  at UTHSCSA  
- 105 - CONFIDENTIAL  
 CTRC # 11-36  Januai y 14.2015 
 
Stage G roupi[INVESTIGATOR_007]:Nasopharynx  
0 Tis NO MO 
I Tl NO MO 
II Tl N I MO 
 T2 NO MO 
 T2 NI MO 
III Tl N2 MO 
 T2 N2 MO 
 T3 NO MO 
 T3 N I MO 
 T3 N2 MO 
IVA  T4 NO MO 
 T4 N I MO 
 T4 N2 MO 
IVB AnyT N3 MO 
IVC  AnyT AnyN Ml 
CTRC  at UTHSCSA 
CTRC#  11-36 Januaiy  14. 2015  
-106 - CONFI DENTIAL  
  
 
Stage Groupi[INVESTIGATOR_007] : Oropharynx and Hypopharynx  
0 Tis NO MO 
I Tl NO MO 
II T2 NO MO 
III T3 NO MO 
 Tl NI MO 
 T2 NI MO 
 T3 NI MO 
IVA  T4a NO MO 
 T4a NI MO 
 Tl N2 MO 
 T2 N2 MO 
 T3 N2 MO 
 T4a N2 MO 
IVB T4b AnyN  MO 
 
IVC AnyT  
AnyT  N3 
AnyN  MO 
Ml 
HistologicGrade(G) (Oropha1yn x, Hypopha1y nx) 
GX Grade cannot be assessed  
GI Well  different iated 
G2 Moderately different iated 
G3 Poorl y differentiated  
G4 Undifferentiated  
 
 
Residual Tumor (R) 
 
RX Presence of residual tumor cannot be assessed 
RO No res idual tumor  
RI Microscopic  residua l tumor (continued) 
R2 Macroscopic residua l tumor 
Additional Descriptor s 
 
For identification of special  cases  of TNM  or pTNM  classification s, the "m" suffix  and "y," "r," and "a" prefixes  are used. 
Although  they do not affect  the stage groupi[INVESTIGATOR_007] , they indicate cases  needing  separate analysis. 
 
m suffix indicates the presence of multiple p1imai y tumors in a single site and is recorded in parentheses : pT(m)NM. 
y prefix indicates those cases in which classification is perfonned during or following initial multimod ality therapy . 
The cTNM or pTNM catego1 y is identified by a "y" prefi x. The ycTNM o r ypTNM categor izes the extent of tumor 
actually present at the time of that examination. The "y" categor ization is not an estimate of t umor p rior to multimodality 
therapy.  
 
r prefix indicates a recmrnnt tum or when staged after a disease -free inter val, and is identified by [CONTACT_941] "r" prefix : rTNM.  
CTRC  at UTHSCSA 
CTRC#  11-36 Januaiy  14. 2015  
-107 - CONFI DENTIAL  
  
 
a prefix designates the stage detennined at autopsy: aTNM.  
 
 
 
Progno stic Indicators (if applicable ) 
 
 
Notes  
 
1. Paraphruyngeal extension denote s posterolateral infiltration of tumor beyond the pha1yngoba silar fascia.  
 
2. Central compa1tmen t soft tissue includes prelruyn geal strap muscles and subcutaneous  fat. 
 
3. Midline node s are considered ipsilateral  node s. 
 
 
 
Additional Descriptor s 
Lymph -Vasculru · Invasion (LVI) 
o Lymph -Vasculru· Invasion Not Present (absent)/Not Identified  
o Lymph-Vasculru· In vasion Present/Identified  
o Not Applic  able 
o Unkn  own/Inde te1minate  
 
 
Physician' s Signature     [CONTACT_1782]  ------------ 
CTRC  at UTHSCSA 
CTRC#  11-36 Januaiy  14. 2015  
-108 - CONFI DENTIAL  
  
 
3. LARYNX  
 
Patient  Name/Information                                                              
Type of Specimen      
Tumo r Size     
 
His topTtpoelog _ 
 
 
Lartily Bilatera l Left Right 
 
 
 
DEFIN ITIONS:  
 
Primaiy T umor (T) 
TX Primaiy tumor cannot be assessed 
TO No evidence of  prima1ytumo r 
Tis Carcinoma in  situ 
 
Supraglottis  
Tl Tmnor  limited  to one subsite of supraglottis  with norma l vocal  cord mobility  
T2  Tmnor invades m ucosa of more than one adjacen t subsite o f suprag lottis or glottis or region outside the 
supraglottis (e.g ., mucosa of base o f tongue , vallecula, medial wall of pyrifmm sinus) without fixation o f the 
laiynx  
T3  Tumor  limited  to laiynx  with vocal  cord fixation  and/o r invades  any of the following : postcricoid  ai·ea, pre­ 
epi[INVESTIGATOR_744560] , pai·aglo ttic space , and/or  minor  thyroid  caitilage  erosion  (e.g., inner  cmtex)  
T4a Moderate ly Advanced Local  Disease  
Tumor  invades  through  the thyroid ca1tilage and/or  invades  tissues  beyond  the la1ynx  (e.g. , trachea  , soft tissues  of 
neck  including  deep  extiins ic muscle  of the tongue , strap  muscles , thyro id, or esophagus ) 
T4b Ve1y Advanced Local  Disease  
Tumor invades preve1tebral space, encases carotid a1te1y, or invades med iastina l strnctures  
 
Glott is 
Tl Tumor limited to the vocal cord (s) (may involve ante1ior or posterior commissure ) with nom1al mobility 
Tl a Tumor  limited  to one vocal  cord 
Tl b Tumor invo lves both voca l cords  
T2 Tumor  extends  to supraglottis  and/o r subglottis, or with impa ired voca l cord mobi lity 
T3  Tumor  limited  to the laiynx  with vocal cord fixation , and/o r invades  paraglott ic space , and/or  minor  thyro id 
ca1ti lage erosion (e.g. , inner co1tex)  
T4a Moderate ly Advanced Local  Disease  
Tumor  invades  through  the thyroid ca1tilage and/or  invades  tissues  beyond  the la1ynx (e.g., trachea , soft tissues  of 
neck  including deep  extiins ic muscle  of the tongue , strap  muscles,  thyro id, or esophagus ) 
T4b Ve1y Advanced Loca l Disease  
Tumor invades preve1tebral space, encases carotid a1te1y , or invades mediastina l strnctures 
Subglott is 
CTRC  at UTHSCSA 
CTRC#  11-[ADDRESS_1018631](s) with n01mal  or impaired  mobil ity 
T3 Tumor  limited  to laiynx:  with  vocal  cord  fixation  (contin ued) 
T4a Moderately Advanced Local  Disease 
Tumo r invade s cricoid or thyroid caitilage and/o r invade s tissues beyond the la1ynx: (e.g., trachea, soft tissues of 
neck including deep extrinsic muscles of the tongue , strap muscle s, thyro id, or esophagu s) 
T4b Ve1y Advanced  Local  Diseas e 
Tumo r invad es prevertebral  space,  encase s cai·oti d ait e1, y  or invade s medi astinal stm ctures 
 
Regiona l Lymph Nodes (N)  
NX Regional lymph nodes cannot be assessed 
NO No reg ional lymph node  meta stasis 
NI Metastasis  in a single ipsilateral  lymph  node , [ADDRESS_1018632]  dimens ion 
 
Distant Metastas is (M) 
MO No distant meta stasis 
Ml Distant  metasta sis 
Biop sy of meta static site pe1f01med  y N 
Source  of patho logic meta static  specimen 
Stage  Group ing 
0 Tis NO MO 
I Tl NO MO 
II T2 NO MO 
III T3 NO MO 
 Tl NI MO 
 T2 NI MO 
 T 3 NI MO 
IVA T4a NO MO 
 T4a NI MO 
 Tl N2 MO 
 T2 N2 MO 
 T3 N2 MO 
 T4a N2 MO 
IVB T4b AnyN  MO 
 An y T N3 MO 
IVC An y T AnyN  Ml 
 
CTRC  at UTHS CSA 
CTRC#  11-36 Januaiy  14. 2015 
- 110 - CONFIDENTIAL  
  
 
Histologic Grade (G) 
GX Grade  cannot  be assess ed 
GI Well  diffe rentiated  
G2 Moderate ly diffe rentiated 
G3 Poorly  differentiated  
G4 Undifferentiated  
 
Residual Tumor (R ) 
RX Presence of re sidual tumor cannot be assesse d 
RO No residua l tumor  
RI Microscopic residual tumor 
R2 Macroscop ic residual tumor  
 
Additional Descriptor s 
For identification  of special  cases  ofTNM  or pTNM  classifications, the "m" suffix  and "y," "r," and "a" prefixe s are used. 
Althou gh they do not affect  the stage groupi[INVESTIGATOR_007] , they indicate  cases  needing  separate  analys is. 
m suffix indicate s the pre sence of multiple prima1y tumor s in a single site and i s recorded in parenthe ses: pT(m )NM. 
y prefix indicate s those cases in which classification is pe rformed durin g or following init ial multimoda lity therapy.  
The cTNM or pTNM catego1y i s identified by a "y" prefix . The ycTNM or ypTNM catego1ize s the extent of tumor 
actually present at the time of that examination. The "y" catego rization is not an est imate of tumor p 1ior to mu ltimoda lity 
therapy . 
r prefix indicate s a recmTent tumor when staged after a disease-free interval , and is identified by [CONTACT_941] "r" prefix: rTNM.  
a prefix designate s the stage detennined at autopsy: aTNM. 
Progno stic Indicator s (if applicable)  
Notes  
 
Additional Desc1iptor s 
Lymph -Vascular In vasion (LVI)  
o Lymph -Vascular  Invasion  Not Present (absent)/Not  Identified  
o Lymph -Vascular Inva sion Present/Identified  
o Not Applicab le 
o Unkn own/Indeterminate  
 
Physician' s Signature     [CONTACT_1782]  ------------ 
CTRC  at UTHS CSA 
CTRC#  11-36 Januaiy  14. 2015 
- 111 - CONFIDENTIAL  
  
 
4. NASAL CAV ITY AND PARANASAL  SINUSES  
Patient  Name/Information       
Type  of Specimen   _ 
TumSioe  
 
His topTt p    elog _ 
 
Latiera lBilatera l Left Right 
 
 
DEFINITIONS : 
Primaiy T umor (T) 
Maxillaiy  SinusTl  Tumor  limited  to the maxi llaiy sinus  muco sa with no erosion  or destluct ion of bone  
T2  Tum or causing bone  erosio n or destm  ction including  extension into the haid·  palate and/or middl e nasal meat us, 
except extens ion to posterior wall of maxillai y sinus and pte1ygoid  plate s 
T3 Tumor  invade s any of the follow ing: bone of the posterior wall of maxilla1y  sinus, subc utaneo us tissues, floor  or 
media l wall of orbit, pte1ygo id fossa, ethmoid  sinuses 
T4a Moderate ly Advanced Local  Disease 
Tumo r invade s anterior orbital contents , skin of cheek , pte1ygoi d plates, infra tempora l fossa, cribrifo1mplate , 
sphe noid or frontal sinuses 
T4b Ve1y  Advanced  Local  Diseas e 
Tmnor invade s any of the follow ing: orbital apex , dura, brain, middle cra nial fo ssa, cranial ne1ve s other than 
maxillaiy division oftiigeminal nerv e V2 , nasopha1ynx , or cliv us 
 
Na sa l Cavity and Ethmoid Sinus 
TX Primaiy tumor cannot be assessed 
TO No evid en ce of pri ma1ytmnor 
Tis Carcinoma in situ 
Tl Tmnor  restricted to any one subsite, with or without bony invasion 
T2 Tmnor  invadin g two subsites in a single region or exten ding to involve an adjacent  region  within the 
nasoethmoidal  complex , with or witho ut bony  invasion 
T3 Tmno r extends to invade the media l wall or floor of the orbit, maxillai y sinus, palate , or cribriform  plate  
T4a  Tumor  invades any of the followin g: anterior  orbita l contents , skin of nose  or cheek , minima l extension  to anterior 
crania l fossa, pterygoid plates, spheno id or fronta l sinuses 
T4b Tumor  invade s any of the followin g: orbital apex , dura, brain , middle  crania l fos,sa cranial nerv es other than V2, 
nasopha1ynx , or clivus 
 
Regional Lymph Node s (N) 
NX Regional lymph nodes cannot be assessed 
NO No reg ional lymph node  meta stasis 
NI Metastasis  in a single ipsilateral  lymph  node , [ADDRESS_1018633] dimen sion 
CTRC  at UTHS CSA 
CTRC#  11-[ADDRESS_1018634] dimens ion 
 
Distant Metastas is (M)  
MO No distant metastasis 
Ml Distant  metastas is 
Biopsy of metastat ic site perfmmed  y N 
Source of patho logic metastat ic specimen 
Stage Group ing 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Histo logic Grade (G)  
GX Grade cannot be  assessed 
G1 Well  differentiated  
G2 Moderately different iated 
G3 Poorly differentiated  
G4 Undifferentiated  
 
Residual Tumor (R) 
RX Presence of residual tumo r cannot be assessed 
RO No residual  tumor  
Rl Microscopic residua l tumor 
R2 Macroscopic residua l tumor  
 
Additional Desc1iptors  
For identification of special cases  of TNM  or pTNM  classification s, the "m" suffix  and "y," "r," and "a" prefixes  are used. 
Although  they do not affect  the stage  groupi[INVESTIGATOR_007], they  indicate  cases  needing  separate  analysis.  
m suffix indicates the presence of multip le primaiy tumors in a single s ite and is reco rded in parentheses: p T(m)NM. 0 Tis NO MO 
I Tl NO MO 
II T2 NO MO 
III T3 NO MO 
 Tl Nl MO 
 T2 Nl MO 
 T3 Nl MO 
IVA T4a NO MO 
 T4a Nl MO 
 Tl N2 MO 
 T2 N2 MO 
 T 3 N2 MO 
 T4a N2 MO 
IVB T4b AnyN  MO 
 AnyT  N3 MO 
IVC  AnyT  AnyN  Ml 
 
CTRC  at UTHSCSA 
CTRC#  11-36 Januaiy  14. 2015  
- 113 - CONFDI ENTIAL  
  
 
y prefix indicates those cases in whic h classification is perfo 1med durin g or following initial multimodality therapy.  
The cTNM or pTNM categ01y is identified by a "y" prefix . The ycTNM or ypTNM categorizes the extent of tumor 
actually  present at the time  of that exalninat ion. The "y" catego rization  is not an estimate  of tumo r prior to multimoda lity 
therapy . 
r prefix indicate s a recun ent tumor when staged afte r a disease -free in terval, and is identified by [CONTACT_941] "r" prefix: rTNM . 
a prefix designates the stage detennined at autopsy: aTNM. 
Progno stic Indicators (if applicable ) 
Note s 
 
Additional Descriptors  
Lymph -Vascular Invasion (LVI) 
o Lymp h-Vascula r Invasion Not Present (absent)/Not  Identified  
o Lymp h-Vascular Invasion  Prese nt/Identified  
o Not Appl icable 
o Unkn own/Indete1minate  
 
Physician' s Signature     [CONTACT_1782] ------------ 
CTR C at UTH SCSA 
CTRC# 11-36 Januaiy 14. 2015 
- 114 - CONFIDENTIAL  
  
 
APPENDIX H: GENEN TECH SAFE TY RE PORTI NG FAX C OVER SHEET 
CTRC at UTHSCSA 
CTRC# 11-36 Janu aiy 14. 2 015  
  
 
 
 
 
Genentech  
B I O N CO L OG Y SAFETY REPORTING FAX COVER  SHEET  
Investigator Sponsored  Trials  
 
SAE FAX No: (650) 225 -4682  
Alternate Fax No: (650) 225 -5288  
 
Study Number  
(Genentech studv number}   
Principal Investigator   
[INVESTIGATOR_112832] #  
Reporter Fax #  
 
 
I 
 
 
 
 
 
Subject Initials  
(Pleas e enter a dash If the patienthasno 
middle name   
 
   
 
[CONTACT_744651]  [CONTACT_744650] (888)  835-2555  
 
 
 
 
Page 1of_  
 
 
Version July 2007  I nit ial Report Date  
(DD/MON/YYYY)     / / _ 
Follow -up Report Date  
(DD/ MO N/ YYYY ) _/ /    
 